Number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
and O
their O
sensitivity O
to O
hormone O
action O
. O

The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
blood O
lymphocytes O
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

In O
the O
lymphocytes O
with O
a O
high O
GR B
number O
, O
dexamethasone O
inhibited O
[ O
3H O
] O
- O
thymidine O
and O
[ O
3H O
] O
- O
acetate O
incorporation O
into O
DNA O
and O
cholesterol O
, O
respectively O
, O
in O
the O
same O
manner O
as O
in O
the O
control O
cells O
. O

On O
the O
other O
hand O
, O
a O
decreased O
GR B
number O
resulted O
in O
a O
less O
efficient O
dexamethasone O
inhibition O
of O
the O
incorporation O
of O
labeled O
compounds O
. O

These O
data O
showed O
that O
the O
sensitivity O
of O
lymphocytes O
to O
glucocorticoids O
changed O
only O
with O
a O
decrease O
of O
GR B
level O
. O

[ O
1 B
, I
25 I
- I
Dihydroxyvitamin I
D3 I
receptors I
in O
lymphocytes O
and O
T O
- O
and O
B O
- O
lymphocyte O
count O
in O
patients O
with O
glomerulonephritis O
] O

Concentration O
of O
the O
receptors B
to O
1 O
. O
25 O
( O
OH O
) O
2D3 O
was O
elevated O
up O
to O
39 O
. O
7 O
fmole O
/ O
mg O
after O
I O
week O
of O
the O
treatment O
, O
whereas O
it O
was O
decreased O
to O
the O
initial O
level O
24 O
. O
8 O
fmole O
/ O
mg O
within O
4 O
weeks O
; O
simultaneous O
alteration O
in O
the O
cAMP O
content O
was O
observed O
in O
lymphocytes O
. O

The O
data O
obtained O
suggest O
that O
under O
conditions O
of O
glomerulonephritis O
only O
high O
content O
of O
receptors B
to O
1 O
. O
25 O
( O
OH O
) O
2D3 O
in O
lymphocytes O
enabled O
to O
perform O
the O
cell O
response O
to O
the O
hormone O
effect O
. O

To O
investigate O
whether O
the O
tumor O
expression O
of O
beta B
- I
2 I
- I
microglobulin I
( O
beta B
2 I
- I
M I
) O
could O
serve O
as O
a O
marker O
of O
tumor O
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O

Presence O
of O
beta B
2 I
- I
M I
was O
analyzed O
by O
immunohistochemistry O
. O

Likewise O
, O
beta B
2 I
- I
M I
was O
not O
associated O
with O
markers O
of O
disease O
extension O
such O
as O
TNM O
, O
( O
UICC O
, O
classification O
of O
malignant O
tumors O
) O
staging O
and O
axillary O
lymph O
node O
involvement O
or O
with O
estrogen O
, O
progesterone O
, O
and O
glucocorticoid O
receptor O
levels O
. O

Beta B
2 I
- I
M I
serum O
levels O
were O
determined O
by O
an O
enzyme O
- O
linked O
immunosorbent O
assay O
in O
samples O
from O
22 O
of O
the O
above O
women O
. O

Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 O
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta B
2 I
- I
M I
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum O
beta O
2 O
- O
M O
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors O
. O

In O
137 O
cases O
of O
childbearing O
- O
aged O
and O
pregnant O
women O
, O
free O
form O
E O
receptor O
levels O
( O
sE B
) O
in O
serum O
were O
measured O
by O
ELISA O
. O

The O
level O
of O
sE B
was O
significantly O
decreased O
during O
the O
first O
trimester O
, O
slightly O
higher O
in O
the O
second O
trimester O
, O
and O
recovered O
to O
normal O
in O
the O
third O
trimester O
. O

Kappa B
B I
- I
specific I
DNA I
binding I
proteins I
: O
role O
in O
the O
regulation O
of O
human B
interleukin I
- I
2 I
gene I
expression O
. O

Transcriptional O
activation O
of O
the O
human B
interleukin I
- I
2 I
( I
IL I
- I
2 I
) I
gene I
, O
like O
induction O
of O
the O
IL B
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
gene I
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa O
B O
- O
like O
enhancer O
element O
. O

Mutation O
of O
a O
kappa O
B O
core O
sequence O
identified O
in O
the O
IL B
- I
2 I
promoter I
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription B
unit I
and O
blocks O
the O
specific O
binding O
of O
two O
inducible O
cellular O
factors O
. O

These O
kappa O
B O
- O
specific O
proteins O
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B
B I
enhancer I
present O
in O
the O
IL B
- I
2R I
alpha I
promoter I
. O

Novel O
region O
within O
the O
V O
kappa O
gene O
promoter O
is O
responsible O
for O
tissue O
and O
stage O
- O
specific O
expression O
of O
immunoglobulin B
genes I
in O
human O
lymphoid O
neoplasms O
. O

Immunoglobulin O
gene O
- O
specific O
transacting O
factors O
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue O
- O
specific O
expression O
of O
immunoglobulin B
genes I
. O

This O
region O
is O
located O
within O
the O
920 O
bp O
fragment O
located O
210 O
bp O
upstream O
from O
the O
coding O
region O
and O
this O
fragment O
represents O
a O
possible O
novel O
DNA O
region O
, O
which O
plays O
a O
role O
in O
the O
stage O
- O
and O
tissue O
- O
specific O
expression O
of O
immunoglobulin B
genes I
. O

A O
modified O
method O
for O
the O
determination O
of O
glucocorticoid B
receptors I
in O
human O
lymphocytes O
is O
suggested O
. O

Octamer B
- I
binding I
proteins I
from O
B O
or O
HeLa O
cells O
stimulate O
transcription O
of O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
in O
vitro O
. O

The O
B O
- O
cell O
- O
type O
specificity O
of O
the O
immunoglobulin B
( O
Ig B
) O
heavy O
- O
chain O
and O
light O
- O
chain O
promoters O
is O
mediated O
by O
an O
octanucleotide O
( O
OCTA O
) O
element O
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B
polymerase I
II I
promoters I
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

Two O
nuclear B
proteins I
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA O
element O
have O
been O
identified O
. O

Because O
NF O
- O
A1 O
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig O
promoter O
to O
the O
same O
degree O
as O
the O
snRNA O
promoters O
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA O
element O
in O
these O
two O
types O
of O
promoters B
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early O
T O
cell O
activation O
genes O
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T O
cell O
activation O
- O
specific O
enhancer O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

One O
of O
these O
sequences O
forms O
a O
protein O
complex O
, O
NFAT B
- I
1 I
, O
specifically O
with O
nuclear O
extracts O
of O
activated O
T O
cells O
. O

This O
complex O
appeared O
10 O
to O
25 O
minutes O
before O
the O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL B
- I
2 I
gene I
in O
Jurkat O
T O
cells O
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT B
- I
1 I
. O

NFAT B
- I
1 I
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B
terminal I
repeat I
( O
LTR B
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

The O
binding B
site I
for O
this O
complex O
activated O
a O
linked O
promoter O
after O
transfection O
into O
antigen O
receptor O
- O
activated O
T O
cells O
but O
not O
other O
cell O
types O
. O

These O
characteristics O
suggest O
that O
NFAT B
- I
1 I
transmits O
signals O
initiated O
at O
the O
T B
cell I
antigen I
receptor I
. O

Characterization O
of O
thyroid B
hormone I
receptors I
in O
human O
IM O
- O
9 O
lymphocytes O
. O

Although O
putatively O
identified O
more O
than O
10 O
years O
ago O
, O
thyroid B
hormone I
receptors I
in O
human O
tissues O
remain O
poorly O
characterized O
. O

The O
binding B
sites I
were O
extracted O
from O
a O
nuclear O
pellet O
by O
treatment O
with O
0 O
. O
4 O
mol O
/ O
l O
KCl O
and O
sonication O
. O

These O
results O
suggest O
that O
the O
T3 O
binding O
sites O
present O
in O
human O
IM O
- O
9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid B
hormone I
receptors I
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 O
+ O
T O
- O
cell O
gene O
Rpt O
- O
1 O
( O
encoding O
regulatory O
protein O
T O
- O
lymphocyte O
1 O
) O
led O
to O
the O
definition O
of O
a O
silencer O
element O
that O
inhibits O
heterologous B
gene I
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

Functional O
silencer B
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer O
- O
DNA O
- O
protein O
complex O
in O
electrophoretic O
mobility O
shift O
assays O
with O
T O
- O
cell O
extracts O
. O

Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B
class I
II I
antigens I
on O
lymphocytes O
result O
from O
distinct O
mutations O
in O
trans B
- I
acting I
factors I
. O

Coordinate O
regulation O
of O
HLA O
class O
II O
gene O
expression O
during O
development O
and O
coinduction O
of O
class B
II I
genes I
by O
soluble B
factors I
suggests O
that O
common O
trans B
- I
acting I
factor I
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

In O
B O
- O
lymphoblastoid O
cell O
lines O
derived O
from O
two O
independent O
class O
II O
- O
deficient O
bare O
lymphocyte O
syndrome O
patients O
, O
we O
observed O
a O
drastic O
decrease O
in O
transcription O
rates O
of O
the O
class B
II I
genes I
. O

When O
these O
cell O
lines O
are O
fused O
, O
class B
II I
genes I
are O
reexpressed O
, O
indicating O
that O
immunodeficiencies O
in O
bare O
lymphocyte O
syndrome O
patients O
are O
the O
result O
of O
two O
distinct O
mutations O
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2 O
. O
2 O
. O
5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X B
box I
, O
clear O
alterations O
in O
either O
NFX1 O
. O
1 O
or O
NFX1 O
. O
2 O
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

In O
vivo O
responsiveness O
to O
glucocorticoid O
correlated O
with O
glucocorticoid B
receptor I
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

Simultaneous O
measurements O
of O
glucocorticoid B
receptor I
content O
by O
whole O
- O
cell O
assay O
revealed O
that O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
linearly O
correlated O
with O
that O
in O
the O
corresponding O
lymphocytes O
( O
r O
= O
0 O
. O
9482 O
, O
p O
less O
than O
0 O
. O
0001 O
) O
. O

There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
( O
r O
= O
0 O
. O
7239 O
, O
p O
less O
than O
0 O
. O
0007 O
) O
, O
and O
between O
the O
maximum O
decrease O
in O
lymphocytes O
and O
glucocorticoid B
receptor I
content O
in O
lymphocytes O
( O
r O
= O
0 O
. O
7703 O
, O
p O
less O
than O
0 O
. O
0002 O
) O
. O

These O
results O
suggest O
that O
individual O
differences O
are O
preserved O
both O
in O
glucocorticoid O
responsiveness O
and O
in O
glucocorticoid B
receptor I
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
in O
hepatitis O
B O
virus O
carriers O
treated O
with O
interferon B
- I
alpha I
. O

Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
on O
estradiol O
receptors O
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

This O
low O
level O
of O
cytosol O
estradiol O
receptors O
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN B
- I
alpha I
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN B
- I
alpha I
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol O
receptors O
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN B
- I
alpha I
. O

Association O
of O
increased O
lytic O
effector O
cell O
function O
with O
high O
estrogen B
receptor I
levels O
in O
tumor O
- O
bearing O
patients O
with O
breast O
cancer O
. O

Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC O
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol O
/ O
mg O
) O
of O
estrogen B
receptor I
( O
ER B
) O
content O
in O
the O
primary O
tumor O
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O

Thus O
, O
ER B
levels O
greater O
than O
31 O
fmol O
/ O
mg O
might O
be O
associated O
with O
increased O
cytotoxic O
effector O
cell O
function O
in O
tumor O
- O
bearing O
patients O
with O
breast O
cancer O
. O

Properties O
of O
glucocorticoid B
receptors I
in O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphocytes O
from O
patients O
with O
familial O
cortisol O
resistance O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B
receptors I
( O
GR B
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B
in O
both O
patients O
. O

Reduced O
numbers O
and O
normal O
affinity O
of O
GR B
were O
found O
in O
the O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphocytes O
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B
. O

The O
thermal O
stability O
of O
GR B
and O
thermal O
activation O
of O
cytosolic O
receptors O
in O
both O
patients O
were O
found O
to O
be O
normal O
. O

Although O
the O
percentages O
of O
nuclear O
bound O
GR B
were O
similar O
in O
both O
patients O
and O
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear O
bound O
GR B
of O
the O
patients O
were O
about O
one O
- O
half O
that O
of O
normal O
controls O
. O

These O
abnormal O
properties O
of O
GR B
( O
reduced O
numbers O
of O
GR B
) O
were O
preserved O
in O
the O
transformed O
cells O
from O
the O
patients O
. O

Octamer O
transcription O
factors O
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional O
elements O
in O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous O
and O
lymphoid O
- O
cell O
- O
specific O
octamer O
transcription O
factors O
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved O
sequence O
elements O
, O
forming O
either O
homo O
- O
or O
heterodimeric O
complexes O
. O

Binding O
of O
either O
factor O
to O
the O
octamer B
element I
occurred O
independently O
. O

The O
degeneracy O
in O
sequences O
recognized O
by O
the O
OTFs B
may O
be O
important O
in O
widening O
the O
range O
over O
which O
gene O
expression O
can O
be O
modulated O
and O
in O
establishing O
cell O
type O
specificity O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin O
( O
Ig O
) O
heavy O
and O
light O
chain O
genes O
and O
in O
the O
heavy O
chain O
enhancer O
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig B
genes I
in O
B O
cells O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream O
promoter O
or O
enhancer O
element O
in O
a O
variety O
of O
housekeeping B
genes I
such O
as O
the O
histone O
H2B O
and O
U O
snRNA O
genes O
. O

The O
differential O
usage O
of O
this O
regulatory O
sequence O
motif O
is O
thought O
to O
be O
mediated O
by O
different O
species O
of O
octamer B
binding I
proteins I
. O

One O
species O
of O
100 O
kd O
, O
designated O
OTF B
- I
1 I
, O
is O
present O
in O
all O
cell O
types O
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B
factors I
. O

The O
lymphoid O
cell O
specific O
octamer O
binding O
protein O
of O
60 O
kd O
( O
OTF O
- O
2A O
) O
specifically O
stimulates O
Ig O
promoters O
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF O
- O
2B O
( O
but O
not O
OTF O
- O
2A O
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel O
octamer O
factor O
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

Inhibition O
of O
interleukin B
2 I
- O
induced O
proliferation O
of O
cloned O
murine O
T O
cells O
by O
glucocorticoids O
. O

Possible O
involvement O
of O
an O
inhibitory B
protein I
. O

The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin B
2 I
( O
IL B
2 I
) O
- O
induced O
T O
cell O
proliferation O
in O
two O
cytotoxic O
T O
cell O
( O
CTL O
) O
clones O
has O
been O
studied O
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2 O
- O
depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone O
prior O
to O
the O
addition O
of O
IL B
2 I
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B
2 I
. O

No O
significant O
reduction O
in O
the O
number O
and O
affinity O
of O
IL B
2 I
receptors I
was O
seen O
after O
6 O
h O
incubation O
with O
Dx O
. O

The O
order O
of O
potency O
observed O
with O
the O
different O
steroids O
indicated O
that O
this O
inhibitory O
effect O
was O
mediated O
through O
binding O
to O
a O
specific O
glucocorticoid B
receptor I
. O

The O
action O
of O
these O
hormones O
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory B
protein I
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O

Furthermore O
, O
supernatant O
from O
Dx O
- O
treated O
CTL O
contained O
a O
nondialyzable O
factor O
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL O
clones O
induced O
by O
IL B
2 I
. O

Blocking O
of O
IL B
2 I
synthesis O
and O
IL B
2 I
receptor I
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Our O
results O
indicate O
that O
these O
hormones O
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL B
2 I
activity O
. O

Identification O
and O
purification O
of O
a O
human O
immunoglobulin O
- O
enhancer O
- O
binding O
protein O
( O
NF B
- I
kappa I
B I
) O
that O
activates O
transcription O
from O
a O
human O
immunodeficiency O
virus O
type O
1 O
promoter O
in O
vitro O
. O

The O
purified O
NF B
- I
kappa I
B I
has O
been O
identified O
as O
a O
51 O
- O
kDa O
polypeptide O
by O
UV O
- O
crosslinking O
analysis O
. O

` O
` O
Footprint O
' O
' O
and O
methylation O
- O
interference O
analyses O
have O
shown O
that O
purified O
NF B
- I
kappa I
B I
has O
a O
binding O
activity O
specific O
for O
the O
kappa O
light O
chain O
enhancer O
sequence O
. O

The O
number O
of O
glucocorticoid B
receptor I
sites O
in O
lymphocytes O
and O
plasma O
cortisol O
concentrations O
were O
measured O
in O
20 O
patients O
who O
had O
recovered O
from O
major O
depressive O
disorder O
and O
20 O
healthy O
control O
subjects O
. O

The O
number O
of O
glucocorticoid B
receptor I
sites O
in O
lymphocytes O
from O
the O
recovered O
depressed O
group O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O

This O
study O
shows O
that O
the O
reduction O
in O
glucocorticoid B
receptor I
numbers O
which O
occurs O
during O
acute O
depressive O
illness O
does O
not O
persist O
on O
recovery O
and O
is O
, O
therefore O
, O
state O
- O
dependent O
. O

Identification O
and O
purification O
of O
a O
human O
lymphoid O
- O
specific O
octamer O
- O
binding O
protein O
( O
OTF B
- I
2 I
) O
that O
activates O
transcription O
of O
an O
immunoglobulin B
promoter I
in O
vitro O
. O

The O
octamer O
sequence O
5 O
' O
- O
ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream O
element O
in O
a O
variety O
of O
promoters B
and O
also O
occurs O
as O
a O
modular O
enhancer O
element O
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B
genes I
since O
it O
is O
found O
in O
the O
upstream O
regions O
of O
all O
heavy O
and O
light O
chain O
promoters O
and O
in O
the O
heavy O
chain O
enhancer O
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

The O
B B
cell I
factor I
was O
purified O
to O
homogeneity O
using O
affinity O
chromatography O
and O
consists O
of O
three O
peptides O
of O
62 O
, O
61 O
, O
and O
58 O
. O
5 O
+ O
/ O
- O
1 O
. O
5 O
kd O
. O

The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B B
cell I
- I
specific I
factor I
was O
indistinguishable O
from O
that O
of O
the O
affinity O
- O
purified O
ubiquitous O
factor O
. O

This O
B O
cell O
- O
specific O
octamer O
- O
binding O
factor O
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa O
light O
chain O
promoter O
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B B
cell I
- I
specific I
transcription I
factor I
for O
this O
gene O
. O

To O
explain O
the O
end O
- O
organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
mononuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O

The O
patient O
' O
s O
GR B
in O
whole O
cell O
assays O
had O
an O
increased O
dissociation O
constant O
( O
Kd O
) O
. O

DNA B
binding O
of O
the O
GR O
complex O
after O
temperature O
- O
induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O

These O
results O
suggest O
that O
the O
patient O
' O
s O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor O
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR O
complex O
to O
DNA B
. O

Granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage O
growth O
factor O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
. O

The O
regulation O
of O
GM B
- I
CSF I
expression O
is O
seen O
in O
both O
normal O
human O
mitogen O
- O
activated O
T O
lymphocytes O
and O
T O
lymphocytes O
from O
a O
line O
( O
S O
- O
LB1 O
) O
transformed O
with O
human O
T O
cell O
lymphotropic O
virus O
1 O
( O
HTLV O
- O
1 O
) O
. O

Inhibition O
of O
GM B
- I
CSF I
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin B
2 I
regulation O
and O
is O
probably O
mediated O
through O
cellular O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptors O
. O

Altered O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B
receptors I
in O
absence O
of O
cortisol O
: O
a O
proposed O
mechanism O
for O
increased O
thyrotropin O
secretion O
in O
corticosteroid O
deficiency O
states O
. O

Therefore O
, O
a O
possible O
role O
of O
cortisol O
in O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B
receptors I
was O
examined O
at O
the O
level O
of O
circulating O
lymphocytes O
obtained O
from O
patients O
with O
primary O
or O
secondary O
adrenocortical O
failure O
. O

The O
influence O
of O
cortisol O
on O
thyroid B
hormone I
receptors I
discussed O
here O
might O
account O
for O
the O
clinical O
observations O
mentioned O
above O
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase O
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate B
cyclase I
- O
phosphodiesterase O
system O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti O
- O
CBG O
antibody O
are O
compatible O
with O
a O
role O
both O
of O
high O
- O
affinity O
glucocorticoid B
receptors I
and O
of O
CBG O
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

Transfection O
studies O
have O
established O
that O
this O
octamer O
is O
involved O
in O
the O
lymphoid O
- O
specific O
transcription O
of O
immunoglobulin B
genes I
. O

We O
have O
also O
detected O
a O
DNA O
- O
protein O
interaction O
that O
may O
be O
involved O
in O
the O
cell O
- O
type O
specificity O
of O
immunoglobulin B
expression O
, O
and O
we O
have O
determined O
that O
a O
sequence O
upstream O
of O
the O
octamer O
participates O
in O
an O
interaction O
with O
a O
nuclear B
protein I
( O
s O
) O
. O

Preferential O
transcription O
of O
HTLV B
- I
I I
LTR I
in O
cell O
- O
free O
extracts O
of O
human O
T O
cells O
producing O
HTLV O
- O
I O
viral O
proteins O
. O

The O
promoters B
of O
the O
adenovirus O
2 O
major O
late O
gene O
, O
the O
mouse O
beta O
- O
globin O
gene O
, O
the O
mouse O
immunoglobulin O
VH O
gene O
and O
the O
LTR B
of O
the O
human O
T O
- O
lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell O
- O
free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein O
- O
Barr O
virus O
- O
transformed O
human O
B O
cell O
line O
) O
, O
MT O
- O
1 O
( O
HTLV O
- O
I O
- O
infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT O
- O
2 O
( O
HTLV O
- O
I O
- O
infected O
human O

T O
cell O
line O
producing O
viral B
proteins I
) O
. O

LTR B
was O
preferentially O
transcribed O
in O
the O
extracts O
of O
MT O
- O
2 O
although O
the O
other O
three O
genes O
were O
transcribed O
with O
relatively O
constant O
efficiencies O
in O
different O
extracts O
. O

The O
results O
agree O
well O
with O
the O
previous O
in O
vivo O
studies O
on O
the O
promoter O
activity O
of O
HTLV B
- I
I I
LTR I
. O

A O
nuclear B
factor I
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional O
control O
elements O
of O
immunoglobulin B
genes I
. O

Trans B
- I
acting I
factors I
that O
mediate O
B O
- O
cell O
specific O
transcription O
of O
immunoglobulin B
genes I
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin O
gene O
recombinants O
in O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

The O
second O
element B
is O
found O
upstream O
of O
both O
heavy O
and O
kappa O
light O
- O
chain O
gene O
promoters O
. O

We O
have O
sought O
nuclear O
factors O
that O
might O
bind O
specifically O
to O
these O
two O
regulatory B
elements I
by O
application O
of O
a O
modified O
gel O
electrophoresis O
DNA O
binding O
assay O
. O

We O
report O
here O
the O
identification O
of O
a O
human O
B O
- O
cell O
nuclear O
factor O
( O
IgNF O
- O
A O
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream O
regions O
of O
both O
the O
mouse O
heavy O
and O
kappa O
light O
- O
chain O
gene O
promoters O
and O
also O
to O
the O
mouse O
heavy O
- O
chain O
gene O
enhancer O
. O

The O
glucocorticoid O
target O
tissues O
that O
have O
been O
examined O
( O
circulating O
mononuclear O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
) O
have O
normal O
concentrations O
of O
glucocorticoid B
receptors I
with O
decreased O
affinity O
for O
dexamethasone O
. O

Transformation O
of O
B O
- O
lymphocytes O
with O
the O
Epstein O
- O
Barr O
virus O
leads O
to O
glucocorticoid B
receptor I
induction O
that O
is O
less O
than O
that O
observed O
with O
cells O
from O
Old O
World O
primates O
. O

Acetylation O
and O
modulation O
of O
erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
activity O
by O
interaction O
with O
histone B
acetyltransferases I
. O

Erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
is O
a O
red B
cell I
- I
specific I
transcriptional I
activator I
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta O
- O
globin O
expression O
during O
erythroid O
ontogeny O
. O

EKLF B
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta B
- I
like I
globin I
locus I
, O
and O
it O
interacts O
with O
a O
positive B
- I
acting I
factor I
in O
vivo O
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

These O
results O
establish O
EKLF B
as O
a O
tissue B
- I
specific I
transcription I
factor I
that O
undergoes O
post O
- O
translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta O
- O
globin O
expression O
within O
the O
beta B
- I
like I
globin I
cluster I
. O

Recognition O
of O
herpes B
simplex I
virus I
type I
2 I
tegument I
proteins I
by O
CD4 O
T O
cells O
infiltrating O
human O
genital O
herpes O
lesions O
. O

T O
cells O
recognizing O
antigens O
encoded O
within O
map O
units O
0 O
. O
67 O
to O
0 O
. O
73 O
of O
HSV B
DNA I
are O
frequently O
recovered O
from O
herpetic O
lesions O
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

Separate O
epitopes B
in O
VP22 B
were O
defined O
for O
T O
- O
cell O
clones O
from O
each O
of O
three O
patients O
. O

Reactivity O
with O
the O
tegument B
protein I
encoded O
by O
UL21 B
was O
identified O
for O
an O
additional O
patient O
. O

Three O
new O
epitopes O
were O
identified O
in O
VP16 B
, O
a O
tegument B
protein I
associated O
with O
VP22 B
. O

These O
results O
suggest O
that O
herpes B
simplex I
tegument I
proteins I
are O
processed O
for O
antigen O
presentation O
in O
vivo O
and O
are O
possible O
candidate O
compounds O
for O
herpes O
simplex O
vaccines O
. O

Fibrinogen B
activates O
NF B
- I
kappa I
B I
transcription I
factors I
in O
mononuclear O
phagocytes O
. O

Mononuclear O
phagocytes O
are O
exposed O
to O
fibrinous O
provisional O
matrix O
throughout O
migration O
into O
inflammatory O
foci O
, O
so O
this O
study O
was O
undertaken O
to O
determine O
whether O
fibrinogen O
triggers O
activation O
of O
NF B
- I
kappa I
B I
transcription I
factors I
. O

U937 O
cells O
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen B
- I
binding I
integrins I
, O
predominately O
CD11b B
/ I
CD18 I
, O
and O
to O
a O
lesser O
extent O
, O
CD11c B
/ I
CD18 I
. O

Cells O
stimulated O
with O
fibrinogen B
( O
10 O
- O
100 O
microg O
/ O
ml O
) O
/ O
Mn2 O
+ O
( O
50 O
microM O
) O
for O
2 O
h O
were O
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

NF B
- I
kappa I
B I
activation O
, O
minimal O
in O
unstimulated O
cells O
, O
was O
substantially O
up O
- O
regulated O
by O
fibrinogen B
. O

Fibrinogen B
also O
caused O
activation O
of O
AP B
- I
1 I
, O
but O
not O
SP1 B
or O
cAMP B
response I
element I
- I
binding I
protein I
( I
CREB I
) I
factors I
. O

Blocking O
mAbs B
against O
CD18 B
and O
CD11b B
abrogated O
fibrinogen B
- O
induced O
NF B
- I
kappa I
B I
activation O
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 O
cells O
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV B
- I
1 I
enhancer I
( O
bearing O
two O
NF B
- I
kappa I
B I
sites I
) O
coupled O
to O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter I
. O

Cells O
were O
subsequently O
stimulated O
with O
1 O
) O
PMA O
for O
24 O
h O
, O
inducing O
CAT O
activity O
by O
2 O
. O
6 O
- O
fold O
, O
2 O
) O
fibrinogen B
/ O
Mn2 O
+ O
for O
2 O
h O
, O
inducing O
CAT O
activity O
by O
3 O
. O
2 O
- O
fold O
, O
or O
3 O
) O
costimulation O
with O
fibrinogen B
and O
PMA O
, O
inducing O
5 O
. O
7 O
- O
fold O
the O
CAT O
activity O
induced O
by O
PMA O
alone O
. O

We O
conclude O
that O
contact O
with O
fibrinogen O
- O
derived O
proteins O
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

These O
cells O
were O
examined O
for O
ER B
mRNA I
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O

Amplified O
cDNA B
were O
sequenced O
by O
standard O
methods O
. O

RESULTS O
: O
In O
all O
cells O
tested O
, O
ER B
mRNA I
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O

Partial O
sequences O
from O
exons B
1 I
- I
8 I
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B
ER I
mRNA I
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone B
binding I
domain I
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

In O
vitro O
stimulation O
did O
not O
affect O
ER B
mRNA I
expression O
. O

CONCLUSION O
: O
Monocytes O
, O
T O
cells O
, O
and O
B O
cells O
in O
patients O
express O
transcripts O
of O
the O
normal O
wild B
type I
ER I
and O
the O
hormone B
binding I
domain I
variants I
in O
vivo O
. O

DNA O
damaging O
agents O
induce O
expression O
of O
Fas B
ligand I
and O
subsequent O
apoptosis O
in O
T O
lymphocytes O
via O
the O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
. O

Apoptosis O
induced O
by O
DNA O
damage O
and O
other O
stresses O
can O
proceed O
via O
expression O
of O
Fas B
ligand I
( O
FasL B
) O
and O
ligation O
of O
its O
receptor O
, O
Fas O
( O
CD95 O
) O
. O

We O
report O
that O
activation O
of O
the O
two O
transcription O
factors O
NF O
- O
kappa O
B O
and O
AP O
- O
1 O
is O
crucially O
involved O
in O
FasL B
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV O
irradiation O
. O

A O
nondegradable O
mutant O
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

A O
1 O
. O
2 O
kb O
FasL B
promoter I
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 B
Rel I
or O
Fos B
/ I
Jun I
. O

Thus O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
contributes O
to O
stress O
- O
induced O
apoptosis O
via O
the O
expression O
of O
FasL B
. O

A O
small O
, O
nonpeptidyl O
mimic O
of O
granulocyte B
- I
colony I
- I
stimulating I
factor I
[ O
see O
commetns O
] O

A O
nonpeptidyl O
small O
molecule O
SB O
247464 O
, O
capable O
of O
activating O
granulocyte B
- I
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
signal O
transduction O
pathways O
, O
was O
identified O
in O
a O
high O
- O
throughput O
assay O
in O
cultured O
cells O
. O

Like O
G B
- I
CSF I
, O
SB O
247464 O
induced O
tyrosine O
phosphorylation O
of O
multiple B
signaling I
proteins I
and O
stimulated O
primary O
murine O
bone O
marrow O
cells O
to O
form O
granulocytic O
colonies O
in O
vitro O
. O

The O
extracellular O
domain O
of O
the O
murine B
G I
- I
CSF I
receptor I
was O
required O
for O
the O
activity O
of O
SB O
247464 O
, O
suggesting O
that O
the O
compound O
acts O
by O
oligomerizing B
receptor I
chains I
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML B
/ I
RAR I
alpha I
or O
AML1 O
/ O
ETO O
mRNA O
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Here O
we O
studied O
minimal O
residual O
disease O
( O
MRD O
) O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
who O
have O
PML B
/ I
RAR I
alpha I
or O
AML1 B
/ I
ETO I
as O
well O
as O
the O
phenotypic O
analysis O
of O
lymphocyte O
subsets O
involved O
in O
antitumor O
immunity O
. O

Using O
the O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
- O
5 O
) O
to O
10 O
( O
- O
6 O
) O
for O
PML B
/ I
RAR I
alpha I
transcript I
and O
10 O
( O
- O
4 O
) O
to O
10 O
( O
- O
5 O
) O
for O
the O
AML1 B
/ I
ETO I
transcript I
. O

The O
total O
populations O
of O
CD4 B
+ O
, O
CD8 B
+ O
and O
CD56 B
+ O
[ O
possible O
T O
- O
cell O
and O
natural O
killer O
( O
T O
/ O
NK O
) O
populations O
] O
in O
the O
BM O
of O
ST O
patients O
and O
MRD O
+ O
/ O
LT O
patients O
were O
significantly O
( O
p O
< O
. O
01 O
) O
low O
. O

Mycobacterium O
tuberculosis O
mannose O
- O
capped O
lipoarabinomannan O
can O
induce O
NF B
- I
kappaB I
- O
dependent O
activation O
of O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
in O
T O
cells O
. O

These O
experiments O
are O
of O
prime O
importance O
considering O
that O
CD4 B
- O
expressing O
T O
lymphocytes O
represent O
the O
major O
virus O
reservoir O
in O
the O
peripheral O
blood O
of O
infected O
individuals O
. O

Using O
the O
1G5 O
cell O
line O
harbouring O
the O
luciferase O
reporter O
gene O
under O
the O
control O
of O
the O
HIV B
- I
1 I
LTR I
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP O
) O
from O
M O
. O
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV B
- I
1 I
LTR I
- I
dependent I
gene I
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM O
. O

The O
implication O
of O
protein O
tyrosine O
kinase O
( O
s O
) O
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

It O
was O
also O
determined O
, O
using O
electrophoresis O
mobility O
shift O
assays O
, O
that O
M O
. O
tuberculosis O
ManLAM O
led O
to O
the O
nuclear O
translocation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

M O
. O
tuberculosis O
ManLAM O
resulted O
in O
clear O
induction O
of O
the O
luciferase B
gene I
placed O
under O
the O
control O
of O
the O
wild B
- I
type I
, I
but I
not I
the I
kappaB I
- I
mutated I
, I
HIV I
- I
1 I
LTR I
region I
. O

Finally O
, O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
transcription O
was O
found O
to O
be O
independent O
of O
the O
autocrine O
or O
paracrine O
action O
of O
endogenous B
TNF I
- I
alpha I
. O

Human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
quasispecies O
differ O
in O
basal O
transcription O
and O
nuclear O
factor O
recruitment O
in O
human O
glial O
cells O
and O
lymphocytes O
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B
terminal I
repeat I
( O
LTR B
) O
sequence O
diversity O
on O
LTR B
- I
directed I
gene I
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B
from O
proviral O
DNA O
in O
HIV O
- O
1 O
- O
infected O
peripheral O
blood O
. O

Sequence O
analysis O
of O
nineteen O
LTRs B
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI B
LTR I
) O
within O
the O
455 B
- I
bp I
U3 I
region I
. O

Transient O
expression O
analyses O
in O
cells O
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs B
had O
activities O
which O
varied O
significantly O
from O
the O
LAI B
LTR I
in O
U O
- O
373 O
MG O
cells O
( O
an O
astrocytoma O
cell O
line O
) O
as O
well O
as O
in O
Jurkat O
cells O
( O
a O
CD4 O
- O
positive O
lymphocyte O
cell O
line O
) O
. O

While O
LTRs B
which O
demonstrated O
the O
highest O
activities O
in O
U O
- O
373 O
MG O
cells O
also O
yielded O
high O
activities O
in O
Jurkat O
cells O
, O
the O
LTRs B
were O
generally O
more O
active O
in O
Jurkat O
cells O
when O
compared O
to O
the O
LAI B
LTR I
. O

Differences O
in O
LTR B
sequence I
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis B
- I
acting I
sites I
within O
the O
U3 B
region I
of O
the O
LTR B
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating O
transcription O
factor O
/ O
cAMP O
response O
element O
binding O
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR O
function O
and O
transcription O
factor O
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

The O
identification O
of O
the O
mammalian B
sex I
- I
determining I
gene I
Sry I
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG B
box I
' O
) O
transcription B
factors I
that O
control O
developmental O
events O
in O
yeast O
, O
C O
. O
elegans O
, O
Drosophila O
and O
vertebrates O
. O

In O
lymphocyte O
differentiation O
, O
several O
HMG B
box I
proteins I
play O
a O
decisive O
role O
. O

Sox B
- I
4 I
is O
important O
for O
very O
early O
B O
- O
cell O
differentiation O
, O
while O
TCF B
- I
1 I
/ O
LEF B
- I
1 I
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O

TCF B
/ I
LEF I
proteins I
have O
recently O
been O
found O
to O
constitute O
a O
downstream O
component O
of O
the O
Wingless O
/ O
Wnt O
signal O
transduction O
pathway O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF O
/ O
LEF O
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid O
calcium O
binding O
protein O
, O
MRP14 B
, O
was O
investigated O
in O
human O
monocytic O
leukemia O
cell O
lines O
. O

The O
level O
of O
MRP14 B
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
was O
two O
- O
fold O
higher O
than O
that O
in O
THP O
- O
1 O
cells O
. O

Among O
several O
known O
transcription O
factor O
binding O
motifs O
, O
nuclear O
protein O
( O
s O
) O
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT O
/ O
enhancer O
binding O
protein O
( O
C O
/ O
EBP O
) O
- O
binding O
motif O
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 O
gene O
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

An O
antibody O
for O
C B
/ I
EBP I
alpha I
super O
- O
shifted O
the O
nucleoprotein B
complex I
in O
THP O
- O
1 O
cells O
but O
not O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
, O
whereas O
an O
antibody O
for O
C B
/ I
EBP I
beta I
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B
factor I
of O
the O
HL O
- O
60 O
cells O
but O
not O
with O
that O
of O
THP O
- O
1 O
cells O
. O

Thus O
, O
it O
was O
concluded O
that O
C O
/ O
EBP O
alpha O
and O
- O
beta O
were O
able O
to O
bind O
to O
the O
C B
/ I
EBP I
motif I
, O
and O
that O
C B
/ I
EBP I
alpha I
bound O
to O
the O
motif O
in O
THP O
- O
1 O
cells O
and O
C B
/ I
EBP I
beta I
bound O
to O
that O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
. O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C B
/ I
EBP I
motif I
, O
we O
transfected O
several O
constructed O
luciferase O
reporter O
DNAs O
into O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
. O

The O
luciferase O
activity O
of O
the O
C B
/ I
EBP I
motif I
in O
HL O
- O
60 O
cells O
was O
increased O
by O
VD3 O
treatment O
. O

The O
C B
/ I
EBP I
motif I
in O
the O
MRP14 O
gene O
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
by O
the O
assay O
. O

Since O
C B
/ I
EBP I
beta I
was O
also O
detected O
in O
VD3 O
- O
untreated O
HL O
- O
60 O
cells O
by O
immunoblotting O
, O
VD3 O
activated O
C B
/ I
EBP I
beta I
to O
bind O
to O
the O
motif O
, O
probably O
through O
post O
- O
translational O
modification O
. O

The O
clonality O
of O
mature O
peripheral O
blood O
- O
derived O
myeloid O
and O
lymphoid O
cells O
and O
bone O
marrow O
haemopoietic O
progenitors O
from O
18 O
females O
with O
myelodysplasia O
( O
MDS O
) O
( O
five O
refractory O
anaemia O
, O
RA O
; O
one O
RA O
with O
ringed O
sideroblasts O
, O
RARS O
; O
three O
chronic O
myelomonocytic O
leukaemia O
, O
CMML O
; O
four O
RA O
with O
excess O
of O
blasts O
, O
RAEB O
; O
five O
RAEB O
in O
transformation O
, O
RAEB O
- O
t O
) O
was O
studied O
by O
X B
- I
chromosome I
inactivation O
analysis O
. O

X B
- I
chromosome I
inactivation O
patterns O
of O
CD19 O
+ O
B O
cells O
were O
highly O
concordant O
with O
CD3 O
+ O
T O
cells O
except O
for O
two O
patients O
( O
one O
RA O
, O
one O
CMML O
) O
with O
monoclonal O
B O
and O
polyclonal O
T O
lymphocytes O
, O
therefore O
suggesting O
a O
clonal O
mutation O
in O
a O
progenitor O
common O
to O
the O
myeloid O
and O
B O
- O
lymphoid O
lineages O
or O
the O
coexistence O
of O
MDS O
and O
a O
B O
- O
cell O
disorder O
in O
these O
particular O
patients O
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A O
, O
CYP17 O
, O
HSD11L O
( O
11beta O
- O
hydroxysteroid O
dehydrogenase O
I O
) O
, O
HSD17B1 O
( O
17beta O
- O
hydroxysteroid O
dehydrogenase O
type O
I O
) O
and O
SRD5A1 O
( O
5alpha O
- O
reductase O
I O
) O
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B
for O
the O
pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
for O
mutation O
detection O
. O

Pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
( O
PCD B
/ I
DCoH I
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O

In O
addition O
, O
it O
is O
the O
dimerization O
cofactor O
of O
HNF1 B
that O
is O
able O
to O
activate O
the O
transcriptional O
activity O
of O
HNF1 B
. O

The O
transcription B
factor I
, O
NF B
- I
Y I
, O
plays O
a O
critical O
role O
in O
tissue O
- O
specific O
major B
histocompatibility I
complex I
class I
II I
gene I
transcription O
. O

The O
NF O
- O
Y O
complex O
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion O
exchangers O
, O
and O
eluted O
as O
an O
intact O
trimeric O
complex O
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF O
- O
YA O
and O
NF O
- O
YB O
: O
C O
subunit O
fractions O
. O

Recombination O
of O
the O
MPC11 O
plasma O
B O
- O
cell O
derived O
NF O
- O
Y O
A O
: O
B O
: O
C O
complex O
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF O
- O
Y O
- O
associated O
factors O
( O
YAFs O
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact O
trimeric O
complex O
. O

Recombination O
of O
the O
native O
NF O
- O
YA O
: O
B O
: O
C O
complex O
with O
the O
transcriptional O
cofactor O
, O
PC4 B
, O
likewise O
conferred O
high O
affinity O
NF O
- O
Y O
binding O
to O
anion O
exchangers O
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT O
- O
box O
DNA O
motifs O
in O
vitro O
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit O
interaction O
subdomain O
of O
the O
highly O
conserved O
DNA O
binding O
- O
subunit O
interaction O
domain O
( O
DBD B
) O
of O
NF O
- O
YA O
. O

These O
results O
suggest O
that O
in O
class O
II O
+ O
mature O
B O
- O
cells O
NF B
- I
Y I
is O
associated O
with O
the O
protein O
cofactor O
, O
PC4 B
, O
which O
may O
play O
an O
important O
role O
in O
NF O
- O
Y O
- O
mediated O
transcriptional O
control O
of O
class B
II I
genes I
. O

Despite O
extensive O
research O
, O
the O
role O
of O
CD40 B
signaling O
in O
B O
cell O
terminal O
differentiation O
remains O
controversial O
. O

Here O
we O
show O
that O
CD40 B
engagement O
arrests O
B O
cell O
differentiation O
prior O
to O
plasma O
cell O
formation O
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B
or O
cytokines B
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B
/ O
gp39 O
interaction O
. O

At O
100 O
microM O
, O
LA O
did O
not O
but O
LA O
- O
Plus O
inhibited O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
and O
NF B
- I
kappaB I
directed O
IL B
- I
2 I
receptor I
expression O
. O

Both O
LA O
and O
LA O
- O
Plus O
synergised O
with O
selenium O
in O
inhibiting O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
. O

At O
150 O
microM O
LA O
- O
Plus O
, O
but O
not O
LA O
, O
inhibited O
TNFalpha B
induced O
NF B
- I
kappaB I
activation O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG O
repeat O
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active O
X O
chromosome O
with O
a O
methylation O
- O
sensitive O
enzyme O
, O
HpaII O
to O
distinguish O
between O
the O
paternal O
and O
maternal O
alleles O
and O
to O
identify O
their O
methylation O
status O
. O

A O
similar O
response O
was O
induced O
by O
endothelial O
stimulation O
with O
IL B
- I
1beta I
, O
here O
used O
as O
positive O
control O
( O
195 O
+ O
/ O
- O
20 O
cells O
/ O
mm2 O
) O
. O

Functional O
blocking O
of O
E B
- I
selectin I
, O
intercellular O
cell O
adhesion O
molecule O
- O
1 O
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
on O
endothelial O
cells O
with O
the O
corresponding O
mouse O
mAb O
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E B
- I
selectin I
, O
intercellular O
cell O
adhesion O
molecule O
- O
1 O
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
. O

Electrophoretic O
mobility O
shift O
assay O
of O
nuclear O
extracts O
of O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVEC O
) O
exposed O
for O
1 O
h O
to O
30 O
mM O
glucose O
revealed O
an O
intense O
NF B
- I
kB I
activation O
. O

A O
significant O
( O
P O
< O
0 O
. O
01 O
) O
inhibitory O
effect O
on O
glucose O
- O
induced O
leukocyte O
adhesion O
was O
observed O
after O
blocking O
protein B
kinase I
C I
activity O
with O
staurosporine O
( O
5 O
nM O
) O
. O

Sera O
from O
diabetic O
patients O
significantly O
( O
P O
< O
0 O
. O
01 O
) O
enhanced O
leukocyte O
adhesion O
as O
compared O
with O
controls O
, O
despite O
normal O
levels O
of O
IL B
- I
1beta I
and O
TNFalpha B
in O
these O
sera O
. O

These O
data O
indicate O
that O
high O
glucose O
concentration O
and O
hyperglycemia O
promote O
leukocyte O
adhesion O
to O
the O
endothelium O
through O
upregulation O
of O
cell O
surface O
expression O
of O
adhesive O
proteins O
, O
possibly O
depending O
on O
NF B
- I
kB I
activation O
. O

Ikaros B
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc O
finger O
transcription O
factors O
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN O
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B
proteins I
exert O
their O
effects O
in O
development O
. O

Induction O
of O
early O
B O
cell O
factor O
( O
EBF B
) O
and O
multiple O
B O
lineage O
genes O
by O
the O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
E12 B
. O

The O
transcription B
factors I
encoded O
by O
the O
E2A B
and O
early B
B I
cell I
factor I
( O
EBF B
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

We O
report O
the O
identification O
of O
a O
novel O
model O
system O
in O
which O
the O
role O
of O
E2A B
and O
EBF B
in O
the O
regulation O
of O
multiple O
B O
lineage O
traits O
can O
be O
studied O
. O

We O
found O
that O
the O
conversion O
of O
70Z O
/ O
3 O
pre O
- O
B O
lymphocytes O
to O
cells O
with O
a O
macrophage O
- O
like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A B
and O
EBF B
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B
, O
IL7Ralpha O
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Activation O
of O
EBF B
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B
- O
inducible O
traits O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B
induces O
expression O
of O
EBF B
and O
together O
these O
transcription B
factors I
coordinately O
regulate O
numerous O
B O
lineage O
- O
associated O
genes O
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B
' I
end I
of O
this O
RNA B
as O
human O
retinoid O
receptor O
RXRalpha O
mRNA O
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3 O
. O
6 O
kilobases O
of O
this O
RNA O
, O
which O
represents O
the O
3 B
' I
end I
of O
RXRalpha O
mRNA O
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Important O
in O
the O
development O
of O
HIV O
- O
associated O
NHL O
are O
cytokines B
and O
other O
factors O
that O
induce O
B O
- O
cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c B
- I
myc I
, O
bcl B
- I
6 I
, O
and O
other O
tumor B
- I
suppressor I
genes I
with O
carcinogenic O
potential O
. O

Matrix O
metalloproteinase O
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin O
D O
, O
type O
IV O
collagen O
, O
laminin O
, O
fibronectin B
, O
EGFR B
, O
c O
- O
erbB O
- O
2 O
oncoprotein O
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix O
metalloproteinase O
3 O
( O
MMP O
- O
3 O
, O
stromelysin O
- O
1 O
) O
in O
correlation O
with O
the O
expression O
of O
Basement O
Membrane O
( O
BM O
) O
antigen O
( O
type O
IV O
collagen O
, O
laminin O
) O
, O
fibronectin B
, O
cathepsin O
D O
, O
p53 B
, O
c O
- O
erbB O
- O
2 O
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 O
expression O
, O
and O
p53 B
tumour O
suppressor O
gene O
product O
( O
p O
= O
0 O
. O
004 O
) O
, O
and O
a O
relationship O
with O
c O
- O
erbB O
- O
2 O
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

There O
is O
increased O
activity O
of O
the O
proinflammatory B
cytokine I
, O
tumor B
necrosis I
factor I
( O
TNF B
) O
in O
alcoholic O
liver O
disease O
( O
ALD O
) O
. O

TNF B
can O
induce O
cellular O
oxidative O
injury O
directly O
, O
and O
indirectly O
by O
inducing O
neutrophil O
chemotactic O
factor O
( O
IL B
- I
8 I
) O
production O
by O
hepatocytes O
. O

IL B
- I
8 I
activates O
and O
chemotactically O
attracts O
neutrophils O
to O
the O
liver O
where O
they O
release O
oxidizing O
substances O
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious O
factor O
( O
IL B
- I
8 I
) O
and O
a O
protective O
factor O
( O
MnSOD O
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

Inactivation O
of O
the O
NF O
- O
kappaB O
and O
3 O
' O
NF O
- O
IL O
- O
6 O
DNA O
binding O
sites O
decreased O
IL B
- I
8 I
gene I
transcriptional O
activation O
in O
response O
to O
TNF B
while O
inactivation O
of O
the O
5 O
' O
NF O
- O
IL O
- O
6 O
binding O
site O
increased O
IL B
- I
8 I
gene I
transcriptional O
activity O
in O
response O
to O
TNF B
. O

This O
system O
may O
be O
useful O
to O
assess O
the O
effects O
of O
ethanol O
on O
TNF B
- O
induced O
hepatocyte O
IL B
- I
8 I
production O
. O

Both O
TNF B
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD O
activity O
in O
short O
- O
term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

However O
, O
after O
long O
- O
term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD O
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD O
in O
response O
to O
TNF B
. O

Tissue O
factor O
transcription O
driven O
by O
Egr B
- I
1 I
is O
a O
critical O
mechanism O
of O
murine O
pulmonary O
fibrin O
deposition O
in O
hypoxia O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B
deposition O
is O
a O
result O
of O
expression O
of O
tissue B
factor I
, O
especially O
in O
oxygen O
- O
deprived O
mononuclear O
phagocytes O
( O
MPs O
) O
. O

We O
now O
show O
that O
transcription O
factor O
early O
- O
growth O
- O
response O
gene O
product O
( O
Egr B
- I
1 I
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue B
factor I
in O
hypoxic O
lung O
. O

Using O
32P O
- O
labeled O
Egr O
consensus O
oligonucleotide O
, O
we O
observed O
induction O
of O
DNA O
- O
binding O
activity O
in O
nuclear O
extracts O
from O
hypoxic O
lung O
and O
HeLa O
cells O
because O
of O
activation O
of O
Egr B
- I
1 I
, O
by O
means O
of O
supershift O
analysis O
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen O
deprivation O
expressed O
tissue O
factor O
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia O
- O
induced O
fibrin B
deposition O
, O
in O
which O
oxygen O
deprivation O
- O
induced O
activation O
of O
Egr B
- I
1 I
, O
resulting O
in O
expression O
of O
tissue B
factor I
, O
has O
an O
unexpected O
and O
central O
role O
. O

Kinetics O
of O
cytokine O
and O
NFAT O
gene O
expression O
in O
human O
interleukin O
- O
2 O
- O
dependent O
T O
lymphoblasts O
stimulated O
via O
T B
- I
cell I
receptor I
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood O
- O
derived O
T O
lymphoblasts O
stimulated O
with O
anti B
- I
CD3 I
antibodies I
or O
Lens O
culinaris O
lectin O
( O
LCL O
) O
. O

T O
cells O
were O
purified O
from O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
primarily O
activated O
with O
anti B
- I
CD3 I
antibodies I
and O
cultured O
in O
the O
presence O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL O
- O
4 O
and O
IL O
- O
10 O
transcripts O
and O
proteins O
. O

No O
IL B
- I
6 I
gene I
expression O
was O
observed O
. O

Steady O
- O
state O
mRNA O
levels O
of O
IL B
- I
2 I
, O
IL B
- I
10 I
and O
IFN B
- I
gamma I
peaked O
at O
3 O
hr O
after O
anti O
- O
CD3 O
stimulation O
and O
declined O
rapidly O
thereafter O
. O

The O
kinetics O
of O
TNF B
- I
alpha I
mRNA I
expression O
was O
faster O
, O
being O
at O
its O
peak O
level O
1 O
hr O
after O
stimulation O
. O

Anti O
- O
CD3 O
- O
stimulated O
IL B
- I
2 I
gene I
expression O
was O
down O
- O
regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL O
- O
10 O
, O
IFN O
- O
gamma O
and O
TNF O
- O
alpha O
genes O
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O

T B
- I
cell I
receptor I
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c O
- O
jun O
, O
c O
- O
fos O
and O
NFATc1 O
( O
NFATc O
) O
genes O
, O
the O
gene O
products O
of O
which O
are O
involved O
in O
cytokine O
gene O
expression O
. O

In O
conclusion O
, O
the O
cytokines B
synthesized O
by O
IL O
- O
2 O
- O
dependent O
T O
cells O
were O
predominantly O
IL B
- I
2 I
, O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
. O

Within O
6 O
hours O
, O
an O
accumulation O
of O
apolipoprotein O
B O
and O
epitopes B
present O
on O
oxLDL O
are O
detected O
in O
the O
arterial O
endothelium O
and O
media O
. O

The O
presence O
of O
oxLDL O
is O
associated O
with O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 O
gene O
was O
activated O
by O
HTLV O
- O
I O
Tax B
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 O
is O
induced O
by O
Tax B
. O

Sequence O
analysis O
demonstrated O
that O
two O
NF O
- O
kappaB O
- O
like O
elements O
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory B
region I
. O

Both O
NF O
- O
kappaB O
- O
like O
elements O
were O
able O
to O
bind O
to O
NF B
- I
kappaB I
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax B
- O
dependent O
manner O
. O

Chloramphenicol B
acetyltransferase I
assays O
indicated O
that O
NF O
- O
kappaB O
- O
like O
element O
1 O
was O
Tax B
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B
promoter I
. O

NF B
- I
kappaB I
- O
like O
element O
2 O
elevated O
promoter O
activity O
when O
combined O
with O
NF O
- O
kappaB O
- O
like O
element O
1 O
, O
indicating O
cooperative O
function O
of O
the O
elements O
for O
maximum O
promoter O
function O
. O

Unlike O
typical O
NF O
- O
kappaB O
elements O
, O
the O
NF O
- O
kappaB O
- O
like O
elements O
in O
gp34 O
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF B
- I
kappaB I
- O
like O
binding O
activity O
. O

Chloramphenicol B
acetyltransferase I
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF O
- O
kappaB O
- O
like O
elements O
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate O
and O
noncognate O
core O
promoters O
in O
a O
Tax O
- O
independent O
manner O
. O

beta O
- O
Amyloid O
fibrils O
activate O
parallel O
mitogen B
- I
activated I
protein I
kinase I
pathways O
in O
microglia O
and O
THP1 O
monocytes O
. O

The O
senile O
plaques O
of O
Alzheimer O
' O
s O
disease O
are O
foci O
of O
local O
inflammatory O
responses O
, O
as O
evidenced O
by O
the O
presence O
of O
acute B
phase I
proteins I
and O
oxidative O
damage O
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar O
Abeta O
results O
in O
the O
tyrosine B
kinase I
- O
dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
superfamily O
. O

Abeta O
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular O
signal O
- O
regulated O
kinase O
1 O
( O
ERK1 B
) O
and O
ERK2 B
in O
microglia O
and O
ERK2 B
in O
THP1 O
monocytes O
. O

A O
second O
superfamily O
member O
, O
p38 B
MAPK I
, O
was O
also O
activated O
with O
similar O
kinetics O
. O

Scavenger O
receptor O
and O
receptor O
for O
advanced O
glycated O
end O
products O
( O
RAGE O
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger O
receptors O
and O
RAGE O
are O
not O
linked O
to O
these O
pathways O
. O

Importantly O
, O
the O
stress B
- I
activated I
protein I
kinases I
( O
SAPKs B
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta O
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP O
kinases O
, O
such O
as O
RSK1 O
and O
RSK2 O
, O
as O
well O
as O
transcription B
factors I
. O

Exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta O
resulted O
in O
the O
activation O
of O
RSK1 O
and O
RSK2 O
and O
phosphorylation O
of O
cAMP B
response I
element I
- I
binding I
protein I
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta O
- O
induced O
changes O
in O
gene O
expression O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP O
II O
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS O
, O
IL B
- I
4 I
, O
and O
GM B
- I
CSF I
. O

Transcription O
factor O
B O
- O
cell O
- O
specific O
activator O
protein O
( O
BSAP B
) O
is O
differentially O
expressed O
in O
B O
cells O
and O
in O
subsets O
of O
B O
- O
cell O
lymphomas O
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

Despite O
its O
known O
involvement O
in O
a O
rare O
subtype O
of O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
NHL O
) O
, O
a O
detailed O
examination O
of O
BSAP B
expression O
in O
NHL O
has O
not O
been O
previously O
reported O
. O

Normal O
lymphoid O
tissues O
showed O
strong O
nuclear O
BSAP B
expression O
in O
mantle O
zone O
B O
cells O
, O
less O
intense O
reactivity O
in O
follicular O
center O
B O
cells O
, O
and O
no O
expression O
in O
cells O
of O
the O
T O
- O
cell O
- O
rich O
zones O
. O

Of O
the O
102 O
B O
- O
cell O
NHLs O
, O
83 O
( O
81 O
% O
) O
demonstrated O
BSAP B
expression O
. O

Eight O
of O
12 O
( O
67 O
% O
) O
marginal O
zone O
lymphoma O
cases O
showed O
negative O
or O
low O
BSAP B
levels O
, O
and O
17 O
of O
24 O
( O
71 O
% O
) O
large O
B O
- O
cell O
lymphomas O
displayed O
moderate O
to O
strong O
expression O
. O

None O
of O
the O
23 O
T O
- O
and O
null O
- O
cell O
lymphomas O
reacted O
with O
the O
BSAP B
antisera O
, O
whereas O
in O
Hodgkin O
' O
s O
disease O
, O
2 O
of O
4 O
( O
50 O
% O
) O
nodular O
lymphocytic O
predominance O
and O
5 O
of O
14 O
( O
36 O
% O
) O
classical O
cases O
showed O
weak O
nuclear O
or O
nucleolar O
BSAP B
reactions O
in O
a O
fraction O
of O
the O
tumor O
cells O
. O

Western O
blot O
analysis O
showed O
a O
52 O
- O
kD O
BSAP B
band O
in O
B O
- O
cell O
lines O
, O
but O
not O
in O
non O
- O
B O
- O
cell O
or O
plasma O
cell O
lines O
. O

We O
conclude O
that O
BSAP B
expression O
is O
largely O
restricted O
to O
lymphomas O
of O
B O
- O
cell O
lineage O
and O
that O
BSAP B
expression O
varies O
in O
B O
- O
cell O
subsets O
and O
subtypes O
of O
B O
- O
cell O
NHL O
. O

The O
high O
levels O
of O
BSAP B
, O
especially O
those O
found O
in O
large O
- O
cell O
lymphomas O
and O
in O
some O
follicular O
lymphomas O
, O
may O
be O
a O
consequence O
of O
deregulated O
gene O
expression O
and O
suggest O
a O
possible O
involvement O
of O
PAX B
- I
5 I
in O
certain O
B O
- O
cell O
malignancies O
. O

A O
monoclonal B
antibody I
against O
human O
STAT6 O
recognizes O
an O
approximately O
100 O
kDa O
molecule O
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating O
cell O
nuclear O
antigen O
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA O
polymerase O
delta O
. O

PCNA B
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE O
sequences O
in O
the O
promoter O
and O
CRE O
binding O
proteins O
; O
IL B
- I
2 I
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

L2 O
and O
L2 O
variant O
cells O
were O
tested O
for O
IL B
- I
2 I
responsiveness O
and O
rapamycin O
sensitivity O
with O
respect O
to O
specific O
kinase O
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
cells O
, O
IL B
- I
2 I
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP O
- O
independent O
CREB B
kinase I
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
variant O
cells O
, O
CREB B
kinase I
activity O
was O
constitutively O
high O
; O
IL B
- I
2 I
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O

These O
results O
indicate O
that O
IL B
- I
2 I
induces O
a O
rapamycin O
- O
sensitive O
, O
cAMP O
- O
independent O
CREB B
kinase I
activity O
in O
L2 O
cells O
. O

However O
, O
phosphorylation O
of O
CREB B
alone O
is O
not O
sufficient O
to O
drive O
PCNA B
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL B
- I
2 I
. O

Serotonin O
derivative O
, O
N O
- O
( O
p O
- O
coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
by O
endotoxin O
- O
stimulated O
human O
blood O
monocytes O
. O

As O
reactive O
oxygen O
species O
( O
ROS O
) O
are O
implicated O
in O
the O
signaling O
of O
lipopolysaccharide O
( O
LPS O
) O
, O
we O
examined O
whether O
CS O
has O
a O
suppressive O
effect O
on O
inflammatory B
cytokine I
generation O
from O
human O
monocyte O
s O
in O
vitro O
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
was O
inhibited O
by O
CS O
. O

Northern O
blot O
analysis O
showed O
that O
LPS O
- O
induced O
expression O
of O
these O
cytokine B
mRNA I
in O
monocytes O
was O
suppressed O
by O
CS O
. O

These O
findings O
indicate O
that O
CS O
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes O
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine B
mRNA I
expression O
through O
inhibition O
of O
NF B
- I
kappaB I
activation O
. O

Differentiation O
inhibitory O
factor O
nm23 B
gene I
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
especially O
in O
acute O
monocytic O
leukemia O
( O
AML O
- O
M5 O
) O
and O
is O
suggested O
as O
a O
new O
prognostic O
factor O
in O
AML O
- O
M5 O
. O

The O
mRNA O
level O
of O
nm23 B
- I
H2 I
was O
slightly O
below O
the O
normal O
level O
. O

These O
findings O
are O
compatible O
with O
our O
previous O
report O
that O
nm23 B
gene I
is O
overexpressed O
in O
monocytic O
leukemia O
. O

In O
our O
TK6i O
- O
G3 O
and O
G9 O
tk O
heterozygous O
cell O
lines O
, O
the O
active O
tk O
allele O
is O
linked O
to O
an O
inducible O
promoter B
element I
. O

Mutation O
of O
BCL B
- I
6 I
gene I
in O
normal O
B O
cells O
by O
the O
process O
of O
somatic O
hypermutation O
of O
Ig B
genes I
. O

Significant O
mutations O
were O
not O
observed O
in O
c O
- O
MYC O
, O
S14 O
, O
or O
alpha O
- O
fetoprotein O
( O
AFP O
) O
genes O
, O
but O
BCL B
- I
6 I
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B O
cells O
of O
normal O
individuals O
. O

The O
mutation O
pattern O
was O
similar O
to O
that O
of O
Ig B
genes I
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti O
- O
CD3 O
plus O
anti O
- O
CD28 O
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF B
- I
kappaB I
DNA O
binding O
in O
CD45RA O
+ O
cells O
than O
in O
CD45RO O
+ O
cells O
. O

Analysis O
of O
the O
nuclear O
c O
- O
Rel O
protein O
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

Analysis O
of O
the O
cytoplasmic B
inhibitor I
IkappaBalpha B
indicated O
that O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
induced O
a O
long O
- O
lasting O
degradation O
in O
CD45RA O
+ O
cells O
but O
in O
CD45RO O
+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Because O
the O
CD28 B
costimulus O
is O
known O
to O
induce O
the O
production O
of O
reactive O
oxygen O
intermediates O
( O
ROIs O
) O
, O
the O
intracellular O
ROI O
levels O
in O
CD45RA O
+ O
and O
CD45RO O
+ O
cells O
were O
compared O
by O
flow O
cytometry O
. O

Lymphoma O
cells O
from O
both O
cases O
showed O
the O
mature O
B O
- O
cell O
immunophenotype O
and O
had O
rearrangements O
of O
the O
BCL6 B
gene I
. O

A O
family O
of O
hematopoietic B
specific I
transcription I
factors I
, O
MIP O
- O
1 O
alpha O
nuclear O
protein O
( O
MNP O
) O
family O
, O
has O
recently O
been O
identified O
. O

One O
member O
of O
the O
family O
( O
MNP B
- I
1 I
) O
is O
essential O
for O
promoter O
activity O
in O
monocytes O
and O
B O
- O
cells O
, O
while O
another O
( O
MNP B
- I
2 I
) O
is O
required O
for O
full O
promotor O
activity O
in O
T O
- O
cells O
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP B
- I
1 I
and O
MNP B
- I
2 I
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP B
- I
1 I
acts O
as O
a O
heterodimer B
. O

Bcl B
- I
3 I
expression O
and O
nuclear O
translocation O
are O
induced O
by O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
erythropoietin B
in O
proliferating O
human O
erythroid O
precursors O
. O

Bcl B
- I
3 I
is O
a O
proto B
- I
oncogene I
involved O
in O
the O
chromosomal O
translocation O
t O
( O
14 O
; O
19 O
) O
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

In O
this O
report O
, O
involvement O
of O
Bcl B
- I
3 I
in O
hematopoietic O
growth O
factor O
- O
stimulated O
erythroid O
proliferation O
and O
differentiation O
was O
examined O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

Bcl B
- I
3 I
protein O
was O
also O
highly O
expressed O
in O
early O
burst O
- O
forming O
unit O
- O
erythroid O
( O
BFU O
- O
E O
) O
- O
derived O
erythroid O
precursors O
( O
day O
7 O
) O
and O
decreased O
during O
maturation O
( O
days O
10 O
and O
14 O
) O
, O
suggesting O
that O
Bcl B
- I
3 I
is O
involved O
in O
normal O
erythroid O
proliferation O
. O

In O
these O
hematopoietic O
cells O
, O
Bcl B
- I
3 I
was O
hyperphosphorylated O
. O

GM B
- I
CSF I
and O
Epo B
modulated O
the O
subcellular O
localization O
of O
Bcl B
- I
3 I
. O

Upon O
stimulation O
of O
TF O
- O
1 O
cells O
with O
GM B
- I
CSF I
or O
Epo B
, O
the O
nuclear O
translocation O
of O
Bcl B
- I
3 I
was O
dramatically O
enhanced O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF O
- O
kappaB O
factors O
p50 O
or O
p52 O
resulted O
in O
significant O
induction O
of O
an O
human O
immunodeficiency O
virus O
- O
type O
1 O
( O
HIV O
- O
1 O
) O
kappaB O
- O
TATA O
- O
luceriferase O
reporter O
plasmid O
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB O
- O
containing O
genes O
in O
erythroid O
cells O
. O

Stimulation O
with O
GM B
- I
CSF I
enhanced O
c B
- I
myb I
mRNA I
expression O
in O
these O
cells O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB O
enhancer O
in O
the O
c O
- O
myb O
promoter O
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

Furthermore O
, O
cotransfection O
of O
Bcl B
- I
3 I
with O
p52 B
or O
p50 B
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c O
- O
myb O
kappaB O
- O
TATA O
- O
luceriferase O
reporter O
plasmid O
. O

These O
findings O
suggest O
that O
Bcl B
- I
3 I
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB O
- O
containing O
genes O
involved O
in O
hematopoiesis O
, O
including O
c B
- I
myb I
. O

5 B
- I
Lipoxygenase I
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal O
bipartite O
nuclear O
localizing O
sequence O
and O
nuclear O
factor O
kappa O
B O
complex O
formation O
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi O
fibroblast O
growth O
factor O
signal O
sequence O
fused O
to O
the O
5 O
- O
lipoxygenase639 O
- O
656 O
bipartite O
nuclear O
localizing O
sequence O
has O
a O
prominent O
inhibitory O
effect O
on O
5 B
- I
lipoxygenase I
catalysis O
in O
granulocytic O
HL O
- O
60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

Recombinant O
5 B
- I
lipoxygenase I
was O
not O
affected O
by O
the O
peptide O
. O

The O
peptide O
also O
inhibited O
redistribution O
of O
5 B
- I
lipoxygenase I
from O
the O
cytosol O
to O
the O
nuclear O
membrane O
of O
HL O
- O
60 O
cells O
stimulated O
by O
A23187 O
. O

In O
cells O
treated O
with O
agents O
that O
block O
5 B
- I
lipoxygenase I
translocation O
to O
the O
nucleus O
, O
5 B
- I
lipoxygenase I
protein O
appearing O
in O
the O
NF B
- I
kappaB I
immunoprecipitate O
was O
diminished O
. O

Our O
results O
implicate O
an O
internal O
bipartite O
nuclear O
localizing O
sequence O
as O
a O
regulatory O
domain O
that O
modulates O
5 B
- I
lipoxygenase I
redistribution O
and O
catalysis O
in O
granulocytic O
cells O
. O

Inhibition O
of O
CD28 O
/ O
CD3 O
- O
mediated O
costimulation O
of O
naive O
and O
memory O
human O
T O
lymphocytes O
by O
intracellular O
incorporation O
of O
polyclonal B
antibodies I
specific O
for O
the O
activator O
protein O
- O
1 O
transcriptional O
complex O
. O

A O
number O
of O
indirect O
methods O
have O
been O
utilized O
in O
demonstrating O
activator B
protein I
- I
1 I
transcription O
factor O
function O
in O
IL O
- O
2 O
promoter O
activity O
. O

However O
, O
there O
has O
been O
no O
direct O
demonstration O
that O
activator B
protein I
- I
1 I
is O
involved O
in O
CD28 O
- O
dependent O
costimulation O
of O
IL B
- I
2 I
gene I
transcription O
in O
freshly O
isolated O
naive O
and O
memory O
human O
T O
lymphocytes O
. O

T O
cells O
retained O
their O
physical O
parameters O
as O
measured O
by O
forward O
and O
side O
light O
scatter O
, O
and O
functional O
activity O
as O
measured O
by O
costimulation O
of O
proliferation O
and O
IL B
- I
2 I
production O
after O
being O
scraped O
off O
this O
substrate O
. O

CD28 O
/ O
CD3 O
- O
costimulated O
T O
cells O
produced O
intracellular O
IL B
- I
2 I
from O
all O
subsets O
measured O
( O
CD4 O
+ O
, O
CD4 O
- O
, O
CD45RO O
+ O
, O
and O
CD45RO O
- O
) O
. O

IL B
- I
2 I
production O
and O
intracellular O
accumulation O
in O
nonscraped O
PB O
- O
T O
cells O
activated O
with O
CD28 O
/ O
CD3 O
coligation O
were O
skewed O
favoring O
CD45RO O
+ O
and O
CD4 O
+ O
subsets O
, O
as O
was O
IL B
- I
2 I
production O
in O
scraped O
PB O
- O
T O
cells O
. O

The O
intracellular O
incorporation O
of O
Abs O
specific O
for O
c O
- O
Fos O
and O
c O
- O
Jun O
family O
members O
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL B
- I
2 I
within O
6 O
h O
of O
costimulation O
with O
PMA O
/ O
ionomycin O
, O
or O
costimulation O
by O
CD28 O
and O
CD3 O
ligation O
. O

Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c B
- I
Fos I
and O
c B
- I
Jun I
are O
involved O
in O
transcription O
of O
the O
IL B
- I
2 I
gene I
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human O
T O
lymphocyte O
subpopulations O
. O

Differential O
expression O
of O
Nur77 O
family O
members O
in O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
- O
infected O
cells O
: O
transactivation O
of O
the O
TR3 O
/ O
nur77 O
gene O
by O
Tax B
protein I
. O

We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 O
transcription O
factor O
family O
by O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax B
transactivation O
of O
the O
TR3 O
/ O
nur77 O
promoter O
but O
not O
the O
NOR O
- O
1 O
promoter O
in O
different O
cell O
types O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B
reporter I
gene I
driven O
by O
the O
NGFI O
- O
B O
( O
rat O
homolog O
of O
TR3 O
/ O
Nur77 O
) O
response O
element O
( O
NBRE O
) O
provided O
evidence O
that O
Tax B
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Cotransfection O
assays O
with O
the O
TR3 O
/ O
nur77 O
promoter O
sequence O
or O
the O
NBRE O
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 O
/ O
nur77 O
expression O
is O
mediated O
by O
CREB O
/ O
ATF O
- O
related O
transcription O
factors O
. O

In O
response O
to O
stress O
, O
heat B
shock I
factor I
1 I
( O
HSF1 B
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non O
- O
DNA O
- O
binding O
monomer O
to O
active O
functional O
trimers O
. O

We O
have O
used O
the O
hydrophobic O
repeats O
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat O
shock O
factor O
binding O
protein O
1 O
( O
HSBP1 O
) O
, O
a O
novel O
, O
conserved O
, O
76 O
- O
amino O
- O
acid O
protein O
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats O
that O
interact O
with O
the O
HSF1 O
heptad O
repeats O
. O

HSBP1 O
is O
nuclear O
- O
localized O
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 B
that O
appears O
during O
heat O
shock O
. O

During O
attenuation O
of O
HSF1 B
to O
the O
inert O
monomer O
, O
HSBP1 O
associates O
with O
Hsp70 O
. O

HSBP1 O
negatively O
affects O
HSF1 B
DNA O
- O
binding O
activity O
, O
and O
overexpression O
of O
HSBP1 O
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B
. O

These O
studies O
have O
begun O
to O
elucidate O
the O
basis O
for O
cell O
- O
specificity O
and O
high O
- O
level O
expression O
of O
cytokine B
genes I
. O

A O
signaling O
complex O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
and O
protein B
phosphatase I
2A I
[ O
see O
comments O
] O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear O
enzyme O
that O
can O
phosphorylate O
and O
activate O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
response O
element O
- O
binding O
protein O
( O
CREB B
) O
. O

However O
, O
inactivation O
of O
CaMKIV B
occurs O
despite O
the O
sustained O
increase O
in O
[ O
Ca2 O
+ O
] O
i O
that O
is O
required O
for O
T O
cell O
activation O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B
with O
protein O
serine O
- O
threonine O
phosphatase O
2A O
( O
PP2A B
) O
was O
identified O
in O
which O
PP2A B
dephosphorylates O
CaMKIV B
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B
signaling O
. O

In O
Jurkat O
T O
cells O
, O
inhibition O
of O
PP2A B
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB B
- O
mediated O
transcription O
by O
CaMKIV B
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein O
serine O
- O
threonine O
kinase O
( O
CaMKIV B
) O
is O
regulated O
by O
a O
tightly O
associated O
protein O
serine O
- O
threonine O
phosphatase O
( O
PP2A B
) O
. O

Hypoxia O
down O
- O
regulates O
MCP B
- I
1 I
expression O
: O
implications O
for O
macrophage O
distribution O
in O
tumors O
. O

Monocyte B
chemoattractant I
protein I
1 I
( O
MCP B
- I
1 I
) O
is O
likely O
to O
contribute O
to O
the O
macrophage O
infiltrate O
in O
human O
ovarian O
carcinomas O
. O

Although O
MCP B
- I
1 I
is O
predominantly O
expressed O
by O
the O
tumor O
parenchyma O
, O
macrophages O
accumulate O
at O
highest O
density O
in O
necrotic O
regions O
, O
which O
are O
associated O
with O
low O
oxygen O
tensions O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
can O
stimulate O
MCP B
- I
1 I
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O

We O
have O
investigated O
the O
effect O
of O
hypoxia O
both O
on O
MCP B
- I
1 I
expression O
in O
ovarian O
cancer O
cell O
lines O
and O
monocyte O
migration O
. O

Monocyte O
migration O
in O
response O
to O
MCP B
- I
1 I
was O
also O
diminished O
under O
hypoxic O
conditions O
. O

Down O
- O
regulation O
of O
MCP B
- I
1 I
expression O
and O
the O
inhibition O
of O
monocyte O
migration O
are O
independent O
effects O
of O
hypoxia O
that O
may O
contribute O
to O
the O
distribution O
of O
macrophages O
within O
ovarian O
tumors O
. O

Activation O
of O
nuclear B
factor I
kappa I
B I
inflammatory O
bowel O
disease O
[ O
see O
comments O
] O

BACKGROUND O
: O
Expression O
of O
pro B
- I
inflammatory I
cytokines I
is O
increased O
in O
the O
intestinal O
lamina O
propria O
of O
patients O
with O
inflammatory O
bowel O
disease O
( O
IBD O
) O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
controls O
transcription O
of O
inflammation O
genes O
. O

On O
activation O
, O
NF B
kappa I
B I
is O
rapidly O
released O
from O
its O
cytoplasmic B
inhibitor I
( O
I B
kappa I
B I
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B
response I
elements I
in O
gene O
promoter O
regions O
. O

AIMS O
: O
To O
investigate O
whether O
increased O
activation O
of O
NF B
kappa I
B I
is O
important O
in O
IBD O
and O
may O
be O
down O
- O
regulated O
by O
anti O
- O
inflammatory O
treatment O
. O

METHODS O
: O
Activation O
of O
NF B
kappa I
B I
was O
determined O
by O
western O
blot O
assessment O
and O
electrophoretic O
mobility O
shift O
assay O
in O
nuclear O
extracts O
of O
colonic O
biopsy O
samples O
as O
well O
as O
lamina O
propria O
mononuclear O
cells O
. O

RESULTS O
: O
Nuclear O
levels O
of O
NF B
kappa I
B I
p65 B
are O
increased O
in O
lamina O
propria O
biopsy O
specimens O
from O
patients O
with O
Crohn O
' O
s O
disease O
in O
comparison O
with O
patients O
with O
ulcerative O
colitis O
and O
controls O
. O

Increased O
activation O
of O
NF B
kappa I
B I
was O
detected O
in O
lamina O
propria O
mononuclear O
cells O
from O
patients O
with O
active O
IBD O
. O

Corticosteroids O
strongly O
inhibit O
intestinal O
NF B
kappa I
B I
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic B
inhibitor I
I B
kappa I
B I
alpha O
against O
activation O
induced O
degradation O
. O

CONCLUSIONS O
: O
In O
both O
IBDs O
, O
but O
particularly O
Crohn O
' O
s O
disease O
, O
increased O
activation O
of O
NF B
kappa I
B I
may O
be O
involved O
in O
the O
regulation O
of O
the O
inflammatory O
response O
. O

Inhibition O
of O
NF B
kappa I
B I
activation O
may O
represent O
a O
mechanism O
by O
which O
steroids O
exert O
an O
anti O
- O
inflammatory O
effect O
in O
IBD O

Insufficient O
glycemic O
control O
increases O
nuclear B
factor I
- I
kappa I
B I
binding O
activity O
in O
peripheral O
blood O
mononuclear O
cells O
isolated O
from O
patients O
with O
type O
1 O
diabetes O
. O

OBJECTIVE O
: O
The O
redox O
- O
sensitive O
transcription O
factor O
nuclear O
factor O
- O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O

It O
is O
unknown O
whether O
NF B
- I
kappa I
B I
is O
influenced O
by O
glycemic O
control O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
To O
determine O
whether O
NF B
- I
kappa I
B I
is O
activated O
in O
patients O
with O
insufficient O
glycemic O
control O
( O
HbA1c O
> O
10 O
% O
) O
, O
we O
developed O
a O
tissue O
culture O
- O
independent O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
- O
based O
semiquantitative O
detection O
system O
that O
allowed O
us O
to O
determine O
NF B
- I
kappa I
B I
activation O
in O
ex O
vivo O
- O
isolated O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
. O

RESULTS O
: O
Monocytes O
of O
patients O
with O
HbA1c O
levels O
> O
10 O
% O
demonstrated O
significantly O
higher O
NF B
- I
kappa I
B I
binding O
activity O
in O
an O
EMSA O
and O
a O
stronger O
NF B
- I
kappa I
B I
staining O
in O
immunohistochemistry O
than O
monocytes O
of O
patients O
with O
HbA1c O
levels O
of O
6 O
- O
8 O
% O
. O

The O
increase O
in O
NF B
- I
kappa I
B I
activation O
correlated O
with O
an O
increase O
in O
plasmatic O
markers O
of O
lipid O
peroxidation O
. O

Treatment O
with O
the O
antioxidant O
thioctic O
acid O
decreased O
NF B
- I
kappa I
B I
binding O
activity O
. O

CONCLUSIONS O
: O
Hyperglycemia O
induces O
activation O
of O
the O
transcription O
factor O
NF B
- I
kappa I
B I
in O
ex O
vivo O
- O
isolated O
PBMCs O
of O
patients O
with O
type O
1 O
diabetes O
. O

NF B
- I
kappa I
B I
activation O
is O
at O
least O
partially O
dependent O
on O
oxidative O
stress O
, O
since O
the O
antioxidant O
thioctic O
acid O
significantly O
lowered O
the O
extent O
of O
NF B
- I
kappa I
B I
binding O
activity O
. O

Synergistic O
activation O
of O
MAP B
kinase I
( O
ERK1 B
/ I
2 I
) O
by O
erythropoietin B
and O
stem B
cell I
factor I
is O
essential O
for O
expanded O
erythropoiesis O
. O

Stem B
cell I
factor I
( O
SCF B
) O
and O
erythropoietin B
( O
EPO B
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Treatment O
of O
the O
cells O
with O
PD98059 O
and O
wortmannin O
, O
inhibitors O
of O
MEK B
and O
PI B
- I
3 I
kinase I
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK B
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O

Wortmannin O
only O
inhibits O
MAPK B
activation O
induced O
by O
EPO B
but O
not O
that O
by O
SCF B
, O
suggesting O
that O
SCF B
and O
EPO B
may O
activate O
MAPK B
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Furthermore O
, O
EPO B
, O
but O
not O
SCF B
, O
led O
to O
activation O
of O
STAT5 B
, O
whereas O
SCF B
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B
- O
induced O
STAT5 B
activation O
, O
suggesting O
that O
STAT5 B
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B
and O
EPO B
. O

Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK B
by O
SCF B
and O
EPO B
is O
essential O
for O
expanded O
erythropoiesis O
. O

Expression O
of O
BCL B
- I
6 I
protein I
, O
which O
is O
restricted O
to O
GC O
B O
cells O
throughout O
physiologic O
B O
- O
cell O
maturation O
, O
was O
detected O
in O
100 O
% O
AIDS O
- O
unrelated O
PCNSL O
and O
in O
56 O
. O
2 O
% O
AIDS O
- O
related O
cases O
. O

Notably O
, O
among O
AIDS O
- O
related O
PCNSL O
, O
expression O
of O
BCL B
- I
6 I
was O
mutually O
exclusive O
with O
expression O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
encoded O
latent O
membrane O
protein O
( O
LMP O
) O
- O
1 O
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL B
- I
2 I
. O

These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC O
B O
cells O
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL B
- I
6 I
, O
LMP B
- I
1 I
, O
and O
BCL B
- I
2 I
. O

BCL B
- I
6 I
( O
+ O
) O
/ O
LMP B
- I
1 I
( O
- O
) O
/ O
BCL B
- I
2 I
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O

Conversely O
, O
BCL B
- I
6 I
( O
- O
) O
/ O
LMP B
- I
1 I
( O
+ O
) O
/ O
BCL B
- I
2 I
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV O
- O
infected O
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O

The O
effect O
was O
significant O
for O
ICAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
and O
VCAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
expression O
in O
cells O
pretreated O
with O
100 O
microM O
alpha O
- O
lipoate O
compared O
to O
PMA O
- O
activated O
untreated O
cells O
. O

The O
regulation O
of O
adhesion O
molecule O
expression O
and O
function O
by O
low O
concentration O
of O
antioxidants O
investigated O
does O
not O
appear O
to O
be O
NF B
- I
kappaB I
regulated O
or O
transcription O
dependent O
because O
no O
change O
in O
the O
mRNA O
response O
was O
observed O
. O

Protein B
kinase I
C I
( O
PKC B
) O
has O
been O
suggested O
to O
regulate O
PMA O
- O
induced O
adhesion O
molecule O
expression O
by O
post O
- O
transcriptional O
stabilization O
of O
adhesion O
molecule O
mRNA O
. O

Alpha O
- O
lipoate O
pretreatment O
did O
not O
influence O
the O
response O
of O
PKC B
activity O
to O
PMA O
. O

Binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 O
and O
CXCR4 O
receptors O
differentially O
regulates O
expression O
of O
inflammatory B
genes I
and O
activates O
the O
MEK B
/ O
ERK O
signaling O
pathway O
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
virions O
to O
CD4 B
receptors I
stimulates O
association O
of O
Lck B
with O
Raf B
- I
1 I
and O
results O
in O
the O
activation O
of O
Raf B
- I
1 I
kinase O
in O
a O
Ras O
- O
independent O
manner O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV O
- O
1 O
envelope O
glycoproteins O
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine O
and O
chemokine O
genes O
. O

The O
activation O
of O
this O
signaling O
pathway O
requires O
functional O
CD4 B
receptors I
and O
is O
independent O
of O
binding O
to O
CXCR4 B
. O

Binding O
of O
the O
natural O
ligand O
stromal O
cell O
- O
derived O
factor O
1 O
( O
SDF O
- O
1 O
) O
to O
CXCR4 B
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP B
kinase I
pathway O
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV O
- O
1 O
envelope O
glycoproteins O
to O
CD4 B
receptor I
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B
receptor I
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B
genes I
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

Antigen O
receptor O
signaling O
induces O
MAP O
kinase O
- O
mediated O
phosphorylation O
and O
degradation O
of O
the O
BCL B
- I
6 I
transcription B
factor I
. O

The O
bcl O
- O
6 O
proto O
- O
oncogene O
encodes O
a O
POZ B
/ I
zinc I
finger I
transcriptional I
repressor I
expressed O
in O
germinal O
center O
( O
GC O
) O
B O
and O
T O
cells O
and O
required O
for O
GC O
formation O
and O
antibody O
affinity O
maturation O
. O

Deregulation O
of O
bcl B
- I
6 I
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl O
- O
6 O
promoter O
region O
are O
implicated O
in O
the O
pathogenesis O
of O
B O
- O
cell O
lymphoma O
. O

The O
signals O
regulating O
bcl B
- I
6 I
expression O
are O
not O
known O
. O

Here O
we O
show O
that O
antigen O
receptor O
activation O
leads O
to O
BCL B
- I
6 I
phosphorylation O
by O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
. O

Phosphorylation O
, O
in O
turn O
, O
targets O
BCL B
- I
6 I
for O
rapid O
degradation O
by O
the O
ubiquitin B
/ O
proteasome B
pathway O
. O

These O
findings O
indicate O
that O
BCL B
- I
6 I
expression O
is O
directly O
controlled O
by O
the O
antigen O
receptor O
via O
MAPK B
activation O
. O

Glucocorticoid B
receptors I
are O
differentially O
expressed O
in O
the O
cells O
and O
tissues O
of O
the O
immune O
system O
. O

Cytosolic O
glucocorticoid O
receptor O
( O
GR B
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR O
protein O
than O
the O
spleen O
. O

High O
levels O
of O
GR B
are O
consistent O
with O
the O
exquisite O
sensitivity O
of O
the O
thymus O
to O
glucocorticoid O
exposure O
. O

Nevertheless O
, O
whole O
cell O
binding O
studies O
reveal O
similar O
levels O
of O
GR B
in O
immature O
thymic O
T O
lymphocytes O
and O
more O
mature O
, O
splenic O
T O
lymphocytes O
. O

Moreover O
, O
whole O
cell O
binding O
techniques O
indicate O
that O
neutrophils O
( O
which O
represent O
roughly O
30 O
% O
of O
splenic O
leukocytes O
) O
exhibit O
higher O
GR B
than O
both O
T O
and O
B O
lymphocytes O
, O
further O
contradicting O
results O
from O
cytosolic O
binding O
studies O
. O

Consistent O
with O
previous O
cytosolic O
receptor O
binding O
studies O
on O
immune O
tissue O
homogenates O
, O
thymic O
T O
cells O
were O
found O
to O
have O
higher O
levels O
of O
GR B
than O
T O
cells O
isolated O
from O
the O
spleen O
. O

In O
addition O
, O
neutrophils O
were O
found O
to O
have O
fewer O
GR B
than O
lymphocytes O
and O
monocytes O
. O

Functional O
replacement O
of O
the O
mouse B
E2A I
gene I
with O
a O
human O
HEB O
cDNA O
. O

The O
mammalian O
E2A O
, O
HEB O
, O
and O
E2 O
- O
2 O
genes O
encode O
a O
unique O
class O
of O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic O
and O
postnatal O
development O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B
products I
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B
, O
but O
not O
HEB B
or O
E2 O
- O
2 O
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 O
- O
2 O
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 O
and O
E47 O
exons O
and O
substitution O
of O
both O
E12 O
and O
E47 O
exons O
with O
a O
human O
HEB O
cDNA O
. O

We O
find O
that O
the O
alternatively O
spliced O
E12 O
and O
E47 O
bHLH O
proteins O
of O
the O
E2A B
gene I
play O
similar O
and O
additive O
roles O
in O
supporting O
B O
lymphopoiesis O
. O

Further O
, O
we O
find O
that O
HEB B
driven O
by O
the O
endogenous O
E2A O
promoter O
can O
functionally O
replace O
E2A B
in O
supporting O
B O
- O
cell O
commitment O
and O
differentiation O
toward O
completion O
. O

Finally O
, O
the O
postnatal O
lethality O
associated O
with O
E2A B
disruption O
is O
fully O
rescued O
by O
the O
addition O
of O
HEB B
. O

This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 B
, O
E47 B
, O
and O
HEB B
in O
different O
cell O
types O
is O
partially O
defined O
by O
the O
context O
of O
gene O
expression O
. O

Biased O
dependency O
of O
CD80 B
versus O
CD86 B
in O
the O
induction O
of O
transcription B
factors I
regulating O
the O
human O
IL O
- O
2 O
promoter O
. O

One O
such O
co O
- O
stimulatory O
signal O
is O
delivered O
when O
CD28 B
on O
T O
cells O
binds O
to O
CD80 B
or O
CD86 B
on O
antigen O
- O
presenting O
cells O
( O
APC O
) O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
ability O
of O
CD80 B
and O
CD86 B
to O
co O
- O
stimulate O
human O
T O
cells O
activated O
by O
superantigen O
. O

Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B
and O
CD86 B
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co O
- O
stimulated O
by O
CD80 B
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co O
- O
stimulatory O
dependency O
, O
we O
employed O
a O
well O
- O
defined O
system O
of O
transfected O
CHO O
cells O
expressing O
human O
MHC O
class O
II O
together O
with O
CD80 B
, O
CD86 B
or O
CD80 B
and O
CD86 B
. O

Proliferation O
of O
freshly O
prepared O
CD4 O
+ O
T O
cells O
required O
the O
presence O
of O
either O
CD80 B
or O
CD86 B
. O

However O
, O
IL B
- I
2 I
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B
but O
optimal O
levels O
with O
CD80 B
. O

To O
analyze O
IL B
- I
2 I
transcriptional O
activity O
in O
CD80 B
and O
CD86 B
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase O
reporter O
gene O
constructs O
. O

CD80 B
induced O
higher O
levels O
of O
IL B
- I
2 I
promoter I
- O
enhancer O
activity O
compared O
to O
CD86 B
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL O
- O
2 O
promoter O
- O
enhancer O
region O
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Our O
results O
suggest O
that O
the O
eventual O
appearance O
of O
CD80 B
on O
recently O
activated O
CD86 O
+ O
APC O
is O
important O
for O
the O
superinduction O
of O
IL B
- I
2 I
production O
and O
to O
support O
vigorous O
T O
cell O
proliferation O
. O

DR3 B
is O
capable O
of O
inducing O
both O
NF B
- I
kappa I
B I
activation O
and O
apoptosis O
when O
overexpressed O
in O
mammalian O
cells O
, O
although O
its O
ligand O
has O
not O
yet O
been O
identified O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 O
gene O
, O
including O
the O
extracellular B
and I
transmembrane I
regions I
but O
not O
the O
cytoplasmic B
domain I
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

In O
most O
NB O
cell O
lines O
, O
both O
the O
DR3 O
and O
the O
DR3L O
sequences O
are O
simultaneously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome B
. O

Primary O
cortisol O
resistance O
accompanied O
by O
a O
reduction O
in O
glucocorticoid B
receptors I
in O
two O
members O
of O
the O
same O
family O
. O

To O
study O
this O
apparent O
end O
- O
organ O
resistance O
to O
cortisol O
, O
we O
examined O
the O
glucocorticoid B
receptors I
in O
peripheral O
mononuclear O
cells O
. O

Using O
whole O
cell O
assays O
, O
glucocorticoid B
receptors I
in O
both O
patients O
were O
found O
to O
have O
reduced O
total O
binding O
capacity O
. O

We O
conclude O
that O
these O
two O
patients O
, O
members O
of O
the O
same O
family O
, O
have O
primary O
cortisol O
resistance O
accompanied O
by O
a O
reduced O
number O
of O
glucocorticoid B
receptors I
. O

[ O
Glucocorticoid B
receptors I
and O
response O
to O
polychemotherapy O
in O
acute O
lymphatic O
leukemia O
] O

Glucocorticoid B
receptor I
( O
GR B
) O
levels O
were O
quantified O
in O
leukemic O
blasts O
from O
peripheral O
blood O
of O
86 O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

The O
study O
of O
glucocorticoid B
receptors I
in O
leukemic O
cells O
may O
predict O
response O
to O
combination O
chemotherapy O
in O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

Presence O
and O
steroid O
inducibility O
of O
glutamine B
synthetase I
in O
human O
leukemic O
cells O
. O

Glutamine B
synthetase I
( O
EC O
6 O
. O
3 O
. O
1 O
. O
2 O
; O
GS O
) O
is O
present O
in O
lymphoblasts O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
as O
well O
as O
in O
normal O
peripheral O
blood O
lymphocytes O
. O

In O
16 O
out O
of O
20 O
ALL O
patients O
studied O
exposure O
of O
the O
cells O
to O
physiological O
concentrations O
of O
dexamethasone O
in O
vitro O
increased O
enzyme B
activity O
above O
the O
control O
levels O
. O

The O
increase O
was O
specific O
for O
glucocorticoid B
receptor I
ligands O
. O

A O
direct O
correlation O
was O
found O
between O
the O
magnitude O
of O
glucocorticoid O
- O
mediated O
increase O
of O
GS O
activity O
and O
the O
cellular O
levels O
of O
specific O
glucocorticoid B
receptors I
assayed O
in O
the O
same O
cell O
specimen O
. O

Moreover O
, O
the O
basal O
levels O
of O
the O
enzyme B
measured O
in O
cells O
prior O
to O
exposure O
to O
dexamethasone O
correlated O
negatively O
with O
receptor O
density O
. O

Binding O
of O
progestins O
to O
the O
glucocorticoid B
receptor I
. O

A O
number O
of O
physiological O
and O
synthetic O
progestins O
were O
tested O
for O
their O
ability O
to O
compete O
with O
[ O
3H O
] O
dexamethasone O
for O
the O
binding O
to O
the O
glucocorticoid B
receptor I
of O
human O
mononuclear O
leukocytes O
and O
their O
ability O
to O
elicit O
glucocorticoid O
- O
like O
effects O
on O
the O
same O
cells O
. O

The O
effective O
binding O
of O
medroxyprogesterone O
acetate O
to O
the O
glucocorticoid B
receptor I
was O
confirmed O
by O
direct O
binding O
studies O
utilizing O
a O
tritiated O
derivative O
of O
this O
steroid O
. O

No O
evidence O
for O
the O
existence O
of O
a O
specific O
progesterone B
receptor I
in O
human O
mononuclear O
leukocytes O
was O
obtained O
as O
judged O
by O
the O
results O
of O
competition O
experiments O
where O
a O
progesterone O
receptor O
- O
specific O
ligand O
[ O
3H O
] O
Org O
2058 O
was O
used O
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T B
- I
cell I
mitogens I
concanavalin O
A O
and O
phytohaemagglutinin B
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen O
- O
stimulated O
cultures O
. O

In O
contrast O
, O
the O
synthetic O
progestins O
related O
structurally O
to O
19 O
- O
nortestosterone O
, O
norethisterone O
and O
d O
- O
norgestrel O
, O
were O
virtually O
devoid O
of O
binding O
affinity O
towards O
the O
glucocorticoid B
receptor I
nor O
did O
they O
measurably O
influence O
the O
in O
vitro O
lymphocyte O
functions O
. O

It O
is O
suggested O
that O
the O
glucocorticoid O
- O
induced O
lysis O
of O
human O
CLL O
cells O
is O
similar O
to O
the O
phenomenon O
observed O
in O
rat O
or O
murine O
lymphocytes O
and O
is O
mediated O
by O
interaction O
of O
the O
steroid O
molecule O
with O
the O
cytoplasmic B
receptor I
. O

The O
resulting O
complex O
appears O
to O
activate O
specific O
gene B
( O
s O
) O
the O
products O
of O
which O
eventually O
cause O
cytolysis O
. O

Glucocorticoid B
receptors I
in O
lymphoid O
tumors O
. O

There O
is O
a O
range O
of O
levels O
of O
glucocorticoid B
receptor I
numbers O
seen O
in O
the O
various O
subclasses O
of O
acute O
lymphatic O
leukemia O
( O
ALL O
) O
. O

All O
clinical O
specimens O
from O
patients O
with O
lymphatic O
leukemia O
have O
some O
measurable O
level O
of O
glucocorticoid B
receptors I
; O
therefore O
, O
the O
resistance O
seen O
in O
vivo O
can O
not O
be O
explained O
by O
the O
lack O
of O
receptors O
. O

[ O
Tumor O
histology O
and O
steroid B
receptors I
in O
breast O
carcinoma O
] O

The O
steroid B
receptor I
content O
does O
not O
correlate O
with O
histological O
parameters O

It O
appears O
that O
pseudohypoaldosteron O
is O
caused O
by O
a O
Type O
I O
receptor O
defect O
, O
that O
the O
defect O
may O
be O
complete O
or O
partial O
, O
that O
transmission O
may O
be O
autosomal O
recessive O
, O
and O
that O
the O
study O
of O
patients O
with O
pseudohypoaldosteron O
may O
indicate O
physiologic O
roles O
for O
Type B
I I
receptors I
in O
nonepithelial O
tissues O
. O

Inhibition O
of O
PA O
in O
both O
cell O
types O
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid B
receptors I
. O

The O
results O
indicate O
that O
mononuclear O
leukocytes O
could O
be O
useful O
for O
studying O
the O
physiological O
significance O
of O
these O
mineralocorticoid B
receptors I
and O
their O
regulation O
in O
humans O
. O

The O
capacity O
and O
the O
affinity O
of O
dexamethasone O
for O
glucocorticoid B
receptors I
ranged O
in O
the O
normal O
values O
. O

These O
data O
suggest O
a O
possible O
down O
- O
regulation O
of O
mineralocorticoid B
receptors I
in O
humans O
. O

Estrogens O
stimulate O
some O
aspects O
of O
macrophage O
activity O
and O
, O
depending O
on O
dose O
and O
mitogen B
, O
inhibit O
or O
stimulate O
lymphocyte O
proliferative O
response O
in O
vitro O
. O

However O
, O
the O
recent O
description O
of O
estrogen B
receptors I
in O
the O
thymus O
and O
in O
some O
lymphocyte O
subpopulations O
, O
as O
well O
as O
a O
deeper O
understanding O
of O
regulating O
factors O
in O
the O
immune O
system O
, O
open O
the O
possibility O
of O
a O
more O
detailed O
understanding O
of O
the O
estrogen O
mechanism O
of O
interference O
. O

Serum O
estradiol O
and O
progesterone O
concentrations O
were O
significantly O
decreased O
during O
the O
treatment O
cycle O
, O
suggesting O
that O
interferon B
interacts O
in O
vivo O
with O
the O
function O
of O
both O
FSH O
and O
LH O
. O

No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH O
, O
LH O
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial O
ERC O
, O
ERN O
, O
PRC O
and O
PRN O
affected O
by O
interferon B
administration O
. O

As O
expected O
, O
interferon B
administration O
resulted O
in O
decreased O
leukocyte O
counts O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum O
alkaline O
phosphatase O
and O
gamma O
- O
glutamyltransferase O
during O
the O
interferon B
therapy O
shows O
that O
interferon B
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

These O
results O
suggest O
that O
one O
of O
the O
mechanisms O
by O
which O
interferon B
treatment O
may O
affect O
the O
growth O
of O
hormone O
- O
dependent O
neoplasms O
could O
be O
the O
interaction O
with O
production O
and O
/ O
or O
function O
of O
circulating O
hormonal O
compounds O
. O

[ O
Glucocorticoid B
receptor I
level O
in O
the O
blood O
leukocytes O
in O
different O
acute O
diseases O
] O

Content O
of O
glucocorticoid B
receptors I
in O
cytosol O
of O
blood O
leukocytes O
, O
concentration O
of O
cortisol O
and O
amount O
of O
leukocytes O
in O
blood O
were O
studied O
in O
20 O
patients O
with O
acute O
impairments O
within O
the O
second O
day O
of O
the O
disease O
. O

The O
role O
of O
glucocorticoid B
receptors I
in O
immunological O
processes O
under O
conditions O
of O
purulent O
complications O
and O
possibility O
to O
regulate O
the O
metabolism O
in O
leukocytes O

Therapeutic O
concentrations O
of O
glucocorticoids O
suppress O
the O
antimicrobial O
activity O
of O
human O
macrophages O
without O
impairing O
their O
responsiveness O
to O
gamma B
interferon I
. O

Proliferating O
lymphocytes O
and O
gamma B
- I
interferon I
thus O
increased O
the O
antimicrobial O
activity O
of O
phagocytes O
exposed O
to O
glucocorticoids O
over O
that O
of O
control O
cells O
. O

Macrophage O
activation O
and O
correction O
of O
the O
dexamethasone O
effect O
by O
gamma B
- I
interferon I
, O
however O
, O
was O
dependent O
on O
the O
pathogen O
. O

The O
lymphokine B
enhanced O
the O
antimicrobial O
activity O
of O
dexamethasone O
- O
treated O
macrophages O
against O
Listeria O
and O
Salmonella O
but O
not O
against O
Aspergillus O
or O
Nocardia O
. O

Suppression O
of O
macrophage O
antimicrobial O
activity O
should O
thus O
be O
considered O
when O
treating O
patients O
with O
glucocorticoids O
; O
its O
prevention O
by O
gamma B
- I
interferon I
might O
be O
beneficial O
for O
some O
but O
not O
all O
pathogens O
. O

Interleukin B
2 I
receptor I
( O
Tac O
antigen O
) O
expression O
in O
HTLV O
- O
I O
- O
associated O
adult O
T O
- O
cell O
leukemia O
. O

Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
is O
a O
lymphokine B
synthesized O
by O
some O
T O
- O
cells O
following O
activation O
. O

Resting O
T O
- O
cells O
do O
not O
express O
IL B
- I
2 I
receptors I
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T O
- O
cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B
antibodies I
with O
the O
antigen O
- O
specific O
T O
- O
cell O
receptor O
complex O
. O

Using O
anti O
- O
Tac O
, O
a O
monoclonal B
antibody I
that O
recognizes O
the O
IL B
- I
2 I
receptor I
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

Normal O
resting O
T O
- O
cells O
and O
most O
leukemic O
T O
- O
cell O
populations O
do O
not O
express O
IL B
- I
2 I
receptors I
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
associated O
adult O
T O
- O
cell O
leukemia O
expressed O
the O
Tac O
antigen O
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open O
reading O
frame O
protein O
encoded O
in O
part O
by O
the O
pX O
region O
of O
this O
virus O
may O
act O
as O
a O
transacting O
transcriptional O
activator O
that O
induces O
IL O
- O
2 O
receptor O
gene O
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

The O
constant O
expression O
of O
large O
numbers O
of O
IL B
- I
2 I
receptors I
which O
may O
be O
aberrant O
may O
play O
a O
role O
in O
the O
uncontrolled O
growth O
of O
adult O
T O
- O
cell O
leukemia O
cells O
. O

One O
of O
the O
patients O
had O
6 O
- O
and O
3 O
- O
mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal B
antibody I
directed O
toward O
this O
growth O
factor O
receptor O
. O

Lymphocyte O
glucocorticoid B
receptor I
binding O
in O
depressed O
patients O
with O
hypercortisolemia O
. O

This O
hypercortisolemia O
in O
the O
absence O
of O
clinical O
effects O
suggests O
a O
state O
of O
hormone O
resistance O
and O
could O
be O
mediated O
by O
alterations O
in O
the O
glucocorticoid B
receptor I
. O

Earlier O
studies O
have O
shown O
that O
small O
doses O
of O
glucocorticoids O
cause O
a O
decrease O
in O
glucocorticoid B
receptor I
binding O
in O
normal O
human O
lymphocytes O
. O

The O
lack O
of O
a O
change O
in O
lymphocyte O
glucocorticoid B
receptor I
concentration O
in O
the O
presence O
of O
cortisol O
excess O
suggests O
the O
possibility O
that O
hypercortisolemia O
in O
depressive O
illness O
represents O
a O
state O
of O
peripheral O
glucocorticoid O
resistance O
. O

The O
glucocorticoid B
receptor I
is O
an O
intracellular O
protein O
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti O
- O
receptor O
antibodies O
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

The O
transformed O
receptor O
then O
interacts O
with O
chromatin B
( O
state O
D O
) O
. O

Thermodynamics O
of O
steroid O
binding O
to O
the O
human B
glucocorticoid I
receptor I
. O

Cells O
in O
G0 O
, O
G1a O
and O
G1b O
phases O
, O
where O
the O
G1a O
- O
G1b O
transition O
is O
an O
Interleukin B
2 I
dependent O
event O
, O
were O
quantitated O
by O
flow O
cytometry O
. O

Few O
but O
significant O
numbers O
of O
glucocorticoid B
receptors I
( O
2700 O
/ O
cell O
) O
and O
no O
insulin O
receptors O
( O
- O
1 O
/ O
cell O
) O
were O
found O
in O
the O
resting O
( O
G0 O
) O
phase O
. O

Glucocorticoid B
receptors I
and O
cortico O
- O
sensitivity O
in O
a O
human O
clonal O
monocytic O
cell O
line O
, O
CM O
- O
SM O
. O

Glucocorticoid B
receptor I
and O
in O
vitro O
sensitivity O
to O
steroid O
hormones O
in O
human O
lymphoproliferative O
diseases O
and O
myeloid O
leukemia O
. O

The O
glucocorticoid B
receptor I
( O
GR B
) O
quantitation O
by O
a O
whole O
- O
cell O
assay O
and O
/ O
or O
cytosol O
technique O
and O
the O
in O
vitro O
sensitivity O
to O
steroids O
have O
been O
assessed O
in O
peripheral O
blood O
cells O
from O
normal O
donors O
and O
patients O
with O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
, O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphosarcoma O
cell O
leukemia O
( O
LSCL O
) O
, O
acute O
nonlymphatic O
leukemia O
( O
ANLL O
) O
, O
and O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

Within O
the O
lymphoproliferative O
diseases O
, O
ALL O
cells O
exhibited O
the O
highest O
GR B
concentration O
( O
regardless O
of O
the O
method O
used O
) O
and O
the O
highest O
in O
vitro O
inhibition O
of O
spontaneous O
[ O
3H O
] O
thymidine O
( O
[ O
3H O
] O
TdR O
) O
uptake O
by O
glucocorticoids O
. O

A O
significant O
relationship O
between O
GR B
concentration O
( O
whole O
- O
cell O
assay O
) O
and O
in O
vitro O
sensitivity O
to O
dexamethasone O
was O
also O
found O
. O

Concerning O
myeloid O
leukemia O
, O
ANLL O
patients O
had O
GR B
concentrations O
slightly O
higher O
than O
those O
found O
in O
the O
ALL O
group O
but O
exhibited O
the O
lowest O
degree O
of O
inhibition O
of O
spontaneous O
[ O
3H O
] O
TdR O
uptake O
by O
dexamethasone O
( O
stimulatory O
effects O
occurred O
in O
some O
cases O
) O
. O

Glucocorticoid B
receptors I
and O
in O
vitro O
corticosensitivity O
of O
peanut O
- O
positive O
and O
peanut O
- O
negative O
human O
thymocyte O
subpopulations O
. O

These O
2 O
cell O
subpopulations O
were O
analyzed O
for O
glucocorticoid B
receptor I
content O
by O
using O
a O
whole O
cell O
assay O
, O
with O
( O
3H O
) O
- O
triamcinolone O
acetonide O
as O
tracer O
. O

Despite O
the O
greater O
number O
of O
glucocorticoid B
receptor I
sites O
, O
the O
peanut O
- O
negative O
thymocyte O
subpopulation O
did O
not O
differ O
from O
the O
peanut O
- O
positive O
one O
in O
its O
sensitivity O
to O
the O
inhibitory O
effects O
of O
triamcinolone O
acetonide O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors O
of O
protein O
and O
DNA O
. O

Thus O
, O
our O
data O
suggest O
that O
glucocorticoid O
receptor O
density O
and O
corticosensitivity O
are O
not O
directly O
correlated O
and O
that O
the O
number O
of O
glucocorticoid B
receptor I
sites O
may O
be O
dependent O
on O
the O
degree O
of O
immunologic O
maturation O

Defective O
binding O
and O
function O
of O
1 B
, I
25 I
- I
dihydroxyvitamin I
D3 I
receptors I
in O
peripheral O
mononuclear O
cells O
of O
patients O
with O
end O
- O
organ O
resistance O
to O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
. O

The O
lymphocytes O
acquire O
specific O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
upon O
activation O
by O
the O
lectins B
. O

Moreover O
, O
in O
contrast O
to O
normal O
lymphocytes O
, O
the O
mitogenic O
stimulation O
of O
these O
patients O
' O
lymphocytes O
by O
phytohemagglutinin B
and O
concanavalin O
A O
was O
not O
inhibited O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

Glucocorticoid B
receptors I
of O
mononuclear O
leukocytes O
from O
myasthenia O
gravis O
patients O
. O

The O
present O
study O
was O
performed O
to O
analyse O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
in O
peripheral O
blood O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
39 O
myasthenia O
gravis O
( O
MG O
) O
patients O
( O
unoperated O
patients O
( O
n O
= O
13 O
) O
, O
thymectomized O
patients O
( O
n O
= O
14 O
) O
and O
patients O
receiving O
glucocorticoids O
: O
thymectomized O
( O
n O
= O
11 O
) O
and O
unoperated O
( O
n O
= O
6 O
] O
. O

GR B
mean O
values O
were O
significantly O
higher O
in O
the O
MNL O
of O
MG O
patients O
( O
thymectomized O
or O
not O
) O
not O
receiving O
glucocorticoid O
than O
in O
the O
MNL O
of O
healthy O
donors O
. O

In O
patients O
receiving O
prednisone O
( O
Pd O
) O
the O
GR B
values O
were O
significantly O
lower O
than O
in O
MG O
patients O
without O
Pd O
therapy O
, O
independent O
of O
Pd O
dose O
or O
time O
of O
administration O
. O

The O
inhibitory O
effect O
on O
B O
- O
cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins O
and O
as O
impaired O
binding O
of O
antibodies B
and O
complement O
to O
the O
cellular O
surface O
. O

Reduced O
T O
- O
cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA B
and O
porkweed O
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O

Antisera O
raised O
against O
human O
lymphoid O
glucocorticoid O
receptors O
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21 O
- O
mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid B
receptors I
of O
the O
human O
B O
- O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
and O
the O
human O
T O
- O
cell O
leukemic O
cell O
line O
CEM O
- O
C7 O
. O

These O
antibodies B
also O
recognized O
rat O
liver O
and O
murine O
S49 O
cell O
glucocorticoid O
receptors O
. O

Effect O
of O
thymosin O
on O
glucocorticoid B
receptor I
activity O
and O
glucocorticoid O
sensitivity O
of O
human O
thymocytes O
. O

The O
glucocorticoid B
receptor I
activity O
in O
normal O
infant O
thymocytes O
was O
found O
to O
be O
2 O
, O
146 O
+ O
/ O
- O
726 O
( O
s O
. O
d O
. O
) O
sites O
per O
cell O
with O
dissociation O
constant O
of O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
6 O
X O
10 O
( O
- O
8 O
) O
M O
. O

Resting O
human O
peripheral O
blood O
T O
lymphocytes O
, O
however O
, O
do O
not O
have O
a O
demonstrable O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
. O

After O
activation O
with O
phytohemagglutinin B
the O
T O
cells O
exhibit O
the O
receptor O
within O
24 O
h O
, O
and O
this O
expression O
is O
blocked O
by O
cycloheximide O
. O

The O
disparity O
of O
results O
between O
endogenous O
and O
exogenous O
hypercorticism O
, O
between O
the O
two O
cell O
types O
, O
and O
between O
the O
present O
studies O
and O
previous O
studies O
suggest O
that O
the O
effects O
of O
glucocorticoid O
excess O
on O
the O
insulin B
receptor I
are O
extremely O
complex O
and O
wide O
- O
ranging O
and O
that O
in O
this O
condition O
, O
extrapolations O
in O
humans O
from O
data O
with O
circulating O
cells O
to O
liver O
and O
muscle O
may O
not O
be O
appropriate O
. O

Reduced O
level O
of O
cellular B
glucocorticoid I
receptors I
in O
patients O
with O
anorexia O
nervosa O
. O

Specific O
glucocorticoid B
receptors I
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
from O
12 O
patients O
with O
anorexia O
nervosa O
and O
21 O
healthy O
control O
subjects O
. O

Cells O
from O
patients O
were O
found O
to O
contain O
a O
significantly O
( O
p O
less O
than O
0 O
. O
01 O
) O
lower O
level O
of O
glucocorticoid B
receptor I
( O
3830 O
+ O
/ O
- O
210 O
sites O
/ O
cell O
, O
mean O
+ O
/ O
- O
SE O
) O
than O
those O
from O
controls O
( O
4930 O
+ O
/ O
- O
250 O
sites O
/ O
cell O
) O
. O

A O
partial O
glucocorticoid B
receptor I
defect O
may O
well O
explain O
the O
abnormal O
cortisol O
metabolism O
and O
glucocorticoid O
resistance O
commonly O
found O
in O
patients O
with O
anorexia O
nervosa O
. O

Regulation O
of O
the O
glucocorticoid B
receptor I
in O
human O
lymphocytes O
. O

The O
presence O
of O
a O
glucocorticoid B
receptor I
in O
human O
lymphocytes O
is O
well O
established O
, O
but O
factors O
affecting O
its O
regulation O
have O
not O
been O
described O
. O

A O
statistically O
significant O
association O
of O
IgA B
and O
IgM B
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B
with O
malignant O
lesions O
. O

In O
both O
primary O
and O
metastatic O
lesions O
, O
IgG B
localization O
was O
associated O
with O
estrogen O
- O
receptor O
- O
poor O
primary O
cancers O
as O
compared O
with O
estrogen O
- O
receptor O
- O
rich O
primary O
cancers O
. O

Among O
primary O
breast O
cancer O
patients O
, O
IgG B
localization O
in O
the O
tumor O
correlated O
with O
relative O
lymphopenia O
. O

A O
shorter O
disease O
- O
free O
interval O
was O
noted O
in O
association O
with O
IgG B
localization O
among O
the O
metastatic O
breast O
lesions O
. O

Correlation O
of O
steroid B
receptors I
with O
histologic O
differentiation O
in O
mammary O
carcinoma O
. O

A O
detailed O
histopathologic O
review O
of O
50 O
primary O
breast O
cancer O
tumors O
analyzed O
for O
estrogen B
receptor I
( O
ER B
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B
results O
to O
identify O
any O
factors O
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O

Tumors O
binding O
more O
than O
5 O
fmol O
/ O
mg O
cytosol B
protein I
were O
classified O
as O
ER B
- O
positive O
. O

Progesterone B
receptor I
( O
PR B
) O
level O
was O
analyzed O
in O
some O
specimens O
with O
the O
use O
of O
a O
similar O
method O
. O

Results O
indicated O
that O
there O
was O
strong O
correlation O
between O
ER B
level O
, O
age O
, O
and O
histologic O
grade O
of O
the O
tumors O
. O

No O
correlation O
existed O
between O
absence O
or O
presence O
of O
lymph O
node O
metastases O
and O
ER B
. O

Although O
there O
was O
a O
trend O
for O
ER B
- O
positive O
tumors O
to O
have O
a O
low O
- O
grade O
lymphocytic O
infiltration O
, O
the O
difference O
was O
not O
statistically O
significant O
. O

Mononuclear O
cells O
infiltrating O
human O
mammary O
carcinomas O
: O
immunohistochemical O
analysis O
with O
monoclonal B
antibodies I
. O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major O
histocompatibility O
antigens O
( O
HLA O
- O
A O
, O
- B
B I
, O
- O
C O
; O
Ia O
- O
like O
) O
. O

A O
case O
of O
male O
pseudohermaphroditis O
with O
normal O
androgen B
receptor I
binding O
and O
47 O
, O
XYY O
karyotype O
. O

The O
proliferative O
response O
of O
murine O
spleen O
and O
thymus O
cells O
to O
antigen O
but O
not O
to O
lectin B
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

To O
directly O
examine O
the O
effect O
of O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
on O
T O
cell O
activation O
in O
the O
absence O
of O
other O
complicating O
interactions O
, O
we O
utilized O
a O
panel O
of O
cloned O
Ia O
- O
restricted O
T O
cell O
hybridomas O
that O
secrete O
IL B
2 I
on O
activation O
by O
cloned O
Ia O
- O
bearing O
stimulator O
cells O
( O
TA3 O
) O
or O
when O
stimulated O
by O
mitogen O
. O

These O
results O
are O
consistent O
with O
the O
finding O
that O
specific O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptors I
are O
present O
on O
the O
T O
cell O
hybridomas O
but O
are O
lacking O
in O
TA3 O
cells O
. O

1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin B
or O
by O
an O
anti O
- O
Thy O
- O
1 O
antibody O
. O

This O
system O
should O
prove O
useful O
in O
studying O
the O
molecular O
mechanisms O
by O
which O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
acts O
to O
inhibit O
T O
cell O
activation O
and O
subsequent O
IL B
2 I
production O
. O

Glucocorticoid B
receptors I
and O
steroid O
sensitivity O
in O
normal O
and O
neoplastic O
human O
lymphoid O
tissues O
: O
a O
review O
. O

The O
determination O
of O
estrogen B
and I
progesterone I
receptors I
in O
breast O
cancer O
has O
been O
shown O
to O
be O
useful O
in O
predicting O
the O
response O
to O
endocrine O
therapy O
. O

Given O
these O
facts O
, O
over O
the O
last O
10 O
years O
, O
several O
investigators O
have O
measured O
the O
number O
of O
glucocorticoid B
receptors I
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
to O
see O
whether O
their O
number O
correlated O
with O
glucocorticoid O
responsiveness O
in O
vitro O
or O
in O
vivo O
. O

No O
clear O
correlation O
could O
be O
established O
between O
the O
level O
of O
glucocorticoid B
receptor I
and O
the O
in O
vitro O
action O
of O
steroids O
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
. O

In O
contrast O
, O
attempts O
to O
correlate O
glucocorticoid B
receptor I
levels O
in O
acute O
lymphocytic O
leukemia O
to O
in O
vivo O
steroid O
responsiveness O
and O
immunological O
type O
using O
the O
whole O
- O
cell O
- O
binding O
assay O
for O
receptor O
determination O
and O
selecting O
the O
patients O
according O
to O
age O
and O
immunological O
criteria O
have O
been O
more O
successful O
. O

[ O
Glucocorticoid B
receptors I
in O
normal O
human O
lymphocytes O
] O

Administration O
of O
fibroblast O
interferon O
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone B
receptors I
. O

Decreased O
glucocorticoid B
receptor I
binding O
in O
adrenal O
insufficiency O
. O

To O
examine O
the O
effect O
of O
glucocorticoid O
deficiency O
on O
the O
glucocorticoid B
receptor I
, O
we O
examine O
the O
binding O
of O
[ O
3H O
] O
dexamethasone O
to O
lymphocytes O
in O
normal O
subjects O
and O
patients O
with O
adrenal O
insufficiency O
before O
and O
after O
glucocorticoid O
replacement O
therapy O
. O

Lymphocytes O
from O
patients O
with O
untreated O
adrenal O
insufficiency O
had O
fewer O
binding B
sites I
( O
3364 O
+ O
/ O
- O
322 O
) O
and O
a O
2 O
- O
fold O
increase O
in O
binding O
affinity O
( O
5 O
. O
4 O
+ O
/ O
- O
0 O
. O
9 O
mM O
) O
. O

Glucocorticoid B
receptor I
concentrations O
and O
terminal O
transferase O
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT O
) O
, O
adenosine B
deaminase I
, O
and O
5 O
' O
nucleotidase O
and O
the O
cellular O
concentration O
of O
glucocorticoid O
( O
dexamethasone O
) O
receptor O
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

The O
glucocorticoid B
receptor I
concentration O
of O
the O
leukaemic O
blast O
cells O
ranged O
from O
0 O
to O
0 O
. O
94 O
fmol O
/ O
microgram O
DNA O
. O

Thirteen O
patients O
had O
blast O
cells O
with O
a O
glucocorticoid B
receptor I
concentration O
over O
0 O
. O
22 O
fmol O
/ O
microgram O
DNA O
. O

Adenosine B
deaminase I
and O
5 O
' O
nucleotidase O
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O

These O
results O
show O
that O
measurements O
of O
TdT O
activity O
and O
the O
glucocorticoid B
receptor I
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non O
- O
lymphocytic O
leukaemia O

[ O
3H O
] O
cortivazol O
: O
a O
unique O
high O
affinity O
ligand O
for O
the O
glucocorticoid B
receptor I
. O

To O
assess O
the O
interaction O
between O
these O
atypical O
steroids O
and O
the O
glucocorticoid B
receptor I
, O
we O
examined O
the O
binding O
of O
[ O
3H O
] O
CVZ O
to O
cytosol O
from O
glucocorticoid O
- O
sensitive O
and O
- O
resistant O
variants O
of O
the O
human O
leukemic O
cell O
line O
CEM O
C7 O
. O

In O
glucocorticoid O
- O
sensitive O
cells O
[ O
3H O
] O
CVZ O
causes O
a O
2 O
- O
fold O
induction O
of O
glutamine B
synthetase I
and O
binds O
to O
a O
protein O
in O
the O
4 O
. O
6 O
S O
region O
of O
high O
salt O
sucrose O
gradients O
. O

In O
cytosol O
from O
a O
glucocorticoid O
- O
resistant O
cell O
line O
with O
virtually O
no O
[ O
3H O
] O
DEX O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high B
affinity I
binding I
site I
that O
was O
similar O
in O
dissociation O
constant O
( O
0 O
. O
8 O
nM O
) O
and O
receptor O
concentration O
( O
0 O
. O
13 O
pmol O
/ O
mg O
protein O
) O
to O
the O
high O
affinity O
site O
detected O
in O
the O
glucocorticoid O
- O
sensitive O
cell O
line O
C7 O
. O

intracytoplasmic O
immunoglobulin O
A O
+ O
and O
G O
+ O
, O
BA O
- O
1 O
+ O
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes O
14 O
and O
17 O
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B
14 I
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

The O
functional O
status O
of O
the O
steroid B
receptors I
was O
confirmed O
by O
nuclear O
transfer O
of O
the O
cytoplasmic O
hormone O
- O
receptor O
complex O
upon O
temperature O
activation O
. O

Previous O
studies O
, O
however O
, O
have O
not O
revealed O
any O
consistent O
relationship O
between O
clinical O
responsiveness O
and O
the O
cellular O
or O
cytosolic O
concentration O
of O
glucocorticoid B
- I
binding I
sites I
. O

The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid B
receptors I
in O
various O
types O
of O
leukemic O
cells O
and O
normal O
lymphocytes O
and O
to O
investigate O
the O
role O
of O
endogenous O
peptidases O
in O
receptor O
degradation O
. O

Fragmentation O
of O
the O
oligomer B
and O
the O
subunit O
was O
evident O
in O
some O
cytosols O
. O

Glucocorticoid B
receptor I
number O
and O
intracellular O
water O
space O
. O

In O
order O
to O
elucidate O
the O
relationship O
between O
cell O
water O
content O
and O
number O
of O
glucocorticoid B
receptors I
, O
eleven O
normal O
and O
malignant O
lymphoid O
or O
myelomonocytic O
cell O
types O
originating O
from O
mouse O
, O
rat O
and O
man O
were O
investigated O
. O

The O
cellular O
water O
space O
was O
measured O
with O
3H2O O
, O
and O
glucocorticoid B
receptor I
number O
was O
measured O
in O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
at O
30 O
and O
37 O
degrees O
C O
. O

The O
intracellular O
water O
phase O
concentration O
of O
glucocorticoid B
receptors I
( O
around O
40 O
nmol O
/ O
l O
cell O
water O
) O
, O
and O
the O
dependence O
of O
receptor O
affinity O
on O
temperature O
were O
similar O
in O
normal O
and O
malignant O
rodent O
and O
human O
cells O
. O

It O
is O
concluded O
that O
comparisons O
of O
glucocorticoid B
receptor I
levels O
are O
best O
made O
on O
the O
basis O
of O
intracellular B
receptor I
concentrations O
. O

Lymphoid O
cells O
contain O
specific O
receptors B
for O
glucocorticoids O
. O

We O
have O
used O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
to O
label O
covalently O
glucocorticoid B
receptors I
in O
rat O
thymic O
lymphocytes O
and O
in O
neoplastic O
cells O
obtained O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
and O
malignant O
lymphoma O
. O

The O
covalently O
labeled O
glucocorticoid B
receptors I
were O
identified O
by O
polyacrylamide O
gel O
electrophoresis O
( O
in O
the O
presence O
of O
0 O
. O
1 O
% O
sodium O
dodecyl O
sulfate O
) O
. O

In O
cytosolic O
fractions O
prepared O
from O
rat O
thymic O
lymphocytes O
, O
[ O
3H O
] O
- O
dexamethasone O
- O
21 O
- O
mesylate O
labels O
a O
protein O
( O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
) O
which O
was O
identified O
as O
the O
glucocorticoid B
receptor I
by O
the O
following O
criteria O
: O
( O
a O
) O
labeling O
of O
this O
moiety O
is O
inhibited O
by O
treatment O
with O
a O
100 O
- O
fold O
molar O
excess O
of O
glucocorticoids O
, O
such O
as O
dexamethasone O
and O
triamcinolone O
acetonide O
; O
and O
( O
b O
) O
the O
covalently O
labeled O
Mr O
approximately O
equal O
to O
95 O
, O

Approximately O
35 O
% O
of O
the O
glucocorticoid B
receptors I
can O
be O
labeled O
covalently O
when O
intact O
thymocytes O
are O
treated O
with O
100 O
nM O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
for O
30 O
min O
at O
4 O
degrees O
. O

Thus O
, O
in O
rat O
and O
human O
lymphoid O
cells O
, O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
can O
be O
used O
to O
label O
covalently O
the O
glucocorticoid B
receptor I
. O

Analysis O
has O
shown O
a O
relative O
interdependence O
between O
the O
steroid B
receptor I
status O
of O
primary O
breast O
cancer O
and O
other O
prognostic O
variables O
such O
as O
histological O
grade O
, O
lymphocytic O
infiltration O
and O
tumour O
elastosis O
. O

Cellularity O
and O
fibrosis O
were O
unrelated O
to O
the O
presence O
or O
absence O
of O
oestrogen B
receptor I
. O

Clinical O
implications O
of O
glucocorticoid B
receptors I
in O
human O
leukemia O
. O

Normal O
lymphoid O
cells O
contain O
glucocorticoid B
receptor I
. O

Similar O
glucocorticoid B
receptors I
can O
be O
detected O
in O
lymphoid O
cells O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O

Absence O
of O
the O
glucocorticoid B
receptor I
( O
usually O
found O
in O
treated O
patients O
) O
predicts O
lack O
of O
glucocorticoid O
responsiveness O
. O

Furthermore O
, O
in O
our O
hands O
, O
glucocorticoid B
receptor I
levels O
correlate O
with O
the O
duration O
of O
complete O
remission O
in O
ALL O
( O
though O
not O
in O
other O
forms O
of O
leukemia O
) O
. O

In O
some O
experimental O
conditions O
, O
corticosteroids O
inhibit O
Interleukin B
1 I
production O
by O
monocytes O
. O

CD28 B
- O
mediated O
activation O
in O
CD45RA O
+ O
and O
CD45RO O
+ O
T O
cells O
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c B
- I
Rel I
nuclear O
translocation O
in O
CD45RA O
+ O
cells O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti B
- I
CD3 I
plus O
anti B
- I
CD28 I
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF B
- I
kappaB I
DNA O
binding O
in O
CD45RA O
+ O
cells O
than O
in O
CD45RO O
+ O
cells O
. O

Analysis O
of O
the O
nuclear O
c O
- O
Rel O
protein O
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

Analysis O
of O
the O
cytoplasmic O
inhibitor O
IkappaBalpha B
indicated O
that O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
induced O
a O
long O
- O
lasting O
degradation O
in O
CD45RA O
+ O
cells O
but O
in O
CD45RO O
+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Ikaros B
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Here O
we O
review O
the O
role O
of O
Ikaros B
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc O
finger O
transcription O
factors O
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN O
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B
proteins I
exert O
their O
effects O
in O
development O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B
in O
the O
production O
and O
differentiation O
of O
these O
populations O
. O

Overexpression O
of O
p65 O
and O
c O
- O
Jun O
substitutes O
for O
B7 O
- O
1 O
costimulation O
by O
targeting O
the O
CD28RE B
within O
the O
IL B
- I
2 I
promoter I
. O

The O
role O
of O
Rel B
and O
activation B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
in O
IL B
- I
2 I
promoter I
activity O
in O
B7 O
- O
1 O
- O
and O
leukocyte O
function O
- O
associated O
Ag O
- O
3 O
( O
LFA O
. O
3 O
) O
- O
costimulated O
T O
cells O
has O
been O
evaluated O
. O

We O
demonstrate O
that O
overexpression O
of O
c B
- I
Jun I
but O
not O
c B
- I
Fos I
increases O
IL B
- I
2 I
promoter I
activity O
in O
both O
B7 O
- O
1 O
- O
and O
LFA O
- O
3 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Cotransfection O
of O
both O
c O
- O
Jun O
and O
c O
- O
Fos O
substitutes O
for O
B7 O
- O
1 O
costimulation O
in O
driving O
an O
activation O
protein O
- O
1 O
response O
element O
but O
not O
for O
the O
IL B
- I
2 I
promoter I
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear O
factor O
kappabeta O
reporter O
construct O
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 O
response O
element O
( O
CD28RE O
) O
- O
driven O
reporters O
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL O
- O
2 O
promoter O
- O
and O
CD28RE O
- O
driven O
reporter O
constructs O
in O
both O
LFA O
- O
3 O
- O
and O
B7 O
- O
1 O
- O
costimulated O
Jurkat O
cells O
. O

Mutating O
the O
CD28RE B
but O
not O
the O
upstream O
nuclear O
factor O
kappabeta O
- O
binding O
site O
in O
the O
IL B
- I
2 I
promoter I
reduced O
B7 B
- I
1 I
- O
driven O
transcription O
> O
90 O
% O
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B
in O
the O
integration O
of O
p65 B
/ O
c B
- I
Jun I
- O
mediated O
transcription O
within O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

BACKGROUND O
: O
Antigen O
- O
receptor O
interactions O
on O
lymphocytes O
result O
in O
local O
clustering O
of O
actin B
, O
receptors O
and O
signaling O
molecules O
into O
an O
asymmetric O
membrane O
structure O
termed O
a O
cap O
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B
( O
vav B
- O
/ O
- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine B
- I
nucleotide I
exchange I
factor I
for O
the O
GTPase B
Rac I
. O

RESULTS O
: O
Lymphocytes O
from O
vav B
- O
/ O
- O
mice O
failed O
to O
form O
T O
- O
cell O
receptor O
caps O
following O
activation O
and O
had O
a O
defective O
actin O
cytoskeleton O
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress O
- O
activated O
kinase O
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF O
- O
ATc1 O
and O
egr O
- O
1 O
genes O
was O
normal O
. O

Despite O
the O
reduced O
Ca2 O
+ O
mobilization O
, O
translocation O
of O
cytoplasmic O
NF O
- O
ATc O
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2 O
+ O
in O
vav O
- O
/ O
- O
cells O
were O
still O
sufficient O
to O
activate O
calcineurin B
. O

In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav B
or O
Rac B
could O
complement O
constitutively O
active O
calcineurin B
to O
activate O
NF O
- O
AT O
- O
dependent O
transcription O
. O

CONCLUSIONS O
: O
These O
results O
indicate O
that O
Vav B
is O
required O
for O
cap O
formation O
in O
lymphocytes O
. O

CD14 B
- O
dependent O
activation O
of O
human O
endothelial O
cells O
by O
Bacteroides O
fragilis O
outer O
membrane O
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E O
- O
selectin O
- O
specific O
mRNA O
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

Exposure O
of O
HUVECs O
to O
B O
. O
fragilis O
outer O
membrane O
fractions O
, O
separated O
from O
other O
components O
of O
the O
B O
. O
fragilis O
cell O
wall O
by O
isopycnic O
, O
sucrose O
gradient O
centrifugation O
, O
significantly O
increased O
surface O
expression O
of O
E B
- I
selectin I
and O
induced O
functional O
endothelial O
cell O
- O
dependent O
leukocyte O
adhesion O
. O

B O
. O
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF B
- I
kappa I
B I
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E B
- I
selectin I
mRNA I
in O
HUVEC O
cytoplasm O
. O

Two O
different O
monoclonal B
antibodies I
directed O
against O
human B
CD14 I
completely O
inhibited O
B O
. O
fragilis O
outer O
membrane O
- O
induced O
NF B
- I
kappa I
B I
activation O
, O
E O
- O
selectin O
transcription O
, O
and O
E O
- O
selectin O
surface O
expression O
. O

We O
conclude O
that O
the O
outer O
membrane O
component O
of O
the O
B O
. O
fragilis O
cell O
wall O
contains O
a O
proinflammatory O
factor O
( O
s O
) O
, O
that O
is O
not O
LPS O
, O
which O
induces O
human O
endothelial O
cell O
activation O
by O
a O
soluble O
CD14 B
- O
dependent O
mechanism O
. O

NF B
- I
kappaB I
protects O
HIV O
- O
1 O
- O
infected O
myeloid O
cells O
from O
apoptosis O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF B
- I
kappaB I
activity O
in O
chronically O
HIV O
- O
1 O
- O
infected O
promonocytic O
U937 O
( O
U9 O
- O
IIIB O
) O
and O
myeloblastic O
PLB O
- O
985 O
( O
PLB O
- O
IIIB O
) O
cells O
affects O
apoptotic O
signaling O
. O

TNFalpha B
and O
cycloheximide O
caused O
infected O
cells O
to O
undergo O
apoptosis O
more O
rapidly O
than O
parental O
U937 O
and O
PLB O
- O
985 O
cells O
. O

Inhibition O
of O
TNFalpha B
- O
induced O
NF O
- O
kappaB O
activation O
using O
the O
antioxidant O
N O
- O
acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9 O
- O
IIIB O
cells O
, O
while O
preactivation O
of O
NF B
- I
kappaB I
with O
the O
non O
- O
apoptotic O
inducer O
IL O
- O
1beta O
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

Inhibition O
of O
constitutive O
NF B
- I
kappaB I
activity O
in O
U9 O
- O
IIIB O
and O
PLB O
- O
IIIB O
cells O
also O
induced O
apoptosis O
, O
suggesting O
that O
NF O
- O
kappaB O
protects O
cells O
from O
a O
persistent O
apoptotic O
signal O
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax O
protein O
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

The O
protective O
role O
of O
NF B
- I
kappaB I
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB O
alpha O
repressor O
mutants O
( O
TD O
- O
IkappaB O
) O
under O
the O
control O
of O
a O
tetracycline O
- O
responsive O
promoter O
. O

Cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha B
only O
when O
NF O
- O
kappaB O
activation O
was O
inhibited O
by O
TD O
- O
IkappaB O
expression O
. O

As O
was O
observed O
for O
the O
U9 O
- O
IIIB O
cells O
, O
TNFalpha B
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
TD O
- O
IkappaB O
expressing O
cells O
. O

The O
heterodimeric O
Ku O
protein O
, O
which O
comprises O
a O
86 O
kDa O
( O
Ku86 O
) O
amd O
a O
70 O
kDa O
( O
Ku70 O
) O
subunits O
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA O
termini O
without O
sequence O
specificity O
. O

Ku B
is O
the O
DNA O
- O
targeting O
component O
of O
the O
large O
catalytic O
sub O
- O
unit O
of O
the O
DNA O
- O
dependent O
protein O
kinase O
complex O
( O
DNA B
- I
PK I
[ I
CS I
] I
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double O
- O
strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

The O
presence O
of O
this O
faster B
migrating I
complex I
was O
restricted O
to O
B O
cells O
among O
the O
circulating O
lymphocyte O
population O
. O

Although O
the O
heterodimer O
Ku70 O
/ O
variant O
- O
Ku86 O
binds O
to O
DNA O
- O
ends O
, O
this O
altered O
form O
of O
the O
Ku O
heterodimer O
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic O
component O
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Co O
- O
stimulation O
of O
human O
peripheral O
blood O
mononuclear O
cells O
with O
IL B
- I
2 I
and O
anti B
- I
CD3 I
monoclonal I
antibodies I
induces O
phosphorylation O
of O
CREB B
. O

Phosphorylation O
of O
the O
cAMP O
- O
response O
element O
binding O
protein O
CREB O
within O
1 O
h O
of O
CD2 B
but O
not O
CD3 B
cross O
- O
linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

The O
absence O
of O
P B
- I
CREB I
following O
CD3 O
cross O
- O
linking O
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB B
following O
CD3 O
cross O
- O
linking O
of O
the O
Jurkat O
lymphocyte O
cell O
line O
. O

Due O
to O
Jurkat O
T O
- O
cells O
being O
IL O
- O
2 O
- O
independent O
, O
it O
was O
postulated O
that O
IL B
- I
2 I
might O
provide O
a O
necessary O
co O
- O
stimulus O
for O
phosphorylation O
of O
CREB B
in O
primary O
lymphocytes O
. O

Therefore O
, O
P B
- I
CREB I
was O
evaluated O
following O
co O
- O
stimulation O
of O
human O
PBMC O
through O
the O
IL O
- O
2 O
and O
CD2 O
or O
CD3 O
receptors O
. O

IL B
- I
2 I
did O
not O
further O
augment O
phosphorylation O
of O
CREB B
following O
CD2 O
cross O
- O
linking O
. O

However O
, O
while O
neither O
IL B
- I
2 I
nor O
CD3 O
cross O
- O
linking O
alone O
induced O
P B
- I
CREB I
, O
a O
4 O
. O
5 O
- O
fold O
increase O
in O
phosphorylation O
of O
CREB B
within O
1 O
h O
of O
IL O
- O
2 O
/ O
CD3 O
co O
- O
stimulation O
was O
observed O
. O

Phosphorylation O
was O
not O
associated O
with O
the O
induction O
of O
cAMP O
, O
and O
inhibition O
of O
PKA O
signaling O
had O
no O
effect O
on O
P B
- I
CREB I
. O

Consistent O
with O
signal O
transduction O
through O
p56lck B
or O
p59fyn B
, O
inhibition O
of O
PTK O
signaling O
reduced O
phosphorylation O
50 O
% O
. O

In O
contrast O
to O
previous O
studies O
performed O
in O
the O
absence O
of O
exogenous B
IL I
- I
2 I
, O
no O
increase O
in O
binding O
of O
CREB B
to O
a O
32P O
- O
labeled O
oligonucleotide O
probe O
was O
observed O
by O
electrophoretic O
mobility O
shift O
assay O
. O

These O
data O
suggest O
that O
the O
IL B
- I
2 I
and O
CD3 B
signaling O
pathways O
provide O
a O
necessary O
and O
co O
- O
operative O
stimulus O
promoting O
phosphorylation O
of O
CREB B
following O
receptor O
cross O
- O
linking O
. O

Loss O
of O
immune O
function O
in O
HIV O
patients O
is O
usually O
associated O
with O
a O
profound O
dysregulation O
of O
cytokine B
production O
. O

To O
investigate O
whether O
cytokine B
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human O
donors O
were O
infected O
with O
two O
strains O
of O
HIV O
- O
1 O
and O
screened O
for O
the O
expression O
of O
STAT B
proteins I
used O
in O
cytokine B
signaling O
. O

A O
selective O
decrease O
in O
STAT5B B
was O
seen O
8 O
days O
after O
infection O
with O
the O
BZ167 O
dual O
- O
tropic O
HIV O
isolate O
, O
but O
not O
with O
the O
Ba O
- O
L O
, O
M O
- O
tropic O
strain O
. O

Based O
on O
these O
findings O
, O
purified O
T O
cells O
from O
HIV O
- O
infected O
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT O
expression O
; O
decreases O
in O
STAT5A B
, O
STAT5B B
, O
and O
STAT1alpha B
were O
observed O
in O
all O
patients O
. O

The O
reduction O
in O
STATs B
seen O
in O
vivo O
and O
in O
vitro O
after O
HIV O
infection O
may O
contribute O
to O
the O
loss O
of O
T O
cell O
function O
in O
HIV O
disease O
. O

Transcription B
factors I
that O
regulate O
monocyte O
/ O
macrophage O
differentiation O
. O

During O
myelopoiesis O
, O
external O
differentiating O
signals O
regulate O
the O
expression O
of O
a O
set O
of O
transcription B
factors I
. O

The O
combined O
action O
of O
these O
transcription B
factors I
subsequently O
determines O
the O
expression O
of O
myeloid B
- I
specific I
genes I
and O
the O
generation O
of O
monocytes O
and O
macrophages O
. O

We O
review O
the O
contribution O
of O
several O
transcription B
factors I
to O
the O
control O
of O
macrophage O
development O

LKLF O
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto B
- I
oncogene I
encoding O
c B
- I
Myc I
. O

Forced O
expression O
of O
LKLF O
was O
associated O
with O
markedly O
decreased O
c B
- I
Myc I
expression O
. O

In O
addition O
, O
many O
effects O
of O
LKLF O
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant O
- O
negative O
MadMyc O
protein O
and O
rescued O
by O
overexpression O
of O
c B
- I
Myc I
. O

HTLV O
- O
1 O
p12 O
( O
I O
) O
protein O
enhances O
STAT5 O
activation O
and O
decreases O
the O
interleukin B
- I
2 I
requirement O
for O
proliferation O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
. O

This O
study O
demonstrated O
that O
p12 O
( O
I O
) O
binds O
to O
the O
cytoplasmic B
domain I
of O
the O
interleukin O
- O
2 O
receptor O
( O
IL O
- O
2R O
) O
beta O
chain O
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 O
and O
Jak3 O
kinases O
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 O
( O
I O
) O
increases O
signal O
transducers O
and O
activators O
of O
transcription O
5 O
( O
STAT5 B
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL O
- O
2R O
beta O
and O
gamma O
( O
c O
) O
chains O
and O
Jak3 B
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human O
immunodeficiency O
virus O
type O
1 O
- O
based O
retroviral O
vector O
expressing O
p12 O
( O
I O
) O
also O
resulted O
in O
increased O
STAT5 B
phosphorylation O
and O
DNA O
binding O
. O

However O
, O
p12 O
( O
I O
) O
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T B
- I
cell I
receptors I
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 O
and O
alphaCD28 O
antibodies O
. O

In O
addition O
, O
the O
proliferative O
advantage O
of O
p12 O
( O
I O
) O
- O
transduced O
PBMCs O
was O
evident O
mainly O
at O
low O
concentrations O
of O
IL B
- I
2 I
. O

Cell O
activation O
was O
further O
confirmed O
by O
immunoprecipitation O
studies O
, O
which O
demonstrated O
phosphorylation O
of O
STAT4 B
but O
not O
STAT6 B
in O
both O
lymph O
nodes O
and O
spleen O
. O

However O
, O
at O
24 O
hours O
, O
STAT4 O
heterodimerisation O
with O
STAT B
3 I
was O
only O
observed O
in O
spleen O
. O

Critical O
downregulatory O
role O
of O
IL B
- I
4 I
. O

To O
determine O
the O
mechanisms O
by O
which O
IL B
- I
18 I
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B
in O
the O
regulation O
of O
IL O
- O
18 O
receptor O
alpha O
chain O
( O
IL O
- O
18Ralpha O
) O
expression O
. O

Upon O
antigen O
stimulation O
in O
the O
presence O
of O
IL B
- I
12 I
, O
marked O
enhancement O
of O
IL O
- O
18Ralpha O
expression O
was O
observed O
. O

IL B
- I
12 I
- O
mediated O
upregulation O
of O
IL O
- O
18Ralpha O
required O
IFN B
- I
gamma I
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL O
- O
18Ralpha O
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL O
- O
18Ralpha O
could O
respond O
to O
IL B
- I
18 I
alone O
. O

In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL B
- I
4 I
resulted O
in O
a O
downregulation O
of O
IL O
- O
18Ralpha O
expression O
. O

Furthermore O
, O
activated O
T O
cells O
from O
Stat6 O
( O
- O
/ O
) O
- O
mice O
produced O
more O
IFN B
- I
gamma I
in O
response O
to O
IL B
- I
18 I
than O
wild O
- O
type O
controls O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL O
- O
18Ralpha O
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

They O
act O
by O
binding O
to O
a O
specific O
receptor O
( O
GR B
) O
that O
, O
upon O
activation O
, O
translocates O
to O
the O
nucleus O
and O
either O
increases O
( O
transactivates O
) O
or O
decreases O
( O
transrepresses O
) O
gene O
expression O
. O

Inhibition O
of O
pro O
- O
inflammatory O
transcription O
factors O
such O
as O
activator B
protein I
( I
AP I
) I
- I
1 I
, O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
, O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
and O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Acetylation O
of O
histones O
allows O
unwinding O
of O
the O
local O
DNA O
structure O
and O
enables O
RNA B
polymerase I
II I
to O
enhance O
gene O
transcription O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B
acetyltransferases I
( O
HATs O
) O
and O
histone B
deacetylases I
( O
HDACs O
) O
. O

GR B
acts O
as O
a O
direct O
inhibitor O
of O
NF O
- O
kappa O
B O
- O
induced O
HAT O
activity O
and O
also O
by O
recruiting O
HDAC2 O
to O
the O
NF O
- O
kappa O
B O
/ O
HAT O
complex O
. O

Upon O
exposure O
to O
ultraviolet O
B O
, O
only O
XPA O
mice O
are O
very O
sensitive O
to O
ultraviolet O
- O
B O
- O
induced O
inhibition O
of O
Th1 O
- O
mediated O
contact O
hypersensitivity O
responses O
and O
interferon B
- I
gamma I
production O
in O
skin O
draining O
lymph O
nodes O
. O

Lipopolysaccharide O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
and O
interleukin B
- I
10 I
production O
are O
significantly O
augmented O
in O
both O
XPA O
and O
CSB O
mice O
after O
ultraviolet O
B O
exposure O
. O

This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class O
B O
scavenger O
receptor O
CD36 O
( O
2 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
- O
fold O
, O
P O
< O
0 O
. O
001 O
) O
but O
not O
by O
increased O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
expression O
. O

Peritoneal O
macrophages O
seem O
to O
participate O
in O
the O
process O
of O
peritoneal O
fibrosis O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
plays O
a O
key O
role O
in O
the O
recruitment O
of O
monocytes O
toward O
the O
peritoneal O
cavity O
. O

However O
, O
little O
is O
known O
about O
the O
effect O
of O
high O
glucose O
on O
MCP B
- I
1 I
expression O
and O
its O
signal O
transduction O
pathway O
in O
human O
peritoneal O
mesothelial O
cells O
. O

MCP B
- I
1 I
expression O
of O
mRNA O
and O
protein O
was O
measured O
by O
Northern O
blot O
analysis O
and O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

EMSA O
revealed O
that O
glucose O
increased O
the O
AP B
- I
1 I
binding O
activity O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
, O
but O
not O
NF B
- I
kappaB I
. O

Curcumin O
, O
an O
inhibitor O
of O
AP B
- I
1 I
, O
dose O
- O
dependently O
suppressed O
the O
induction O
of O
MCP O
- O
1 O
mRNA O
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12 O
. O
5 O
to O
50 O
micromol O
/ O
L O
) O
and O
herbimycin O
A O
( O
0 O
. O
1 O
to O
1 O
micromol O
/ O
L O
) O
inhibited O
the O
high O
- O
glucose O
- O
induced O
MCP O
- O
1 O
mRNA O
expression O
in O
a O
dose O
- O
dependent O
manner O
, O
and O
also O
suppressed O
the O
high O
- O
glucose O
- O
induced O
AP B
- I
1 I
binding O
activity O
. O

CONCLUSIONS O
: O
: O
High O
glucose O
induced O
mesothelial O
MCP B
- I
1 I
expression O
partly O
via O
the O
tyrosine O
kinase O
- O
AP B
- I
1 I
pathway O
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti O
- O
CD54 O
. O

The O
principal O
downstream O
component O
contributed O
by O
BCR B
signaling O
, O
toward O
both O
CD80 B
and O
CD86 B
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
Ca O
( O
2 O
+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O

This O
alone O
was O
sufficient O
to O
generate O
an O
increase O
in O
CD86 B
levels O
. O

However O
, O
CD80 B
enhancement O
required O
the O
concerted O
action O
of O
both O
intracellular O
Ca O
( O
2 O
+ O
) O
concentration O
and O
CD54 O
- O
initiated O
pathways O
. O

The O
nexus O
between O
anti O
- O
IgM O
and O
anti O
- O
CD54 O
stimulation O
, O
in O
the O
context O
of O
CD80 B
regulation O
, O
was O
identified O
to O
involve O
a O
self O
- O
propagating O
process O
of O
sequential O
synergy O
. O

The O
first O
step O
involved O
amplified O
accumulation O
of O
intracellular O
cAMP O
, O
as O
a O
result O
of O
cross O
- O
talk O
between O
BCR B
- O
mobilized O
Ca O
( O
2 O
+ O
) O
and O
CD54 O
- O
derived O
signals O
. O

This O
then O
facilitated O
a O
second O
synergistic O
interaction O
between O
Ca O
( O
2 O
+ O
) O
and O
cAMP O
, O
culminating O
in O
CD80 B
expression O
. O

LMP1 B
acts O
like O
a O
constitutively B
activated I
receptor I
of O
the O
tumor O
necrosis O
factor O
receptor O
family O
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor O
necrosis O
factor O
receptor O
- O
associated O
factor O
( O
TRAF O
) O
family O
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

The O
ability O
of O
LMP1 B
to O
suppress O
germinal O
center O
formation O
and O
its O
capacity O
to O
mediate O
its O
own O
transcriptional O
activation O
shed O
new O
light O
on O
the O
pathogenesis O
of O
EBV O
- O
associated O
latency O
type O
II O
lymphoproliferations O
like O
Hodgkin O
' O
s O
disease O
and O
angioimmunoblastic O
lymphadenopathy O
. O

The O
carboxy B
terminus I
of O
LMP1 B
is O
also O
a O
reliable O
marker O
for O
individual O
EBV O
strain O
identification O
and O
thus O
offers O
new O
possibilities O
in O
tracing O
the O
molecular O
events O
leading O
to O
posttransplant O
lymphoproliferative O
disorders O
( O
PTLDs O
) O
. O

Interferon B
- I
alpha I
drives O
T O
cell O
- O
mediated O
immunopathology O
in O
the O
intestine O
. O

We O
have O
recently O
described O
enhanced O
expression O
of O
IFN B
- I
alpha I
in O
the O
mucosa O
of O
patients O
with O
celiac O
disease O
( O
CD O
) O
, O
a O
gluten O
- O
sensitive O
Th1 O
- O
mediated O
enteropathy O
, O
characterized O
by O
villous O
atrophy O
and O
crypt O
cell O
hyperplasia O
. O

We O
have O
, O
therefore O
, O
examined O
changes O
that O
take O
place O
in O
explant O
cultures O
of O
human O
fetal O
gut O
after O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
and O
/ O
or O
IFN B
- I
alpha I
. O

We O
show O
that O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
alone O
elicits O
a O
small O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
response O
with O
no O
tissue O
injury O
. O

Similarly O
, O
no O
changes O
are O
seen O
in O
explants O
cultured O
with O
IFN B
- I
alpha I
alone O
. O

However O
, O
addition O
of O
IFN B
- I
alpha I
with O
anti B
- I
CD3 I
results O
in O
enhanced O
Th1 O
response O
and O
crypt O
cell O
hyperplasia O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 B
, O
STAT3 B
, O
and O
Fyn O
, O
a O
Src O
homology O
tyrosine O
kinase O
, O
which O
interacts O
with O
both O
TCR O
and O
IFN O
- O
alpha O
signal O
components O
. O

Together O
these O
data O
indicate O
that O
IFN B
- I
alpha I
can O
facilitate O
activation O
of O
Th1 O
- O
reactive O
cells O
in O
the O
gut O
and O
drive O
immunopathology O
. O

Suppression O
of O
tumor B
necrosis I
factor I
alpha I
production O
by O
cAMP O
in O
human O
monocytes O
: O
dissociation O
with O
mRNA O
level O
and O
independent O
of O
interleukin B
- I
10 I
. O

BACKGROUND O
: O
Elevation O
of O
cellular O
cAMP O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
production O
and O
increases O
the O
expression O
of O
interleukin B
( I
IL I
) I
- I
10 I
in O
mononuclear O
cells O
. O

TNF B
- I
alpha I
gene I
expression O
obligates O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
. O

Exogenous O
IL B
- I
10 I
inhibits O
NF B
- I
kappaB I
in O
monocytes O
and O
thus O
attenuates O
TNF B
- I
alpha I
production O
. O

We O
examined O
the O
role O
of O
endogenous O
IL B
- I
10 I
in O
the O
regulation O
of O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
in O
human O
monocytes O
by O
cAMP O
. O

Cytokine B
( O
TNF B
- I
alpha I
and O
IL B
- I
10 I
) O
release O
was O
measured O
by O
immunoassay O
. O

TNF B
- I
alpha I
mRNA I
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF B
- I
kappaB I
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O

RESULTS O
: O
cAMP O
- O
elevating O
agents O
inhibited O
LPS O
- O
stimulated O
TNF B
- I
alpha I
release O
( O
0 O
. O
77 O
+ O
/ O
- O
0 O
. O
13 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
0 O
. O
68 O
+ O
/ O
- O
0 O
. O
19 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0 O
. O
05 O
vs O
1 O
. O
61 O
+ O
/ O
- O
0 O
. O
34 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Conversely O
, O
cAMP O
enhanced O
LPS O
- O
stimulated O
IL B
- I
10 I
release O
( O
100 O
+ O
/ O
- O
21 O
. O
5 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
110 O
+ O
/ O
- O
25 O
. O
2 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0 O
. O
05 O
vs O
53 O
. O
3 O
+ O
/ O
- O
12 O
. O
8 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Neither O
TNF B
- I
alpha I
mRNA I
expression O
nor O
NF B
- I
kappaB I
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP O
- O
elevating O
agents O
. O

Neutralization O
of O
IL B
- I
10 I
with O
a O
specific O
antibody B
did O
not O
attenuate O
the O
effect O
of O
cAMP O
- O
elevating O
agents O
on O
TNF B
- I
alpha I
production O
. O

CONCLUSION O
: O
The O
results O
indicate O
that O
cAMP O
inhibits O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
through O
a O
posttranscriptional O
mechanism O
that O
is O
independent O
of O
endogenous O
IL B
- I
10 I
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP O
- O
2 O
activated O
the O
mouse O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
promoter O
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 O
- O
base O
pair O
( O
b O
) O
region O
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP O
- O
2 O
as O
well O
as O
expression O
of O
Smad1 O
, O
Smad4 O
, O
and O
constitutively O
active O
mutants O
of O
BMP O
type O
I O
receptors O
. O

Dendritic O
cells O
( O
DCs O
) O
are O
professional O
antigen O
- O
presenting O
cells O
which O
both O
initiate O
adaptive O
immune O
responses O
and O
control O
tolerance O
to O
self B
- I
antigens I
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll O
- O
like O
receptors O
2 O
and O
4 O
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal O
- O
transducing O
receptors O
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular O
signal O
- O
regulated O
kinases O
( O
Erk O
) O
1 O
/ O
2 O
, O
in O
the O
absence O
of O
detectable O
Jun B
N I
- I
terminal I
kinase I
( O
JNK B
) O
or O
p38 O
mitogen O
- O
activated O
kinase O
activation O
. O

Furthermore O
, O
STAT1 B
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B
or O
STAT5 B
respectively O
, O
could O
be O
detected O
in O
MB O
- O
stimulated O
MDM O
. O

Using O
MonoMac6 O
cells O
, O
we O
observed O
high O
C B
/ I
EBPbeta I
and O
AP B
- I
1 I
but O
weaker O
and O
transient O
NF B
- I
kappaB I
activation O
by O
MB O
. O

Moreover O
, O
the O
truncated O
form O
of O
C B
/ I
EBPbeta I
, O
known O
to O
repress O
HIV O
- O
1 O
transcription O
, O
was O
detected O
in O
extracts O
from O
MB O
- O
treated O
THP O
- O
1 O
cells O
. O

Surprisingly O
, O
neither O
MB O
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 B
and O
TLR2 O
or O
4 O
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co O
- O
receptors O
other O
than O
TLR2 B
and O
TLR4 B
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

The O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
alpha O
and O
gamma O
are O
nuclear B
receptors I
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O

In O
this O
study O
, O
we O
examined O
the O
possible O
role O
of O
PPARs B
in O
macrophage O
attraction O
into O
the O
peritoneal O
cavity O
of O
patients O
with O
endometriosis O
. O

Long O
- O
term O
- O
impaired O
expression O
of O
nuclear B
factor I
- I
kappa I
B I
and O
I B
kappa I
B I
alpha I
in O
peripheral O
blood O
mononuclear O
cells O
of O
trauma O
patients O
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
expression O
and O
dimer O
characteristics O
were O
studied O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
major O
- O
trauma O
patients O
and O
healthy O
controls O
. O

The O
ex O
vivo O
expression O
of O
I B
kappa I
B I
alpha I
was O
higher O
in O
PBMCs O
of O
controls O
than O
of O
trauma O
patients O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin B
- I
10 I
or O
transforming B
growth I
factor I
- I
beta I
and O
NF B
- I
kappa I
B I
, O
these O
immunosuppressive O
cytokines O
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

The O
long O
- O
term O
low O
- O
basal O
and O
LPS O
- O
induced O
nuclear O
translocation O
of O
NF B
- I
kappa I
B I
recalled O
long O
- O
term O
immunoparalysis O
observed O
in O
patients O
with O
severe O
inflammatory O
stress O
such O
as O
trauma O
. O

Keywords O
included O
reperfusion O
injury O
, O
transplantation O
, O
liver O
resection O
, O
nitric O
oxide O
, O
endothelin O
, O
cytokines B
, O
Kupffer O
cells O
, O
ischemic O
/ O
ischaemic O
preconditioning O
, O
and O
nuclear B
factor I
- I
kappa I
B I
. O

Activation O
of O
nuclear B
factor I
- I
kappa I
B I
in O
the O
liver O
promotes O
proinflammatory B
cytokine I
and O
adhesion B
molecule I
synthesis O
. O

Although O
IL B
- I
12 I
together O
with O
IFN B
- I
gamma I
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL O
- O
12 O
p70 O
protein O
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

The O
inhibition O
was O
induced O
by O
interaction O
with O
macrophages O
that O
had O
contacted O
with O
P O
. O
berghei O
- O
infected O
erythrocytes O
and O
was O
mediated O
by O
a O
soluble O
factor O
, O
IL B
- I
10 I
. O

There O
was O
comparable O
activation O
of O
NF B
- I
kappaB I
in O
uninfected O
and O
infected O
cells O
. O

The O
induction O
of O
IFN O
- O
regulatory O
factor O
- O
1 O
gene O
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected O
cells O
, O
while O
the O
unidentified O
complex O
formation O
of O
IFN B
- I
regulatory I
factor I
- I
1 I
was O
observed O
in O
infected O
cells O
. O

The O
RING O
finger O
protein O
Siah O
- O
1 O
regulates O
the O
level O
of O
the O
transcriptional B
coactivator I
OBF B
- I
1 I
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer O
site O
DNA O
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

Here O
we O
have O
identified O
the O
RING O
finger O
protein O
Siah O
- O
1 O
as O
a O
protein O
interacting O
specifically O
with O
OBF B
- I
1 I
. O

This O
interaction O
is O
mediated O
by O
the O
C O
- O
terminal O
part O
of O
Siah O
- O
1 O
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct O
POU O
domains O
and O
the O
DNA O
. O

Interaction O
between O
Siah O
- O
1 O
and O
OBF B
- I
1 I
leads O
to O
downregulation O
of O
OBF O
- O
1 O
protein O
level O
but O
not O
mRNA O
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site O
- O
dependent O
transcription O
activation O
. O

The O
association O
of O
trans O
- O
acting O
T O
cell O
factors O
( O
TCFs O
) O
or O
lymphoid O
enhancer O
factor O
1 O
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta O
- O
catenin O
- O
- O
binding O
domain O
in O
TCF B
- I
1 I
. O

Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF B
- I
1 I
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti O
- O
apoptotic O
protein O
Bcl B
- I
x I
( I
L I
) I
. O

Thus O
, O
TCF B
- I
1 I
, O
upon O
association O
with O
beta O
- O
catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T O
cell O
receptor O
( O
TCR O
) O
alpha O
chains O
and O
attempt O
TCR B
- O
mediated O
positive O
selection O
. O

TRAIL O
/ O
Apo2L O
also O
overcame O
the O
survival O
effect O
of O
interleukin B
6 I
on O
MM O
cells O
and O
did O
not O
affect O
the O
survival O
of O
peripheral O
blood O
and O
bone O
marrow O
mononuclear O
cells O
and O
purified O
B O
cells O
from O
healthy O
donors O
. O

The O
anti O
- O
MM O
activity O
of O
TRAIL O
/ O
Apo2L O
was O
confirmed O
in O
nu O
/ O
xid O
/ O
bg O
mice O
xenografted O
with O
human O
MM O
cells O
; O
TRAIL B
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL O
receptor O
death O
receptor O
5 O
( O
DR5 O
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Nuclear O
factor O
( O
NF O
) O
- O
kappaB O
inhibitors O
, O
such O
as O
SN50 O
( O
a O
cell O
- O
permeable O
inhibitor O
of O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
NF B
- I
kappaB I
) O
or O
the O
proteasome O
inhibitor O
PS O
- O
341 O
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL O
/ O
Apo2L O
against O
TRAIL O
- O
sensitive O
MM O
cells O
, O
whereas O
SN50 O
reversed O
the O
TRAIL O
resistance O
of O
ARH O
- O
77 O
and O
IM O
- O
9 O
MM O
cells O
. O

Importantly O
, O
normal O
B O
lymphocytes O
were O
not O
sensitized O
to O
TRAIL B
by O
either O
Dox O
, O
SN50 O
, O
or O
PS O
- O
341 O
. O

These O
preclinical O
studies O
suggest O
that O
TRAIL O
/ O
Apo2L O
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL B
- O
based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
MM O
. O

CD28 B
costimulation O
is O
required O
not O
only O
to O
induce O
IL B
- I
12 I
receptor I
but O
also O
to O
render O
janus O
kinases O
/ O
STAT4 O
responsive O
to O
IL B
- I
12 I
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

Here O
, O
we O
investigated O
how O
CD28 O
costimulation O
functions O
to O
allow O
TCR B
- O
triggered O
resting O
T O
cells O
to O
acquire O
IL B
- I
12 I
responsiveness O
. O

When O
T O
cells O
are O
stimulated O
with O
low O
doses O
of O
anti B
- I
CD3 I
mAb I
, O
CD28 O
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL B
- I
12 I
receptor I
( O
IL B
- I
12R I
) O
expression O
. O

However O
, O
stimulation O
of O
T O
cells O
with O
high O
doses O
of O
anti B
- I
CD3 I
alone O
induced O
comparable O
levels O
of O
IL B
- I
12R I
expression O
to O
those O
induced O
upon O
CD28 O
costimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 O
/ O
TYK2 O
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up O
- O
regulating O
IL B
- I
12R I
expression O
but O
is O
also O
required O
to O
render O
JAKs O
/ O
STAT4 O
responsive O
to O
IL B
- I
12 I
stimulation O
. O

Role O
of O
Mcl O
- O
1 O
, O
independent O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
, O
Bad B
, O
or O
caspase O
activation O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin O
homologue O
deleted O
from O
chromosome B
10 I
or O
src O
homology O
2 O
domain O
- O
containing O
5 O
' O
inositol O
phosphatase O
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Akt O
- O
1 O
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K B
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt O
- O
1 O
and O
induced O
cell O
death O
. O

Furthermore O
, O
suppression O
of O
Akt O
- O
1 O
by O
inhibition O
of O
PI3K B
or O
a O
dominant O
negative O
( O
DN O
) O
Akt O
- O
1 O
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases O
- O
9 O
and O
- O
3 O
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K B
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt O
- O
1 O
or O
Bcl B
- I
x I
( I
L I
) I
. O

Inhibition O
of O
PI3K B
/ O
Akt O
- O
1 O
pathway O
either O
by O
LY294002 O
or O
DN O
Akt O
- O
1 O
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
in O
human O
macrophages O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt O
- O
1 O
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl O
- O
1 O
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl O
- O
1 O
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt O
- O
1 O
regulates O
macrophage O
survival O
through O
Mcl O
- O
1 O
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid O
receptor O
splice O
variant O
GRbeta B
in O
inflammatory O
cells O
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O

OBJECTIVE O
: O
The O
purposes O
of O
this O
investigation O
were O
to O
determine O
whether O
nasal O
polyp O
( O
NP O
) O
inflammatory O
cells O
overexpress O
GRbeta B
and O
to O
examine O
whether O
GRbeta B
overexpression O
is O
associated O
with O
insensitivity O
to O
the O
potent O
topical O
steroid O
fluticasone O
propionate O
( O
FP O
) O
. O

Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta B
and O
probed O
for O
various O
cytokine B
mRNA I
. O

The O
percentage O
of O
inflammatory O
cells O
expressing O
GRbeta B
was O
also O
increased O
( O
40 O
. O
5 O
% O
+ O
/ O
- O
19 O
. O
2 O
% O
vs O
16 O
. O
1 O
% O
+ O
/ O
- O
4 O
. O
0 O
% O
, O
P O
= O
. O
009 O
) O
. O

GRbeta B
expression O
in O
NPs O
was O
almost O
exclusive O
to O
T O
lymphocytes O
, O
eosinophils O
, O
and O
macrophages O
. O

An O
inverse O
correlation O
was O
observed O
between O
the O
baseline O
inflammatory O
cell O
GRbeta B
expression O
and O
the O
reduction O
after O
FP O
treatment O
in O
EG2 O
- O
positive O
eosinophils O
, O
CD4 O
- O
positive O
T O
lymphocytes O
, O
endothelial O
VCAM B
- I
1 I
expression O
, O
and O
IL O
- O
4 O
mRNA O
- O
positive O
cells O
. O

` O
` O
FP O
- O
insensitive O
' O
' O
NPs O
also O
demonstrated O
a O
higher O
percentage O
of O
IL O
- O
5 O
- O
positive O
inflammatory O
cells O
expressing O
GRbeta B
before O
and O
after O
FP O
treatment O
. O

CONCLUSION O
: O
GRbeta B
expression O
appears O
to O
be O
a O
marker O
of O
steroid O
insensitivity O
in O
NPs O
. O

Expression O
of O
GRbeta B
by O
NP O
inflammatory O
cells O
, O
particularly O
T O
cells O
and O
eosinophils O
, O
might O
render O
them O
resistant O
to O
suppression O
by O
topical O
steroids O
and O
thereby O
contribute O
to O
persistent O
NP O
inflammation O
. O

Transcriptional O
regulation O
of O
galectin O
- O
10 O
( O
eosinophil O
Charcot O
- O
Leyden O
crystal O
protein O
) O
: O
a O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal O
promoters O
of O
galectins O
- O
1 O
, O
- O
2 O
, O
and O
- O
3 O
. O

The O
decrease O
in O
gal O
- O
10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
or O
the O
Oct O
site O
( O
- O
255 O
to O
- O
261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA O
and O
EoTF O
sites O
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus O
GC O
box O
and O
the O
Oct O
site O
, O
respectively O
. O

Similar O
to O
gal O
- O
1 O
, O
gal O
- O
10 O
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC B
box I
. O

Evidence O
is O
presented O
that O
if O
they O
are O
to O
grow O
, O
end O
buds O
must O
condition O
proximal O
fatty O
stroma O
by O
recruiting O
white O
blood O
cells O
as O
well O
as O
inducing O
stromal O
cell O
division O
and O
, O
possibly O
, O
estrogen B
receptors I
. O

Although O
the O
signals O
governing O
fibrotic O
induction O
, O
ductal O
morphogenesis O
, O
and O
growth O
inhibition O
are O
unknown O
, O
a O
role O
for O
transforming O
growth B
factor I
- I
beta I
is O
highly O
likely O
and O
is O
discussed O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin O
mRNA O
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

Constitutive O
expression O
of O
MHC B
class I
II I
genes I
in O
melanoma O
cell O
lines O
results O
from O
the O
transcription O
of O
class B
II I
transactivator I
abnormally O
initiated O
from O
its O
B B
cell I
- I
specific I
promoter I
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA B
- I
DR I
and O
HLA B
- I
DP I
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA B
- I
DQ I
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA O
- O
D O
isotypes O
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA O
- O
D O
genes O
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA O
( O
class O
II O
transactivator O
) O
transcripts O
, O
CIITA B
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

Unexpectedly O
, O
these O
transcripts O
initiate O
from O
promoter O
III O
of O
the O
CIITA B
gene I
, O
a O
promoter O
that O
is O
mainly O
used O
constitutively O
in O
B O
lymphocytes O
. O

Constitutive O
transcription O
of O
CIITA B
from O
promoter O
III O
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines O
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O

Caspase B
- O
mediated O
calcineurin O
activation O
contributes O
to O
IL B
- I
2 I
release O
during O
T O
cell O
activation O
. O

Calcineurin B
, O
a O
Ca O
( O
2 O
+ O
) O
/ O
calmodulin O
- O
dependent O
Ser O
/ O
Thr O
phosphatase O
( O
protein O
phosphatase O
2B O
) O
, O
plays O
a O
critical O
role O
in O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

It O
has O
been O
previously O
reported O
that O
IL B
- I
2 I
release O
in O
activated O
Jurkat O
T O
requires O
caspase O
- O
like O
activity O
( O
Posmantur O
et O
al O
. O
( O
1998 O
) O
Exp O
. O
Cell O
. O
Res O
. O
244 O
, O
302 O
- O
309 O
) O
. O

We O
report O
here O
that O
the O
60 O
- O
kDa O
catalytic O
subunit O
of O
calcineurin O
A O
( O
Cn O
A O
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases B
( O
caspase O
- O
8 O
and O
- O
9 O
) O
as O
well O
as O
effector O
caspase O
- O
3 O
was O
also O
observed O
. O

Cn O
A O
cleavage O
was O
also O
observed O
when O
purified O
calcineurin B
was O
digested O
in O
vitro O
with O
caspase B
- I
3 I
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I O
- O
activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B
substrate O
NFATc B
( O
a O
transcription B
factor I
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL B
- I
2 I
gene I
) O
, O
was O
also O
suppressed O
by O
Z O
- O
D O
- O
DCB O
. O

METHODS O
: O
We O
prepared O
immature O
dendritic O
cells O
by O
incubating O
CD14 O
- O
positive O
cells O
in O
the O
presence O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
interleukin B
( I
IL I
) I
- I
4 I
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
a O
, O
IL B
- I
1 I
beta I
, O
and O
prostaglandin B
E2 I
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
- O
- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

We O
quantified O
the O
effect O
of O
drugs O
on O
the O
dendritic O
cell O
characteristics O
, O
such O
as O
stimulation O
of O
autologous O
and O
allogeneic O
pan O
- O
T O
cell O
proliferation O
, O
surface O
marker O
phenotype O
, O
IL O
- O
12 O
p40 O
subunit O
secretion O
, O
and O
activation O
of O
nuclear B
transcription I
factor I
( I
NF I
) I
- I
kappa I
B I
. O

In O
distinction O
to O
drug O
- O
free O
maturing O
dendritic O
cells O
, O
2 O
. O
5 O
micromol O
/ O
L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B
and O
CD68 B
and O
downregulated O
the O
levels O
of O
CD40 B
, O
CD80 B
, O
and O
CD83 O
( O
for O
all O
CD O
markers O
, O
p O
< O
0 O
. O
03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

Defective O
function O
of O
the O
proteasome B
in O
autoimmunity O
: O
involvement O
of O
impaired O
NF O
- O
kappaB O
activation O
. O

Type O
1 O
diabetes O
( O
also O
known O
as O
insulin O
- O
dependent O
diabetes O
mellitus O
or O
juvenile O
- O
onset O
diabetes O
) O
is O
usually O
caused O
by O
T O
cell O
- O
mediated O
autoimmunity O
, O
with O
a O
prediabetic O
state O
characterized O
by O
the O
production O
of O
autoantibodies B
specific O
for O
proteins O
expressed O
by O
pancreatic O
beta O
cells O
. O

A O
specific O
proteasome B
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down O
- O
regulation O
of O
expression O
of O
the O
proteasome O
subunit O
LMP2 O
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC O
genomic O
region O
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
. O

The O
novel O
role O
of O
the O
proteasome B
in O
dysfunction O
in O
autoimmunity O
is O
presented O
and O
documented O
to O
be O
both O
tissue O
and O
developmental O
stage O
specific O
. O

We O
propose O
a O
role O
of O
the O
proteasome B
as O
a O
step O
in O
disease O
pathogenesis O
and O
tissue O
targeting O
. O

Down O
- O
regulation O
of O
TDT O
transcription O
in O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocytes O
by O
Ikaros B
proteins I
in O
direct O
competition O
with O
an O
Ets O
activator O
. O

Ikaros B
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric O
heterochromatin O
and O
has O
been O
implicated O
in O
heritable O
gene O
inactivation O
. O

However O
, O
these O
mutations O
abolished O
down O
- O
regulation O
on O
differentiation O
, O
providing O
evidence O
that O
Ikaros B
plays O
a O
direct O
role O
in O
repression O
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B
should O
be O
disrupted O
by O
a O
small O
isoform O
that O
retains O
the O
dimerization B
domain I
and O
lacks O
the O
DNA B
- I
binding I
domain I
. O

Surprisingly O
, O
in O
the O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small O
Ikaros O
isoform O
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA O
- O
binding O
properties O
of O
Ikaros B
. O

Type B
I I
interferons I
and O
IL B
- I
12 I
: O
convergence O
and O
cross O
- O
regulation O
among O
mediators O
of O
cellular O
immunity O
. O

Therapeutic O
use O
of O
type O
I O
IFN O
( O
IFN B
- I
alpha I
/ I
beta I
) O
has O
become O
common O
. O

We O
characterized O
the O
effects O
of O
type O
I O
IFN O
on O
the O
production O
of O
IL B
- I
12 I
, O
the O
central O
immunoregulatory O
cytokine O
of O
the O
CD4 O
( O
+ O
) O
T O
cell O
arm O
of O
CMI O
. O

Type O
I O
IFN O
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL B
- I
12 I
in O
driving O
IFN O
- O
gamma O
production O
from O
T O
and O
NK O
cells O
. O

The O
ability O
of O
IFN B
- I
alpha I
/ I
beta I
to O
suppress O
IL O
- O
12 O
production O
while O
up O
- O
regulating O
IFN O
- O
gamma O
production O
suggests O
a O
possible O
mechanistic O
basis O
for O
the O
difficulties O
of O
employing O
these O
cytokines B
in O
diseases O
involving O
abnormalities O
of O
CMI O
. O

Nuclear B
factor I
- I
kappaB I
suppressive O
and O
inhibitor O
- O
kappaB O
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with O
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
? O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory O
transcription O
factor O
nuclear O
factor O
- O
kappaB O
and O
its O
inhibitory O
protein O
IkappaB O
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma O
soluble O
intracellular O
adhesion O
molecule O
- O
1 O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen O
activator O
inhibitor O
- O
1 O
, O
and O
C B
- I
reactive I
protein I
. O

Nuclear B
factor I
- I
kappaB I
binding O
activity O
in O
MNC O
nuclear O
extracts O
was O
significantly O
inhibited O
after O
troglitazone O
treatment O
at O
week O
1 O
and O
continued O
to O
be O
inhibited O
up O
to O
week O
4 O
. O

Reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 O
( O
phox O
) O
subunit O
protein O
quantities O
, O
plasminogen O
activator O
inhibitor O
- O
1 O
, O
and O
C B
- I
reactive I
protein I
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

OX40 O
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
superfamily I
and O
known O
to O
be O
an O
important O
costimulatory O
molecule O
expressed O
on O
activated O
T O
cells O
. O

Endogenous O
TNF B
alpha I
( O
TNF B
- I
alpha I
) O
and O
TNF O
- O
beta O
production O
were O
not O
involved O
in O
the O
enhanced O
HIV O
- O
1 O
production O
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 O
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 O
and O
p65 O
subunits O
. O

Peroxizome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPARgamma B
) O
is O
a O
member O
of O
the O
nuclear B
receptor I
family I
of O
transcription B
factors I
that O
regulate O
adipocyte O
differentiation O
. O

In O
this O
study O
, O
we O
examined O
whether O
PPARgamma B
ligand O
regulates O
osteopontin O
gene O
expression O
in O
THP O
- O
1 O
cells O
, O
a O
cell O
line O
derived O
from O
human O
monocytic O
leukemia O
cells O
which O
can O
differentiate O
to O
macrophage O
upon O
stimulation O
with O
phorbol O
ester O
PMA O
. O

Troglitazone O
, O
a O
PPARgamma B
ligand O
, O
dramatically O
attenuated O
the O
PMA O
- O
induced O
osteopontin O
expression O
. O

Transient O
transfection O
assays O
of O
the O
human O
osteopontin O
promoter O
/ O
luciferase O
construct O
which O
contains O
a O
5 B
' I
- I
flanking I
region I
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription B
start I
site I
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma O
expression O
vector O
inhibits O
osteopontin O
promoter O
activity O
. O

These O
data O
indicate O
that O
troglitazone O
reduces O
osteopontin O
gene O
expression O
at O
transcriptional O
level O
through O
PPARgamma B
activation O
, O
and O
suggest O
the O
role O
of O
troglitazone O
in O
inhibiting O
the O
ability O
of O
macrophages O
to O
produce O
extracellular O
matrix O
, O
which O
is O
particularly O
relevant O
to O
atherosclerotic O
plaque O
formation O
. O

Transcription B
factor I
NF I
- I
kappa I
B I
regulates O
Ig O
lambda O
light O
chain O
gene O
rearrangement O
. O

Accessibility O
within O
a O
given O
locus O
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B
factors I
with O
cognate B
enhancer I
elements I
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene O
segments O
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa O
locus O
is O
regulated O
by O
the O
inducible B
transcription I
factor I
NF B
- I
kappaB I
. O

In O
contrast O
to O
the O
Igkappa O
locus O
, O
known O
transcriptional O
control O
elements O
in O
the O
Iglambda O
locus O
lack O
functional O
NF B
- I
kappaB I
binding I
sites I
. O

Consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda O
genes O
in O
mature O
B O
cells O
has O
been O
shown O
to O
be O
NF B
- I
kappaB I
independent O
. O

Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF B
- I
kappaB I
inhibits O
germline O
transcription O
and O
recombination O
of O
Iglambda O
gene O
segments O
in O
precursor O
B O
cells O
. O

Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF B
- I
kappaB I
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase O
accessibility O
. O

In O
contrast O
, O
the O
activities O
of O
known O
Iglambda O
promoter O
and O
enhancer B
elements I
are O
unaffected O
in O
the O
same O
cellular O
background O
. O

These O
findings O
expand O
the O
range O
of O
NF B
- I
kappaB I
action O
in O
precursor O
B O
cells O
beyond O
Igkappa B
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L O
chain O
loci O
. O

Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda O
regulatory O
element O
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF B
- I
kappaB I
during O
the O
early O
stages O
of O
B O
cell O
development O
. O

Transcription B
factor I
STAT5A B
is O
a O
substrate O
of O
Bruton O
' O
s O
tyrosine O
kinase O
in O
B O
cells O
. O

STAT5A B
is O
a O
molecular O
regulator O
of O
proliferation O
, O
differentiation O
, O
and O
apoptosis O
in O
lymphohematopoietic O
cells O
. O

Here O
we O
show O
that O
STAT5A B
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton O
' O
s O
tyrosine O
kinase O
( O
BTK B
) O
. O

BTK B
was O
also O
capable O
of O
tyrosine O
- O
phosphorylating O
ectopically O
expressed O
recombinant O
STAT5A O
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus B
kinase I
3 I
- O
independent O
fashion O
. O

BTK B
phosphorylated O
the O
Y665F O
, O
Y668F O
, O
and O
Y682F O
, O
Y683F O
mutants O
but O
not O
the O
Y694F O
mutant O
of O
STAT5A B
. O

STAT5A O
mutations O
in O
the O
Src O
homology O
2 O
( O
SH2 O
) O
and O
SH3 O
domains O
did O
not O
alter O
the O
BTK B
- O
mediated O
tyrosine O
phosphorylation O
. O

Recombinant O
BTK O
proteins O
with O
mutant O
pleckstrin O
homology O
, O
SH2 O
, O
or O
SH3 O
domains O
were O
capable O
of O
phosphorylating O
STAT5A B
, O
whereas O
recombinant O
BTK O
proteins O
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

In O
pull O
- O
down O
experiments O
, O
only O
full O
- O
length O
BTK O
and O
its O
SH1 O
/ O
kinase O
domain O
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 O
, O
or O
SH3 O
domains O
) O
were O
capable O
of O
binding O
STAT5A B
. O

Ectopically O
expressed O
BTK O
kinase O
domain O
was O
capable O
of O
tyrosine O
- O
phosphorylating O
STAT5A B
both O
in O
vitro O
and O
in O
vivo O
. O

BTK B
- O
mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr O
( O
694 O
) O
mutant O
) O
STAT5A B
enhanced O
its O
DNA O
binding O
activity O
. O

In O
BTK B
- O
competent O
chicken O
B O
cells O
, O
anti O
- O
IgM O
- O
stimulated O
tyrosine O
phosphorylation O
of O
STAT5 O
protein O
was O
prevented O
by O
pretreatment O
with O
the O
BTK B
inhibitor O
LFM O
- O
A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI O
- O
P131 O
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
wild O
type O
human O
BTK O
but O
not O
in O
BTK B
- O
deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase O
- O
inactive O
mutant O
BTK O
. O

Similarly O
, O
anti O
- O
IgM O
stimulation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5A B
in O
BTK B
- O
competent O
B O
cells O
from O
wild O
type O
mice O
but O
not O
in O
BTK B
- O
deficient O
B O
cells O
from O
XID O
mice O
. O

These O
findings O
provide O
unprecedented O
experimental O
evidence O
that O
BTK B
plays O
a O
nonredundant O
and O
pivotal O
role O
in O
B O
cell O
antigen O
receptor O
- O
mediated O
STAT5A O
activation O
in O
B O
cells O

Role O
of O
T O
- O
bet O
in O
commitment O
of O
TH1 O
cells O
before O
IL B
- I
12 I
- O
dependent O
selection O
. O

How O
cytokines B
control O
differentiation O
of O
helper O
T O
( O
TH O
) O
cells O
is O
controversial O
. O

We O
show O
that O
T O
- O
bet O
, O
without O
apparent O
assistance O
from O
interleukin O
12 O
( O
IL O
- O
12 O
) O
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon O
- O
gamma O
( O
IFN O
- O
gamma O
) O
alleles O
and O
by O
inducing O
IL O
- O
12 O
receptor O
beta2 O
expression O
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth O
signal O
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

These O
results O
suggest O
that O
a O
cytokine B
does O
not O
simply O
induce O
TH O
fate O
choice O
but O
instead O
may O
act O
as O
an O
essential O
secondary O
stimulus O
that O
mediates O
selective O
survival O
of O
a O
lineage O
. O

Stat6 B
is O
necessary O
and O
sufficient O
for O
IL O
- O
4 O
' O
s O
role O
in O
Th2 O
differentiation O
and O
cell O
expansion O
. O

IL B
- I
4 I
plays O
a O
critical O
role O
in O
the O
differentiation O
of O
T O
CR O
- O
stimulated O
naive O
CD4 O
T O
cells O
to O
the O
Th2 O
phenotype O
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine O
binding O
domain O
- O
containing O
proteins O
, O
including O
insulin O
receptor O
substrate O
1 O
/ O
2 O
, O
Shc B
, O
and O
IL O
- O
4R O
interacting O
protein O
, O
as O
well O
as O
Stat6 B
. O

Stat6 B
has O
been O
shown O
to O
be O
required O
for O
Th2 O
differentiation O
. O

Furthermore O
, O
IL O
- O
4 O
- O
driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F O
, O
although O
cells O
infected O
with O
Y497F O
were O
not O
capable O
of O
phosphorylating O
insulin B
receptor I
substrate I
2 I
. O

These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 O
is O
dispensable O
for O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O

A O
constitutively O
activated O
form O
of O
Stat6 B
introduced O
into O
CD4 O
T O
cells O
resulted O
in O
both O
Th2 O
differentiation O
and O
enhanced O
cell O
expansion O
. O

Thus O
, O
activated O
Stat6 O
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 O
T O
cells O
. O

The O
effect O
of O
HIV O
- O
1 O
regulatory O
proteins O
on O
cellular O
genes O
: O
derepression O
of O
the O
IL B
- I
2 I
promoter I
by O
Tat B
. O

Increase O
secretion O
of O
IL B
- I
2 I
, O
the O
major O
T O
cell O
growth O
and O
differentiation O
cytokine B
, O
may O
play O
a O
decisive O
role O
in O
sensitization O
of O
T O
cells O
for O
activation O
induced O
apoptosis O
and O
indirect O
death O
of O
activated O
T O
cells O
through O
augmented O
virus O
replication O
. O

We O
investigated O
the O
cause O
of O
enhanced O
IL O
- O
2 O
secretion O
and O
found O
that O
the O
HIV B
Tat I
induces O
this O
effect O
. O

We O
demonstrate O
that O
increased O
IL O
- O
2 O
secretion O
is O
due O
to O
Tat B
- O
enhanced O
IL B
- I
2 I
promoter I
activation O
. O

Tat B
derepresses O
and O
activates O
the O
distal O
AP O
- O
1 O
site O
( O
position O
- O
185 O
to O
- O
177 O
) O
in O
the O
IL B
- I
2 I
promoter I
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP O
- O
1 O
( O
IL O
- O
2 O
/ O
d O
) O
site O
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric O
activator O
containing O
p65 B
and O
c B
- I
Jun I
binds O
to O
the O
AP O
- O
1 O
( O
IL O
- O
2 O
/ O
d O
) O
site O
. O

HIV B
Tat I
enhances O
activation O
of O
NF B
- I
kappaB I
and O
consequently O
, O
activates O
the O
AP O
- O
1 O
( O
IL O
- O
2 O
/ O
d O
) O
site O
. O

Our O
data O
provide O
evidence O
for O
a O
novel O
mechanism O
by O
which O
HIV B
Tat I
dysregulates O
IL O
- O
2 O
production O
and O
therefore O
may O
contribute O
to O
the O
HIV O
- O
1 O
infection O
in O
a O
way O
yet O
to O
be O
clarified O
. O

Transforming B
growth I
factor I
- I
beta1 I
interferes O
with O
thrombopoietin O
- O
induced O
signal O
transduction O
in O
megakaryoblastic O
and O
erythroleukemic O
cells O
. O

OBJECTIVE O
: O
Thrombopoietin B
( O
TPO B
) O
and O
transforming B
growth I
factor I
- I
beta I
( I
1 I
) I
( O
TGF B
- I
beta I
( I
1 I
) I
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

To O
determine O
whether O
TGF B
- I
beta I
( I
1 I
) I
interferes O
directly O
with O
TPO B
- O
induced O
signal O
transduction O
in O
hematopoietic O
cells O
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO B
- O
responsive O
cell O
lines O
Mo O
- O
7e O
and O
HEL O
. O

MATERIALS O
AND O
METHODS O
: O
The O
cells O
were O
stimulated O
by O
100 O
ng O
/ O
mL O
TPO B
and O
/ O
or O
100 O
ng O
/ O
mL O
TGF B
- I
beta1 I
and O
analyzed O
for O
proliferation O
( O
3H O
thymidine O
incorporation O
) O
, O
viability O
( O
trypan O
blue O
exclusion O
) O
, O
and O
protein O
expression O
and O
phosphorylation O
( O
Western O
blot O
) O
. O

RESULTS O
: O
TPO B
enhanced O
the O
proliferation O
of O
Mo O
- O
7e O
cells O
as O
determined O
by O
3H O
- O
thymidine O
incorporation O
, O
whereas O
TGF B
- I
beta1 I
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B
. O

TPO B
- O
induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK O
extracellular O
signal O
- O
regulated O
kinases O
( O
ERK B
) O
ERK1 B
and O
ERK2 B
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus O
kinase O
- O
2 O
, O
which O
completely O
blocked O
TPO B
- O
induced O
proliferation O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF B
- I
beta1 I
reduced O
the O
TPO B
- O
stimulated O
ERK1 B
/ O
ERK2 B
and O
STAT5 O
phosphorylation O
in O
Mo O
- O
7e O
and O
HEL O
cells O
. O

This O
effect O
was O
completely O
reversed O
by O
preincubation O
with O
a O
tyrosine O
phosphatase O
inhibitor O
( O
Na3VO4 O
) O
, O
which O
suggests O
that O
TGF B
- I
beta1 I
activated O
a O
phosphatase B
. O

Although O
STAT3 B
also O
was O
activated O
by O
TPO B
, O
STAT3 B
activation O
remained O
unaltered O
by O
TGF B
- I
beta1 I
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF B
- I
beta1 I
modulates O
TPO B
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK O
ERK1 O
/ O
ERK2 O
and O
STAT5 O
. O

This O
final O
maturation O
step O
is O
crucial O
for O
the O
B O
cells O
to O
become O
responsive O
to O
antigens B
and O
to O
participate O
in O
the O
immune O
response O
. O

Recently O
, O
invariant O
chain O
( O
Ii B
) O
, O
a O
major O
histocompatibility O
complex O
class O
II O
chaperone O
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

In O
this O
study O
, O
we O
investigated O
a O
possible O
link O
between O
Ii B
- O
dependent O
B O
cell O
maturation O
and O
the O
NF O
- O
kappaB O
pathway O
. O

Our O
studies O
indicate O
that O
Ii B
- O
induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF O
- O
kappaB O
p65 O
/ O
RelA O
homodimer O
and O
requires O
the O
B O
cell O
- O
enriched O
coactivator O
TBP O
- O
associated O
factor O
( O
II O
) O
105 O
. O

To O
investigate O
whether O
the O
observed O
thymolytic O
effects O
were O
due O
to O
the O
presence O
of O
hormone B
receptors I
on O
thymocytes O
, O
cells O
were O
isolated O
from O
the O
thymus O
and O
incubated O
with O
androgens O
or O
oestrogens O
to O
measure O
apoptosis O
. O

Therefore O
, O
upon O
in O
vivo O
androgen O
treatment O
, O
other O
cells O
containing O
androgen B
receptors I
than O
thymocytes O
are O
probably O
involved O
in O
inducing O
the O
increase O
in O
thymic O
apoptosis O
. O

To O
study O
the O
role O
of O
the O
androgen B
receptor I
on O
thymocyte O
apoptosis O
, O
androgen B
receptor I
mutant O
( O
Tfm O
/ O
Y O
) O
mice O
were O
treated O
with O
androgens O
. O

No O
alterations O
of O
thymocyte O
subpopulations O
were O
seen O
, O
suggesting O
that O
changes O
in O
the O
percentage O
of O
CD4 O
+ O
CD8 O
+ O
thymocytes O
after O
administration O
of O
androgens O
depend O
on O
the O
presence O
of O
functional O
androgen B
receptors I
. O

Inhibition O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappaB I
in O
CD4 O
T O
cells O
by O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
ligands O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
a O
member O
of O
the O
nuclear O
hormone O
receptor O
superfamily O
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

PPARgamma B
has O
been O
found O
recently O
to O
regulate O
macrophage O
activation O
in O
response O
to O
mitogens B
and O
inflammation O
. O

Our O
study O
shows O
PPARgamma B
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting O
T O
cells O
and O
to O
increase O
upon O
activation O
of O
T O
cells O
by O
either O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
phorbol O
myristyl O
acetate O
( O
PMA O
) O
. O

We O
also O
found O
the O
PPARgamma B
ligand I
ciglitizone O
to O
attenuate O
the O
activation O
of O
T O
cells O
by O
inhibiting O
cytokine O
gene O
expression O
and O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
PMA O
- O
induced O
proliferative O
responses O
. O

Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 O
T O
cells O
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B
factors I
AP1 B
and O
NF B
- I
kappaB I
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma O
ligands O
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma B
as O
a O
negative O
regulator O
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

PPARgamma B
may O
thus O
be O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmunity O
. O

A O
prominent O
role O
for O
activator B
protein I
- I
1 I
in O
the O
transcription O
of O
the O
human O
2B4 O
( O
CD244 O
) O
gene O
in O
NK O
cells O
. O

The O
cell O
surface O
glycoprotein O
2B4 O
( O
CD244 O
) O
of O
the O
Ig B
superfamily I
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

We O
have O
recently O
identified O
CD48 B
as O
the O
high O
affinity O
counterreceptor O
for O
2B4 O
in O
both O
mice O
and O
humans O
. O

The O
cytoplasmic B
domain I
of O
2B4 O
associates O
with O
src O
homology O
2 O
domain O
- O
containing O
protein O
or O
signaling O
lymphocyte O
activation O
molecule O
- O
associated O
protein O
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

We O
isolated O
h2B4 O
genomic O
clones O
and O
PCR O
amplified O
the O
5 B
' I
untranslated I
region I
containing O
the O
promoter B
elements I
. O

We O
have O
identified O
a O
functional O
AP B
- I
1 I
site I
that O
lies O
between O
( O
- O
106 O
to O
- O
100 O
) O
through O
transient O
transfection O
analysis O
in O
YT O
cells O
, O
a O
human O
NK O
cell O
line O
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun O
family O
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 O
gene O
. O

Mutation O
of O
the O
AP B
- I
1 I
site I
not O
only O
abolishes O
protein O
/ O
DNA O
interactions O
but O
also O
promoter O
activity O
. O

These O
results O
demonstrate O
a O
significant O
role O
for O
AP B
- I
1 I
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 O
gene O
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C O
- O
complementation O
group O
( O
FA O
- O
C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon B
gamma I
( O
IFNgamma B
) O
, O
the O
products O
of O
certain O
IFNgamma O
- O
inducible O
genes O
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma O
- O
inducible O
genes O
, O
IFN O
- O
stimulated O
gene O
factor O
3 O
gamma O
subunit O
( O
ISGF3gamma O
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
( O
WAF1 B
) O
was O
found O
in O
FANCC O
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Levels O
of O
the O
IFNgamma B
- O
inducible O
factor O
IFN O
consensus O
sequence O
binding O
protein O
( O
ICSBP B
) O
, O
a O
negative O
trans O
- O
acting O
regulator O
of O
some O
IFNgamma O
- O
inducible O
genes O
, O
were O
quantified O
. O

ICSBP B
levels O
were O
reduced O
in O
FA O
- O
C O
B O
lymphoblasts O
and O
MEFs O
. O

However O
, O
enforced O
expression O
of O
ICSBP B
failed O
to O
down O
- O
regulate O
IRF B
- I
1 I
, O
ISGF3gamma O
, O
and O
p21 O
( O
WAF1 O
) O
. O

Thus O
, O
the O
FANCC O
protein O
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes O
that O
in O
normal O
cells O
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN O
- O
STAT1 O
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP B
expression O
. O

These O
committed O
lymphoid O
cells O
must O
then O
undergo O
V O
( O
D O
) O
J O
recombination O
at O
the O
immunoglobulin B
gene I
or O
T O
cell O
receptor O
gene O
locus O
resulting O
in O
clonal O
production O
of O
functional O
B O
or O
T O
lymphocytes O
, O
respectively O
. O

The O
basic B
- I
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
encoded O
by O
the O
E2A B
gene I
are O
involved O
in O
several O
differentiation O
events O
during O
B O
and O
T O
cell O
development O
, O
including O
lineage O
commitment O
, O
initiation O
of O
V O
( O
D O
) O
J O
recombination O
, O
and O
antigen O
receptor O
mediated O
proliferation O
and O
differentiation O
. O

Most O
of O
these O
activities O
have O
been O
largely O
attributed O
to O
the O
inhibitory O
effect O
of O
D609 O
on O
phosphatidylcholine O
- O
specific O
phospholipase B
C I
. O

Furthermore O
, O
preincubation O
of O
lymphocytes O
with O
D609 O
resulted O
in O
a O
significant O
diminution O
of O
ionizing O
radiation O
( O
IR O
) O
- O
induced O
1 O
) O
production O
of O
reactive O
oxygen O
species O
; O
2 O
) O
decrease O
in O
intracellular O
reduced O
glutathione O
; O
3 O
) O
oxidative O
damage O
to O
proteins O
and O
lipids O
; O
and O
4 O
) O
activation O
of O
nuclear B
factor I
- I
kappaB I
. O

Inhibition O
of O
AP B
- I
1 I
by O
the O
glucocorticoid O
- O
inducible O
protein O
GILZ O
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B
receptor I
and O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

Here O
we O
show O
that O
glucocorticoid O
- O
induced O
inhibition O
of O
interleukin O
- O
2 O
mRNA O
expression O
in O
activated O
normal O
T O
cells O
required O
new O
protein O
synthesis O
, O
suggesting O
that O
this O
phenomenon O
is O
secondary O
to O
expression O
of O
glucocorticoid O
- O
regulated O
genes B
. O

One O
of O
the O
most O
prominent O
glucocorticoid O
- O
induced O
genes B
is O
glucocorticoid O
- O
induced O
leucine O
zipper O
( O
GILZ O
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation O
- O
induced O
up O
- O
regulation O
of O
Fas O
ligand O
( O
FasL O
) O
mRNA O
. O

Indeed O
, O
transient O
expression O
of O
GILZ O
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B
construct I
driven O
by O
the O
FasL B
promoter I
. O

This O
could O
be O
accounted O
for O
by O
GILZ O
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT O
/ O
AP O
- O
1 O
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

GILZ O
also O
potently O
inhibited O
AP O
- O
1 O
- O
driven O
and O
IL O
- O
2 O
promoter O
- O
driven O
reporter O
constructs O
, O
and O
recombinant O
GILZ O
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active O
AP O
- O
1 O
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ O
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 O
- O
amino O
acid O
region O
of O
GILZ O
. O

Thus O
, O
GILZ O
represents O
a O
glucocorticoid O
- O
induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation O
- O
induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP B
- I
1 I
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Smad3 O
and O
Smad4 O
mediate O
transforming B
growth I
factor I
- I
beta1 I
- O
induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA O
isotype O
switching O
factor O
and O
Smad O
molecules O
have O
been O
reported O
to O
act O
as O
transducers O
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

We O
examined O
the O
involvement O
of O
Smad O
proteins O
in O
TGF B
- I
beta1 I
- O
induced O
IgA O
expression O
. O

First O
, O
we O
found O
that O
TGF B
- I
beta1 I
significantly O
increases O
endogenous O
germ O
- O
line O
( O
GL O
) O
alpha O
transcripts O
by O
LPS O
- O
stimulated O
CH12 O
. O
LX O
. O
4933 O
( O
mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 O
that O
contains O
the O
TGF O
- O
beta O
- O
responsive O
element O
of O
the O
GLalpha O
promoter O
, O
and O
stimulated O
with O
TGF B
- I
beta1 I
. O

Similar O
to O
endogenous O
GLalpha O
transcripts O
, O
TGF B
- I
beta1 I
induces O
GLalpha O
promoter O
activity O
and O
overexpression O
of O
Smad3 O
markedly O
enhances O
the O
promoter O
activity O
. O

On O
the O
other O
hand O
, O
Smad7 B
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3 O
/ O
4 O
on O
GLalpha O
promoter O
activity O
. O

In O
addition O
, O
overexpression O
of O
Smad3 O
/ O
4 O
enhances O
TGF B
- I
beta1 I
- O
induced O
endogenous O
GLalpha O
transcripts O
in O
normal O
spleen O
B O
cell O
s O
. O

Finally O
, O
in O
the O
presence O
of O
TGF B
- I
beta1 I
, O
overexpression O
of O
Smad3 O
/ O
4 O
selectively O
increases O
both O
surface O
IgA O
expression O
and O
IgA O
production O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 O
, O
Smad4 O
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA O
switching O
related O
gene O
and O
regulation O
of O
IgA O
class O
switching O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase O
( O
pol B
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

Upon O
B O
cell O
receptor O
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol O
zeta O
, O
downregulated O
pol O
eta O
, O
and O
mutated O
the O
Ig O
and O
bcl O
- O
6 O
genes O
. O

We O
previously O
reported O
that O
Tax B
induced O
cell O
cycle O
progression O
from O
G0 O
/ O
G1 O
phase O
to O
S O
and O
G2 O
/ O
M O
phases O
in O
human O
T O
- O
cell O
line O
Kit O
225 O
cells O
. O

To O
elucidate O
molecular O
mechanism O
of O
Tax B
- O
induced O
cell O
cycle O
progression O
, O
we O
systematically O
examined O
the O
effects O
of O
Tax B
on O
biochemical O
events O
associated O
with O
cell O
cycle O
progression O
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin O
dependent O
kinase O
2 O
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb O
family O
proteins O
and O
an O
increase O
in O
free O
E2F B
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell O
cycle O
regulatory O
molecules O
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 O
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK O
inhibitors O
p19 O
( O
INK4d O
) O
and O
p27 B
( I
Kip1 I
) I
. O

These O
modulations O
by O
Tax B
always O
paralleled O
the O
ability O
of O
Tax B
to O
activate O
the O
NF O
- O
kappaB O
transcription O
pathway O
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax B
- O
mediated O
trans O
- O
activation O
of O
the O
genes O
for O
cell O
cycle O
regulatory O
molecules O
in O
Tax B
- O
induced O
cell O
cycle O
progression O
. O

Cot O
kinase O
induces O
cyclooxygenase O
- O
2 O
expression O
in O
T O
cells O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
. O

Cyclooxygenase B
- I
2 I
( O
COX B
- I
2 I
) O
is O
induced O
in O
human O
T O
lymphocytes O
upon O
T B
cell I
receptor I
triggering O
. O

Here O
we O
report O
that O
Cot O
kinase O
, O
a O
mitogen O
- O
activated O
protein O
kinase O
kinase O
kinase O
involved O
in O
T O
cell O
activation O
, O
up O
- O
regulates O
COX B
- I
2 I
gene I
expression O
in O
Jurkat O
T O
cells O
. O

Induction O
of O
COX O
- O
2 O
promoter O
activity O
by O
Cot O
kinase O
occurred O
mainly O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot O
kinase O
- O
mediated O
COX O
- O
2 O
promoter O
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium O
- O
dependent O
phosphatase O
calcineurin O
synergizes O
with O
Cot O
kinase O
in O
the O
up O
- O
regulation O
of O
COX O
- O
2 O
promoter O
- O
driven O
transcription O
. O

Strikingly O
, O
Cot O
kinase O
increased O
transactivation O
mediated O
by O
a O
GAL4 O
- O
NFAT O
fusion O
protein O
containing O
the O
N B
- I
terminal I
transactivation I
domain I
of O
NFATp B
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot O
kinase O
increases O
both O
COX O
- O
2 O
promoter O
activity O
and O
NFAT B
- O
mediated O
transactivation O
in O
a O
cyclosporin O
A O
- O
independent O
manner O
. O

These O
data O
indicate O
that O
Cot O
kinase O
up O
- O
regulates O
COX O
- O
2 O
promoter O
- O
driven O
transcription O
through O
the O
NFAT O
response O
elements O
, O
being O
the O
Cot O
kinase O
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

The O
acquisition O
of O
one O
Ly O
- O
49 O
receptor O
, O
Ly O
- O
49A O
is O
strictly O
dependent O
on O
the O
transcriptional O
trans O
- O
acting O
factor O
T O
cell O
- O
specific O
factor O
- O
1 O
( O
TCF B
- I
1 I
) O
. O

Indeed O
, O
TCF B
- I
1 I
binds O
to O
two O
sites O
in O
the O
Ly O
- O
49a O
promoter O
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly O
- O
49a O
gene O
is O
a O
direct O
TCF B
- I
1 I
target O
. O

TCF B
- I
1 I
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly O
- O
49 O
receptors O
. O

Our O
findings O
rather O
suggest O
a O
TCF B
- I
1 I
- O
dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly O
- O
49 O
receptors O
. O

Besides O
reduced O
receptor O
usage O
( O
Ly O
- O
49A O
and O
D O
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly O
- O
49C O
) O
and O
significantly O
expanded O
( O
Ly O
- O
49G O
and O
I O
) O
receptor O
usage O
in O
the O
absence O
of O
TCF B
- I
1 I
. O

These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF O
binding O
sites O
in O
the O
respective O
proximal B
promoter I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF B
- I
1 I
for O
Ly O
- O
49 O
receptor O
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF O
site O
in O
certain O
proximal O
Ly O
- O
49 O
promoters O
. O

These O
findings O
reveal O
an O
important O
role O
of O
TCF B
- I
1 I
for O
the O
formation O
of O
the O
NK O
cell O
receptor O
repertoire O
. O

Ligation O
of O
CD11b B
and O
CD11c O
beta O
( O
2 O
) O
integrins B
by O
antibodies B
or O
soluble O
CD23 O
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP O
- O
1beta O
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Chemokines B
and O
adhesion B
molecules I
such O
as O
integrins B
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a O
alpha O
chains O
of O
beta O
( O
2 O
) O
integrins O
by O
antibodies B
or O
soluble O
CD23 O
( O
sCD23 O
) O
fusion O
proteins O
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage O
inflammatory O
protein O
( O
MIP O
) O
1alpha O
, O
and O
MIP O
- O
1beta O
. O

Because O
the O
promoters B
of O
these O
chemokine O
genes O
contain O
kappaB O
binding O
sites O
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 O
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

Activation O
of O
NF B
- I
kappaB I
was O
accompanied O
by O
degradation O
of O
its O
cytosolic O
inhibitor O
IkappaB O
- O
alpha O
. O

Blockade O
of O
depletion O
of O
IkappaB B
- I
alpha I
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl O
- O
leucinyl O
- O
leucinyl O
- O
norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF O
- O
kappaB O
DNA O
- O
binding O
activity O
and O
expression O
of O
MIP O
- O
1alpha O
and O
MIP O
- O
1beta O
messenger O
RNA O
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c O
beta O
( O
2 O
) O
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP O
- O
1beta O
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

Synergistic O
transcriptional O
activation O
of O
human O
Acyl O
- O
coenzyme O
A O
: O
cholesterol O
acyltransterase O
- O
1 O
gene O
by O
interferon B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
THP O
- O
1 O
cells O
. O

Human O
ACAT O
- O
1 O
gene O
contains O
two O
promoters B
( O
P1 B
and O
P7 O
) O
, O
each O
located O
in O
a O
different O
chromosome O
( O
1 O
and O
7 O
) O
( O
Li O
, O
B O
. O
L O
. O
, O
Li O
, O
X O
. O
L O
. O
, O
Duan O
, O
Z O
. O
J O
. O
, O
Lee O
, O
O O
. O
, O
Lin O
, O
S O
. O
, O
Ma O
, O
Z O
. O
M O
. O
, O
Chang O
, O
C O
. O
C O
. O
, O
Yang O
, O
X O
. O
Y O
. O
, O
Park O
, O
J O
. O
P O
. O
, O
Mohandas O
, O
T O
. O
K O
. O
, O
Noll O
, O
W O
. O
, O
Chan O
, O
L O
. O
, O
and O
Chang O
, O
T O
. O
Y O
. O
( O
1999 O
) O
J O
. O
Biol O
Chem O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
a O
cytokine B
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT O
- O
1 O
mRNA O
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

This O
region O
contains O
4 O
Sp1 O
elements O
and O
an O
IFN B
- I
gamma I
activated I
sequence I
( O
GAS B
) O
that O
overlaps O
with O
the O
second O
Sp1 B
element I
. O

In O
the O
monocytic O
cell O
line O
THP O
- O
1 O
cell O
, O
the O
combination O
of O
IFN B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT O
- O
1 O
P1 O
promoter O
but O
not O
the O
P7 O
promoter O
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS O
/ O
Sp1 O
site O
in O
the O
ACAT O
- O
1 O
P1 O
promoter O
. O

Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN B
- I
gamma I
in O
causing O
transcriptional O
activation O
of O
ACAT O
- O
1 O
in O
macrophage O
- O
like O
cells O
. O

OBJECTIVE O
: O
To O
examine O
whether O
inhaled O
nitric O
oxide O
( O
NO O
) O
affected O
the O
intrapulmonary O
production O
of O
NO O
, O
reactive O
oxygen O
species O
, O
and O
nuclear B
factor I
- I
kappaB I
in O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
model O
of O
acute O
lung O
injury O
. O

Inhaled O
NO O
also O
blocked O
the O
activities O
of O
reactive O
oxygen O
species O
and O
nuclear B
factor I
- I
kappaB I
binding O
to O
DNA O
in O
lavage O
cells O
and O
in O
alveolar O
macrophages O
. O

The O
mechanism O
of O
reducing O
NO O
production O
resulting O
from O
inhaled O
NO O
may O
involve O
, O
in O
part O
, O
the O
activities O
of O
reactive O
oxygen O
species O
and O
/ O
or O
nuclear B
factor I
- I
kappaB I
. O

Treatment O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
by O
antisense O
- O
induced O
local O
blockade O
of O
GATA B
- I
3 I
expression O
. O

Recent O
studies O
in O
transgenic O
mice O
have O
revealed O
that O
expression O
of O
a O
dominant O
negative O
form O
of O
the O
transcription B
factor I
GATA I
- I
3 I
in O
T O
cells O
can O
prevent O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
- O
mediated O
allergic O
airway O
inflammation O
in O
mice O
. O

However O
, O
it O
remains O
unclear O
whether O
GATA B
- I
3 I
plays O
a O
role O
in O
the O
effector O
phase O
of O
allergic O
airway O
inflammation O
and O
whether O
antagonizing O
the O
expression O
and O
/ O
or O
function O
of O
GATA B
- I
3 I
can O
be O
used O
for O
the O
therapy O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
. O

Here O
, O
we O
analyzed O
the O
effects O
of O
locally O
antagonizing O
GATA B
- I
3 I
function O
in O
a O
murine O
model O
of O
asthma O
. O

We O
could O
suppress O
GATA O
- O
3 O
expression O
in O
interleukin B
( I
IL I
) I
- I
4 I
- O
producing O
T O
cells O
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation B
start I
site I
of O
GATA B
- I
3 I
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O

These O
data O
indicate O
a O
critical O
role O
for O
GATA B
- I
3 I
in O
the O
effector O
phase O
of O
a O
murine O
asthma O
model O
and O
suggest O
that O
local O
delivery O
of O
GATA O
- O
3 O
antisense O
oligonucleotides O
may O
be O
a O
novel O
approach O
for O
the O
treatment O
of O
airway O
hyperresponsiveness O
such O
as O
in O
asthma O
. O

This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory O
Th2 O
cytokines O
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine B
. O

METHODS O
AND O
RESULTS O
: O
BALB O
/ O
c O
mice O
, O
making O
a O
CD4 O
+ O
Th2 O
( O
IL O
- O
4 O
+ O
) O
cell O
response O
, O
express O
both O
MHC B
class I
II I
antigens I
( O
IA O
( O
d O
) O
, O
IE O
( O
d O
) O
) O
and O
are O
atherosclerosis O
- O
resistant O
. O

C57Bl O
/ O
6 O
mice O
produce O
a O
CD4 O
+ O
Th1 O
( O
interferon O
[ O
IFN O
] O
gamma O
+ O
) O
response O
, O
express O
IA O
( O
b O
) O
but O
no O
IE B
, O
and O
are O
atherosclerosis O
- O
prone O
. O

Decreasing O
Th1 O
cells O
by O
antibodies B
( O
alpha O
- O
CD4 O
) O
or O
cytokines B
( O
IL B
- I
4 I
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

Immunohistology O
revealed O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
colocalized O
with O
activated O
macrophages O
. O

CONCLUSIONS O
: O
In O
mildly O
hypercholesterolemic O
C57Bl O
/ O
6 O
mice O
, O
presence O
of O
IA O
( O
b O
) O
and O
absence O
of O
IE B
regulated O
CD4 O
+ O
T O
helper O
- O
cell O
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma O
+ O
Th1 O
cells O
in O
both O
C57Bl O
/ O
6 O
and O
BALB O
/ O
c O
strains O
. O

IFN B
- I
gamma I
may O
participate O
through O
macrophage O
activation O
, O
whereas O
IL B
- I
4 I
may O
act O
to O
limit O
Th1 O
- O
cell O
response O
. O

Requirement O
for O
p38 B
and O
p44 O
/ O
p42 O
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE O
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

We O
demonstrate O
here O
that O
human O
serum O
albumin O
modified O
with O
N O
( O
varepsilon O
) O
- O
( O
carboxymethyl O
) O
lysine O
( O
CML O
) O
, O
a O
major O
AGE O
adduct O
that O
progressively O
accumulates O
with O
aging O
, O
diabetes O
, O
and O
renal O
failure O
, O
induced O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
- O
driven O
reporter O
gene O
expression O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative O
ligand O
- O
binding O
domain O
of O
RAGE O
, O
with O
anti O
- O
RAGE O
antiserum O
, O
and O
by O
coexpression O
of O
truncated O
receptors O
lacking O
the O
intracellular B
domain I
. O

Signal O
transduction O
from O
RAGE O
to O
NF B
- I
kappaB I
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter O
gene O
expression O
was O
blocked O
with O
the O
antioxidant O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

CML O
- O
modified O
albumin O
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular O
signal O
- O
regulated O
kinase O
1 O
and O
2 O
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
, O
but O
not O
c O
- O
Jun O
NH O
( O
2 O
) O
- O
terminal O
kinase O
. O

RAGE O
- O
mediated O
NF O
- O
kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 B
MAPK I
inhibitor O
SB203580 O
and O
by O
coexpression O
of O
a O
kinase O
- O
dead O
p38 O
dominant O
- O
negative O
mutant O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML O
- O
modified O
albumin O
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

These O
results O
indicate O
that O
p38 B
MAPK I
activation O
mediates O
RAGE O
- O
induced O
NF B
- I
kappaB I
- O
dependent O
secretion O
of O
proinflammatory B
cytokines I
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

Antigen O
- O
receptor O
cross O
- O
linking O
and O
lipopolysaccharide O
trigger O
distinct O
phosphoinositide B
3 I
- I
kinase I
- O
dependent O
pathways O
to O
NF O
- O
kappa O
B O
activation O
in O
primary O
B O
cells O
. O

Nuclear B
NF I
- I
kappaB I
is O
induced O
in O
B O
cells O
by O
engagement O
of O
either O
the O
BCR B
or O
CD40 B
or O
by O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

Despite O
the O
importance O
of O
NF B
- I
kappaB I
to O
B O
cell O
function O
, O
little O
is O
known O
about O
the O
signaling O
pathways O
leading O
to O
NF O
- O
kappaB O
activation O
. O

In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide B
3 I
' I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
in O
BCR B
- O
and O
LPS O
- O
induced O
NF O
- O
kappaB O
activation O
using O
populations O
of O
primary O
murine O
resting O
B O
cells O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B
3 I
- I
kinase I
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B
3 I
- I
kinase I
activity O
is O
vital O
for O
BCR B
- O
induced O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
. O

Furthermore O
, O
we O
show O
that O
this O
is O
achieved O
via O
protein B
kinase I
C I
- O
dependent O
degradation O
of O
IkappaBalpha B
. O

Similar O
analyses O
reveal O
that O
PI B
3 I
- I
kinase I
is O
also O
critical O
in O
triggering O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
and O
IkappaBalpha B
degradation O
following O
LPS O
stimulation O
. O

Interestingly O
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR B
- O
induced O
IkappaBalpha B
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B
after O
LPS O
stimulation O
. O

Taken O
together O
, O
our O
results O
indicate O
the O
involvement O
of O
PI B
3 I
- I
kinase I
in O
at O
least O
two O
distinct O
signaling O
pathways O
leading O
to O
activation O
of O
NF B
- I
kappaB I
in O
B O
cells O
. O

Tetramer O
- O
guided O
epitope O
mapping O
: O
rapid O
identification O
and O
characterization O
of O
immunodominant O
CD4 O
+ O
T O
cell O
epitopes O
from O
complex O
antigens B
. O

T O
cell O
responses O
to O
Ags B
involve O
recognition O
of O
selected O
peptide O
epitopes O
contained O
within O
the O
antigenic O
protein O
. O

In O
this O
report O
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4 O
+ O
T O
cell O
epitopes O
of O
complex O
Ags B
that O
uses O
human O
class O
II O
tetramers O
to O
identify O
reactive O
cells O
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 O
protein O
, O
a O
major O
Ag B
for O
HSV O
- O
2 O
, O
we O
generated O
a O
panel O
of O
class O
II O
MHC O
tetramers O
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV O
- O
2 O
infected O
individual O
. O

By O
using O
tetramers O
to O
sort O
individual O
cells O
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes B
. O

This O
rapid O
approach O
to O
detecting O
CD4 O
+ O
T O
cell O
epitopes O
from O
complex O
Ags B
can O
be O
applied O
to O
any O
known O
Ag B
that O
gives O
a O
T O
cell O
response O
. O

Transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
is O
activated O
in O
cerulein O
pancreatitis O
and O
mediates O
cytokine O
expression O
. O

Here O
we O
report O
upregulation O
of O
NF B
- I
kappaB I
and O
inflammatory O
molecules O
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury O
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible O
nitric O
oxide O
synthase O
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

AP B
- I
1 I
was O
strongly O
activated O
in O
both O
pancreatic O
segments O
after O
either O
taurocholate O
or O
saline O
infusion O
. O

NF B
- I
kappaB I
inhibition O
with O
N O
- O
acetylcysteine O
ameliorated O
the O
local O
inflammatory O
response O
. O

Correlation O
between O
localized O
NF B
- I
kappaB I
activation O
, O
cytokine O
upregulation O
, O
and O
tissue O
damage O
suggests O
a O
key O
role O
for O
NF B
- I
kappaB I
in O
the O
development O
of O
the O
inflammatory O
response O
of O
acute O
pancreatitis O
. O

CD45 O
tyrosine O
phosphatase O
controls O
common O
gamma O
- O
chain O
cytokine O
- O
mediated O
STAT B
and O
extracellular O
signal O
- O
related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

In O
contrast O
, O
after O
addition O
of O
OKT O
- O
3 O
to O
IL B
- I
4 I
- O
and O
IL B
- I
7 I
- O
stimulated O
proliferation O
assays O
, O
UCHL O
- O
1 O
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

In O
Western O
blots O
using O
mAbs B
detecting O
phosphorylated O
STAT O
- O
3 O
, O
STAT O
- O
5 O
, O
STAT O
- O
6 O
, O
or O
extracellular O
signal O
- O
related O
kinase O
1 O
/ O
2 O
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

Using O
RT O
- O
PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL O
- O
2 O
mRNA O
production O
without O
major O
influence O
on O
IL B
- I
13 I
, O
IL B
- I
5 I
, O
or O
IFN B
- I
gamma I
mRNA I
levels O
. O

Costimulation O
with O
OKT O
- O
3 O
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Pax5 B
determines O
the O
identity O
of O
B O
cells O
from O
the O
beginning O
to O
the O
end O
of O
B O
- O
lymphopoiesis O
. O

The O
Pax5 B
gene I
encoding O
the O
transcription O
factor O
BSAP O
is O
required O
for O
progression O
of O
B O
- O
lymphopoiesis O
beyond O
the O
pro O
- O
B O
cell O
stage O
. O

Pax5 B
appears O
to O
mediate O
B O
- O
lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non O
- O
B O
- O
lymphoid O
genes O
and O
by O
simultaneously O
activating O
the O
expression O
of O
B O
- O
lineage O
- O
specific O
genes O
. O

Pax5 B
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors O
of O
the O
Groucho O
protein O
family O
or O
with O
positive O
regulators O
such O
as O
the O
TATA B
- I
binding I
protein I
. O

Once O
committed O
to O
the O
B O
- O
lineage O
, O
B O
cells O
require O
Pax5 B
function O
to O
maintain O
their O
B O
- O
lymphoid O
identity O
throughout O
B O
cell O
development O

Partners O
in O
transcription O
: O
NFAT B
and O
AP B
- I
1 I
. O

Combinatorial O
regulation O
is O
a O
powerful O
mechanism O
that O
enables O
tight O
control O
of O
gene O
expression O
, O
via O
integration O
of O
multiple O
signaling O
pathways O
that O
induce O
different O
transcription B
factors I
required O
for O
enhanceosome O
assembly O
. O

The O
four O
calcium O
- O
regulated O
transcription B
factors I
of O
the O
NFAT B
family I
act O
synergistically O
with O
AP O
- O
1 O
( O
Fos O
/ O
Jun O
) O
proteins O
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT O
and O
AP O
- O
1 O
binding O
sites O
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein O
kinase O
C O
( O
PKC O
) O
/ O
Ras O
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos O
and O
Jun O
families O
of O
transcription B
factors I
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 O
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

Balanced O
activation O
of O
NFAT B
and O
AP B
- I
1 I
is O
known O
to O
be O
required O
for O
productive O
immune O
responses O
, O
but O
the O
role O
of O
NFAT O
: O
AP O
- O
1 O
interactions O
in O
other O
cell O
types O
and O
biological O
processes O
remains O
to O
be O
understood O
. O

Infection O
with O
H3 O
, O
but O
not O
H310A1 O
, O
preferentially O
activates O
Vgamma4 O
Vdelta4 O
cells O
, O
which O
are O
strongly O
positive O
for O
gamma B
interferon I
( O
IFN B
- I
gamma I
) O
, O
whereas O
Vgamma1 O
Vdelta4 O
cells O
are O
increased O
in O
both O
H3 O
and O
H310A1 O
virus O
- O
infected O
animals O
. O

Depletion O
of O
Vgamma1 O
( O
+ O
) O
cells O
using O
monoclonal O
anti O
- O
Vgamma1 O
antibody O
enhanced O
myocarditis O
and O
CD4 O
( O
+ O
) O
- O
, O
IFN B
- I
gamma I
( O
+ O
) O
- O
cell O
responses O
in O
both O
H3 O
- O
and O
H310A1 O
- O
infected O
mice O
yet O
decreased O
the O
CD4 O
( O
+ O
) O
- O
, O
IL O
- O
4 O
( O
+ O
) O
- O
cell O
response O
. O

The O
role O
of O
cytokine O
production O
by O
Vgamma1 O
( O
+ O
) O
and O
Vgamma4 O
( O
+ O
) O
T O
cells O
was O
investigated O
by O
adoptively O
transferring O
these O
cells O
isolated O
from O
H3 O
- O
infected O
BALB O
/ O
c O
Stat4 O
knockout O
( O
Stat4ko O
) O
( O
defective O
in O
IFN B
- I
gamma I
expression O
) O
or O
BALB O
/ O
c O
Stat6ko O
( O
defective O
in O
IL O
- O
4 O
expression O
) O
mice O
into O
H3 O
virus O
- O
infected O
wild O
- O
type O
BALB O
/ O
c O
recipients O
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL B
- I
4 I
but O
no O
or O
minimal O
IFN B
- I
gamma I
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN B
- I
gamma I
but O
no O
IL B
- I
4 I
. O

The O
cytokines B
produced O
by O
the O
Vgamma O
subpopulation O
have O
a O
significant O
influence O
on O
the O
CD4 B
( O
+ O
) O
- O
Th O
- O
cell O
phenotype O
. O

Plasmin O
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

Here O
it O
is O
demonstrated O
that O
plasmin O
induces O
proinflammatory B
cytokine I
release O
and O
tissue B
factor I
( O
TF B
) O
expression O
by O
monocytes O
. O

Plasmin O
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active O
site O
- O
blocked O
plasmin O
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration O
- O
and O
time O
- O
dependent O
release O
of O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
and O
by O
TF B
expression O
on O
monocyte O
surfaces O
. O

Neither O
cytokines B
nor O
TF B
could O
be O
detected O
when O
monocytes O
were O
preincubated O
with O
actinomycin O
D O
or O
cycloheximide O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin O
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
/ I
Rel I
proteins I
coincided O
with O
IkappaBalpha O
degradation O
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin O
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B
, O
c B
- I
Fos I
, O
and O
FosB B
. O

STAT3 B
is O
constitutively O
active O
in O
some O
patients O
with O
Polycythemia O
rubra O
vera O
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin O
- O
like O
growth O
factor O
- O
1 O
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte O
/ O
monocyte O
colony O
- O
stimulating O
factor O
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines B
, O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( O
STATs B
) O
. O

A O
constitutive O
activation O
of O
STAT B
factors I
could O
explain O
the O
increased O
proliferation O
of O
P O
. O
vera O
cells O
even O
in O
the O
absence O
of O
growth O
factor O
stimulation O
. O

None O
of O
the O
subjects O
showed O
constitutive O
STAT1 B
or O
STAT5 B
activity O
. O

Western O
blotting O
demonstrated O
that O
, O
in O
the O
three O
patients O
, O
STAT3 B
is O
constitutively O
phosphorylated O
on O
Tyr O
705 O
, O
whereas O
it O
is O
unphosphorylated O
in O
the O
other O
patients O
and O
in O
controls O
. O

Interestingly O
, O
constitutive O
STAT3 B
activity O
did O
not O
correlate O
with O
the O
duration O
of O
disease O
or O
the O
treatment O
regimen O
. O

CONCLUSION O
: O
Our O
data O
suggest O
that O
constitutive O
phosphorylation O
and O
activation O
of O
STAT3 B
is O
not O
a O
secondary O
event O
induced O
by O
mutagenizing O
agents O
or O
by O
prolonged O
hyperproliferation O
of O
hematopoietic O
cells O
, O
but O
rather O
represents O
a O
primary O
molecular O
aberration O
. O

Identification O
of O
phosphorylation B
sites I
for O
Bruton O
' O
s O
tyrosine O
kinase O
within O
the O
transcriptional O
regulator O
BAP O
/ O
TFII O
- O
I O
. O

Bruton O
' O
s O
tyrosine O
kinase O
( O
Btk B
) O
, O
a O
member O
of O
the O
Tec O
family O
of O
cytosolic O
kinases O
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

BAP O
/ O
TFII O
- O
I O
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk B
in O
B O
cells O
and O
is O
transiently O
phosphorylated O
on O
tyrosine O
following O
B O
cell O
receptor O
engagement O
. O

BAP O
/ O
TFII O
- O
I O
is O
a O
substrate O
for O
Btk B
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk B
in O
mammalian O
cells O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP O
/ O
TFII O
- O
I O
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site O
- O
directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP O
/ O
TFII O
- O
I O
phosphorylation O
by O
Btk B
in O
vitro O
. O

These O
residues O
, O
Tyr248 O
, O
Tyr357 O
, O
and O
Tyr462 O
, O
were O
also O
found O
to O
be O
the O
major O
sites O
for O
Btk B
- O
dependent O
phosphorylation O
of O
BAP O
/ O
TFII O
- O
I O
in O
vivo O
. O

Residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop B
regions I
of O
adjacent O
helix O
- O
loop O
- O
helix O
- O
like O
repeats O
within O
BAP O
/ O
TFII O
- O
I O
. O

Mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c B
- I
fos I
promoter I
relative O
to O
wild O
- O
type O
BAP O
/ O
TFII O
- O
I O
in O
transfected O
COS O
- O
7 O
cells O
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

Phosphorylation O
of O
BAP O
/ O
TFII O
- O
I O
by O
Btk B
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin B
to O
modulation O
of O
gene O
expression O
. O

Mice O
deficient O
in O
the O
interferon O
consensus O
sequence O
binding O
protein O
( O
ICSBP B
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR O
/ O
ABL O
oncoprotein O
. O

Interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
induces O
ICSBP B
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O

This O
study O
examined O
whether O
enforced O
expression O
of O
ICSBP B
might O
antagonize O
BCR O
/ O
ABL O
- O
induced O
leukemia O
; O
results O
demonstrated O
that O
ICSBP O
- O
modified O
cells O
generated O
a O
protective O
CD8 O
( O
+ O
) O
cytotoxic O
T O
- O
cell O
response O
against O
BCR O
/ O
ABL O
- O
transformed O
BaF3 O
cells O
in O
a O
murine O
leukemia O
model O
. O

ICSBP B
expression O
represents O
a O
novel O
means O
of O
stimulating O
a O
host O
immune O
response O
to O
BCR O
/ O
ABL O
( O
+ O
) O
leukemia O
cells O
and O
a O
potential O
strategy O
for O
immunotherapy O
of O
CML O
. O

A O
transcriptional O
block O
in O
the O
IL B
- I
2 I
promoter I
at O
the O
- O
150 O
AP O
- O
1 O
site O
in O
effector O
CD8 O
+ O
T O
cells O
. O

Both O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
that O
produce O
IL B
- I
2 I
in O
response O
to O
Ag O
recognition O
have O
been O
isolated O
. O

However O
, O
most O
effector O
CD8 O
+ O
T O
cells O
recovered O
after O
exposure O
to O
Ag B
do O
not O
produce O
sufficient O
IL B
- I
2 I
to O
sustain O
growth O
, O
and O
depend O
on O
CD4 O
+ O
T O
helper O
cells O
for O
this O
obligate O
growth O
factor O
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL B
- I
2 I
gene I
in O
CD8 O
+ O
T O
cells O
, O
we O
stably O
transfected O
reporter B
genes I
into O
Ag B
- O
specific O
CD8 O
+ O
T O
cell O
clones O
. O

CD28 O
+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL B
- I
2 I
gene I
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
- O
150 O
CD28 O
response O
element O
( O
CD28RE O
) O
/ O
AP O
- O
1 O
site O
of O
the O
IL B
- I
2 I
promoter I
, O
but O
did O
transactivate O
the O
composite O
NFAT O
/ O
AP O
- O
1 O
and O
OCT O
/ O
AP O
- O
1 O
sites O
, O
and O
a O
consensus O
AP O
- O
1 O
motif O
. O

Mutation O
of O
the O
nonconsensus O
- O
150 O
AP O
- O
1 O
site O
to O
a O
consensus B
AP I
- I
1 I
site I
, O
or O
insertion O
of O
a O
CD28RE O
/ O
AP O
- O
1 O
consensus O
site O
upstream O
of O
the O
native O
- O
150 O
CD28RE O
/ O
AP O
- O
1 O
site O
restored O
transactivation O
of O
the O
altered O
promoter B
. O

These O
results O
suggest O
that O
the O
defect O
at O
the O
- O
150 O
site O
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor O
rather O
than O
repression O
of O
the O
IL B
- I
2 I
promoter I
. O

Stem B
cell I
factor I
and O
interleukin B
- I
3 I
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast O
growth O
factor O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

Those O
cells O
were O
positive O
for O
stem O
cell O
markers O
, O
c B
- I
kit I
and O
CD34 B
, O
and O
a O
myeloid O
cell O
marker O
, O
F4 O
/ O
80 O
. O

They O
also O
showed O
the O
expression O
of O
mRNA O
for O
the O
myeloid O
- O
specific O
PU O
. O
1 O
but O
did O
not O
that O
for O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta O
- O
major O
globin O
. O

The O
quantitative O
analysis O
showed O
that O
erythroid O
precursor O
cells O
were O
newly O
produced O
from O
the O
immature O
myeloid O
cells O
by O
cultivation O
with O
IL B
- I
3 I
. O

SCF B
and O
IL B
- I
3 I
induced O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
an O
A O
- O
6 O
hematopoietic O
stem O
cell O
line O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein O
- O
350 O
upregulate O
IL B
- I
6 I
in O
human O
B O
- O
lymphocytes O
via O
CD21 B
, O
involving O
activation O
of O
NF B
- I
kappaB I
and O
different O
signaling O
pathways O
. O

We O
had O
previously O
shown O
that O
EBV O
is O
capable O
of O
modulating O
the O
synthesis O
of O
a O
number O
of O
cytokines B
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant O
gp350 O
( O
rgp350 O
) O
and O
EBV O
upregulate O
IL B
- I
6 I
mRNA I
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 O
) O
. O

Moreover O
, O
the O
half O
- O
life O
of O
EBV O
- O
induced O
IL B
- I
6 I
mRNA I
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 O
( O
about O
6 O
hours O
) O
. O

Both O
EBV O
and O
gp350 O
enhance O
the O
binding O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF B
- I
kappaB I
- O
mediated O
activation O
of O
a O
CAT O
reporter O
plasmid O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus O
envelope O
glycoprotein O
to O
CR2 O
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

Also O
, O
multiplex O
PCR O
analysis O
of O
genomic B
DNA I
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt O
gene O
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O

The O
differences O
between O
N O
- O
OH O
- O
AAF O
mutation O
in O
the O
endogenous B
gene I
and O
transgene O
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes O
. O

Caspase B
- O
dependent O
cleavage O
of O
the O
hematopoietic O
specific O
adaptor O
protein O
Gads O
alters O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads O
is O
a O
SH2 O
and O
SH3 O
domain O
- O
containing O
, O
hematopoietic O
- O
specific O
adaptor O
protein O
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads O
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy O
- O
terminal O
Gads O
SH3 O
domain O
, O
to O
tyrosine O
phosphorylated O
LAT O
which O
contains O
binding O
sites O
for O
the O
Gads O
SH2 O
domain O
. O

Gads O
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap O
protein O
by O
the O
presence O
of O
a O
120 O
amino O
acid O
unique O
region O
between O
the O
SH2 B
domain I
and O
the O
carboxy O
terminal O
SH3 O
domain O
. O

The O
Gads O
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP B
- I
76 I
and O
LAT B
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads O
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

Targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
promoter I
via O
CREB O
- O
Rel O
cross O
- O
talk O
during O
mitogen B
and O
oncogenic O
molecular O
signaling O
in O
activated O
T O
- O
cells O
. O

In O
this O
report O
, O
we O
explore O
the O
mechanisms O
of O
targeting O
of O
p300 B
to O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
in O
response O
to O
mitogenic O
and O
oncogenic O
molecular O
signals O
. O

Recruitment O
of O
p300 B
by O
cAMP O
- O
responsive O
element O
- O
binding O
protein O
- O
Rel O
cross O
- O
talk O
at O
the O
composite O
CD28 O
response O
element O
( O
CD28RE B
) O
- O
TRE O
element O
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE O
- O
TRE O
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein O
Tax O
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N O
- O
terminal O
743 O
residues O
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE O
- O
TRE O
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

Mutational O
analysis O
of O
p300 B
reveals O
differential O
structural O
requirements O
for O
the O
N O
- O
terminal O
p300 O
module O
by O
individual O
cis B
- I
elements I
within O
the O
IL B
- I
2 I
promoter I
. O

These O
findings O
provide O
evidence O
that O
p300 B
assembles O
at O
the O
IL B
- I
2 I
promoter I
to O
form O
an O
enhanceosome O
- O
like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE O
- O
TRE O
element O
of O
the O
IL B
- I
2 I
promoter I
through O
specific O
protein O
module O
- O
targeted O
associations O
in O
activated O
T O
- O
cells O
. O

Regulation O
of O
cytokine O
production O
in O
T O
- O
cell O
responses O
to O
inhalant O
allergen O
: O
GATA B
- I
3 I
expression O
distinguishes O
between O
Th1 O
- O
and O
Th2 O
- O
polarized O
immunity O
. O

As O
an O
alternative O
to O
cytokine O
measurement O
, O
this O
study O
focuses O
on O
expression O
of O
the O
transcription B
factor I
GATA I
- I
3 I
for O
analysis O
of O
allergen O
- O
specific O
Th O
cell O
responses O
. O

RESULTS O
: O
Cytokine B
- O
driven O
Th2 O
polarization O
of O
naive O
T O
cells O
is O
associated O
with O
marked O
upregulation O
of O
GATA B
- I
3 I
expression O
, O
whereas O
a O
reciprocal O
expression O
pattern O
accompanies O
differentiation O
towards O
the O
Th1 O
cytokine O
phenotype O
. O

In O
T O
cells O
from O
HDM O
skin O
prick O
test O
- O
positive O
( O
HDM O
- O
SPT O
+ O
/ O
HDM O
- O
IgE O
+ O
) O
volunteers O
, O
overnight O
stimulation O
results O
in O
marked O
upregulation O
of O
GATA B
- I
3 I
expression O
, O
compared O
to O
an O
equally O
marked O
downregulation O
of O
expression O
in O
T O
cells O
from O
SPT O
- O
/ O
IgE O
- O
subjects O
. O

In O
subjects O
who O
are O
HDM O
- O
SPT O
+ O
but O
IgE O
- O
, O
GATA B
- I
3 I
expression O
levels O
remained O
relatively O
stable O
during O
culture O
with O
HDM O
. O

CONCLUSIONS O
: O
Upregulation O
of O
GATA B
- I
3 I
expression O
in O
PBMC O
is O
a O
hallmark O
of O
the O
early O
phase O
of O
Th2 O
recall O
responses O
to O
specific O
allergen O
in O
atopics O
. O

The O
stress O
response O
( O
SR O
) O
can O
block O
inflammatory O
gene O
expression O
by O
preventing O
activation O
of O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappaB I
) O
. O

The O
HSR O
attenuated O
leukocyte O
infiltration O
into O
CNS O
assessed O
by O
quantitation O
of O
perivascular O
infiltrates O
, O
and O
by O
reduced O
staining O
for O
CD4 B
and O
CD25 B
immunopositive O
T O
- O
cells O
. O

T O
- O
cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon B
gamma I
( O
IFNgamma B
) O
in O
response O
to O
MOG O
( O
35 O
- O
55 O
) O
, O
was O
also O
decreased O
by O
the O
HSR O
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES B
( O
regulated O
on O
activation O
of O
normal O
T O
- O
cell O
expressed O
and O
secreted O
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric B
oxide I
synthase I
. O

The O
early O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
was O
also O
blocked O
by O
the O
HSR O
. O

This O
approach O
uses O
reporter B
- I
plasmids I
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen B
- I
activated I
protein I
kinase I
or O
cyclic B
AMP I
- I
dependent I
protein I
kinase I
. O

Reporter B
- I
plasmids I
are O
transfected O
into O
thymocytes O
in O
fetal O
thymic O
organ O
culture O
by O
accelerated O
DNA O
/ O
particle O
bombardment O
( O
gene O
gun O
) O
, O
and O
the O
activation O
of O
a O
signaling O
pathway O
is O
determined O
in O
the O
form O
of O
a O
standard O
luciferase O
assay O
. O

Genes O
encoding O
CBFbeta O
( O
CBFB O
) O
, O
and O
one O
of O
the O
DNA O
- O
binding O
CBFalpha O
subunits O
, O
Runx1 O
( O
also O
known O
as O
CBFalpha2 O
, O
AML1 B
, O
and O
PEBP2alphaB O
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta O
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC O
portion O
of O
the O
fusion B
protein I
. O

The O
latency O
pattern O
of O
Epstein O
- O
Barr O
virus O
infection O
and O
viral O
IL B
- I
10 I
expression O
in O
cutaneous O
natural O
killer O
/ O
T O
- O
cell O
lymphomas O
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV O
- O
encoded O
nuclear O
RNA O
( O
EBER O
) O
and O
a O
clonality O
of O
EBV O
- O
DNA O
fragments O
containing O
the O
terminal O
repeats O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q O
promoter O
, O
whereas O
both O
the O
Q O
promoter O
and O
another O
upstream O
promoter O
( O
Cp O
/ O
Wp O
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Oxidized O
low O
density O
lipoprotein O
( O
oxLDL B
) O
is O
inflammatory O
and O
signals O
through O
PPARs B
. O

We O
showed O
, O
by O
phospholipase O
A O
( O
1 O
) O
digestion O
, O
that O
PPARgamma O
agonists O
in O
oxLDL B
arise O
from O
the O
small O
pool O
of O
alkyl O
phosphatidylcholines O
in O
LDL B
. O

We O
identified O
an O
abundant O
oxidatively O
fragmented O
alkyl O
phospholipid O
in O
oxLDL B
, O
hexadecyl O
azelaoyl O
phosphatidylcholine O
( O
azPC O
) O
, O
as O
a O
high O
affinity O
ligand O
and O
agonist O
for O
PPARgamma B
. O

Overexpression O
of O
PPARalpha B
or O
PPARgamma B
revealed O
that O
azPC O
was O
a O
specific O
PPARgamma O
agonist O
. O

The O
scavenger O
receptor O
CD36 O
is O
encoded O
by O
a O
PPRE O
- O
responsive O
gene O
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B
in O
primary O
human O
monocytes O
. O

Thus O
, O
certain O
alkyl O
phospholipid O
oxidation O
products O
in O
oxLDL B
are O
specific O
, O
high O
affinity O
extracellular O
ligands O
and O
agonists O
for O
PPARgamma B
that O
induce O
PPAR O
- O
responsive O
genes O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B
subunit I
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B O
gene O
, O
determined O
its O
organization O
, O
characterized O
its O
5 B
' I
- I
flanking I
sequences I
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B
. O

Transcription O
of O
the O
MAT2B O
gene O
initiates O
at O
position O
- O
203 O
relative O
to O
the O
translation B
start I
site I
. O

Promoter O
deletion O
analysis O
defined O
a O
minimal B
promoter I
between O
positions O
+ O
52 O
and O
+ O
93 O
base O
pairs O
, O
a O
GC O
- O
rich O
region O
. O

The O
inclusion O
of O
sequences O
up O
to O
position O
- O
115 O
provided O
full O
activity O
; O
this O
was O
attributed O
to O
a O
TATA B
at O
- O
32 O
. O

The O
Sp1 B
site I
at O
position O
+ O
9 O
was O
key O
for O
the O
formation O
of O
protein O
. O
DNA O
complexes O
. O

Mutation O
of O
both O
the O
Sp1 B
site I
at O
+ O
9 O
and O
the O
TATA B
at O
- O
32 O
reduced O
promoter O
activity O
to O
its O
minimal O
level O
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti O
- O
Sp1 O
antibody O
on O
complex O
formation O
, O
whereas O
the O
anti O
- O
Sp3 O
antibody O
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B
site I
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 B
and O
Sp3 B
in O
complexes O
formed O
on O
the O
MAT2B O
promoter O
. O

The O
data O
show O
that O
the O
5 O
' O
- O
untranslated O
sequences O
play O
an O
important O
role O
in O
regulating O
the O
MAT2B O
gene O
and O
identifies O
the O
Sp1 B
site I
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet O
levels O
. O

Molecular O
pathogenesis O
of O
influenza O
A O
virus O
infection O
and O
virus O
- O
induced O
regulation O
of O
cytokine B
gene I
expression O
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP O
- O
3 O
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral O
( O
IFN O
- O
alpha O
/ O
beta O
) O
cytokines O
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
STAT B
and O
IRF O
signal O
transducing O
molecules O
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

In O
addition O
of O
upregulating O
cytokine B
gene I
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase O
- O
1 O
enzyme O
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL B
- I
1 I
beta I
and O
proIL O
- O
18 O
into O
their O
biologically O
active O
forms O
. O

Influenza O
A O
virus O
- O
induced O
IFN B
- I
alpha I
/ I
beta I
is O
essential O
in O
host O
' O
s O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral O
Mx O
, O
PKR O
and O
oligoadenylate O
synthetase O
genes O
. O

IFN B
- I
alpha I
/ I
beta I
also O
prolongs O
T O
cell O
survival O
, O
upregulates O
IL O
- O
12 O
and O
IL O
- O
18 O
receptor O
gene O
expression O
and O
together O
with O
IL B
- I
18 I
stimulates O
NK O
and O
T O
cell O
IFN O
- O
gamma O
production O
and O
the O
development O
of O
Th1 O
- O
type O
immune O
response O
. O

This O
proliferative O
defect O
is O
not O
reversed O
by O
addition O
of O
exogenous B
IL I
- I
2 I
and O
is O
p53 O
- O
independent O
. O

PU B
. I
1 I
is O
a O
member O
of O
the O
Ets O
family O
of O
transcription O
factors O
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

The O
study O
shows O
that O
PU B
. I
1 I
is O
expressed O
in O
NK O
cells O
and O
that O
, O
on O
cell O
transfer O
into O
alymphoid O
Rag2 O
/ O
gammac O
( O
- O
/ O
- O
) O
mice O
, O
hematopoietic O
progenitors O
of O
PU O
. O
1 O
( O
- O
/ O
- O
) O
fetal O
liver O
cells O
could O
generate O
functional O
NK O
cells O
but O
not O
B O
or O
T O
cells O
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B
cell I
factor I
and O
interleukin O
( O
IL O
) O
- O
7 O
, O
suggesting O
a O
nonredundant O
role O
for O
PU B
. I
1 I
in O
regulating O
the O
expression O
of O
these O
cytokine O
receptor O
genes O
during O
NK O
cell O
development O
. O

PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 O
family O
and O
failed O
to O
proliferate O
in O
response O
to O
IL B
- I
2 I
and O
IL B
- I
12 I
. O

Thus O
, O
despite O
the O
less O
stringent O
requirement O
for O
PU B
. I
1 I
in O
NK O
cell O
development O
compared O
to O
B O
and O
T O
cells O
, O
PU B
. I
1 I
regulates O
NK O
cell O
differentiation O
and O
homeostasis O
. O

Benzene O
- O
extracted O
components O
are O
important O
for O
the O
major O
activity O
of O
diesel O
exhaust O
particles O
: O
effect O
on O
interleukin B
- I
8 I
gene I
expression O
in O
human O
bronchial O
epithelial O
cells O
. O

We O
have O
shown O
that O
DEPs O
augmented O
the O
production O
of O
inflammatory B
cytokines I
by O
human O
airway O
epithelial O
cells O
in O
vitro O
. O

We O
used O
several O
agents O
active O
on O
signal O
transduction O
pathways O
in O
cytokine O
expression O
, O
such O
as O
the O
protein O
kinase O
C O
inhibitor O
staurosporin O
, O
antioxidant O
agents O
including O
N O
- O
acetyl O
cysteine O
( O
NAC O
) O
and O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
inhibitor O
SB203580 O
. O

Benzene O
- O
extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL O
- O
8 O
gene O
expression O
, O
release O
of O
several O
cytokines B
( O
IL B
- I
8 I
; O
granulocyte B
macrophage I
colony I
- I
stimulating I
factor I
; O
and O
regulated O
on O
activation O
, O
normal O
T O
cells O
expressed O
and O
secreted O
) O
and O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
activation O
. O

Activation O
of O
NF B
- I
kappaB I
and O
production O
of O
NF B
- I
kappaB I
- O
dependent O
chemokines B
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O

Calpain O
- O
1 O
inhibitor O
( O
CI O
- O
1 O
) O
blocks O
activation O
of O
NF B
- I
kappaB I
by O
preventing O
proteolysis O
of O
the O
inhibitory O
protein O
IkappaB B
- I
alpha I
by O
the O
ubiquitin O
/ O
proteasome O
pathway O
. O

Treatment O
with O
Cl O
- O
1 O
prevented O
degradation O
of O
IkappaB B
- I
alpha I
and O
activation O
of O
NF B
- I
kappaB I
in O
the O
liver O
in O
response O
to O
LPS O
; O
however O
, O
Cl O
- O
1 O
treatment O
had O
no O
detected O
effect O
on O
NF O
- O
kappaB O
activation O
in O
lung O
tissue O
. O

Notch1 B
regulates O
maturation O
of O
CD4 O
+ O
and O
CD8 O
+ O
thymocytes O
by O
modulating O
TCR O
signal O
strength O
. O

We O
demonstrate O
in O
this O
report O
that O
retroviral O
expression O
of O
activated O
Notch1 B
in O
mouse O
thymocytes O
abrogates O
differentiation O
of O
immature O
CD4 O
+ O
CD8 O
+ O
thymocytes O
into O
both O
CD4 O
and O
CD8 O
mature O
single O
- O
positive O
T O
cells O
. O

The O
ability O
of O
Notch1 B
to O
inhibit O
T O
cell O
development O
was O
observed O
in O
vitro O
and O
in O
vivo O
with O
both O
normal O
and O
TCR O
transgenic O
thymocytes O
. O

Notch1 B
- O
mediated O
developmental O
arrest O
was O
dose O
dependent O
and O
was O
associated O
with O
impaired O
thymocyte O
responses O
to O
TCR O
stimulation O
. O

Notch1 B
also O
inhibited O
TCR O
- O
mediated O
signaling O
in O
Jurkat O
T O
cells O
. O

These O
data O
indicate O
that O
constitutively O
active O
Notch1 B
abrogates O
CD4 O
+ O
and O
CD8 O
+ O
maturation O
by O
interfering O
with O
TCR O
signal O
strength O
and O
provide O
an O
explanation O
for O
the O
physiological O
regulation O
of O
Notch O
expression O
during O
thymocyte O
development O
. O

Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
Rta O
protein O
powerfully O
stimulates O
the O
promoter B
of O
its O
own O
gene O
, O
Rp O
, O
in O
EBV O
- O
positive O
B O
cells O
in O
transient O
- O
transfection O
reporter O
- O
based O
assays O
. O

We O
analyzed O
the O
activity O
of O
RpCAT O
in O
response O
to O
Rta B
by O
deletional O
and O
site O
- O
directed O
mutagenesis O
. O

Two O
cognate O
Sp1 O
binding O
sites O
located O
at O
- O
279 O
and O
- O
45 O
relative O
to O
the O
transcriptional B
start I
site I
proved O
crucial O
for O
Rta O
- O
mediated O
activation O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription O
factor O
Zif268 O
and O
the O
viral O
transactivator O
ZEBRA O
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT O
by O
Rta B
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B
and O
Sp3 B
as O
the O
predominant O
cellular B
proteins I
bound O
to O
Rp O
near O
- O
45 O
. O

During O
the O
lytic O
cycle O
, O
ZEBRA B
bound O
Rp O
near O
the O
Sp1 O
/ O
Sp3 O
site O
. O

The O
binding O
of O
Sp1 B
and O
Sp3 B
to O
Rp O
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp O
by O
Rta B
and O
DNA O
binding O
by O
Sp1 B
and O
/ O
or O
Sp3 B
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B
and O
Sp3 B
transcription B
factors I
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 O
promoter O
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

Hypoxia O
inducible O
factor O
- O
1 O
( O
HIF O
- O
1 O
) O
is O
a O
constitutively O
expressed O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
, O
formed O
by O
the O
assembly O
of O
HIF O
- O
1alpha O
and O
HIF O
- O
1beta O
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

We O
have O
recently O
shown O
that O
over O
- O
expression O
of O
the O
full O
- O
length O
, O
most O
highly O
expressed O
Runx2 O
isoform O
in O
the O
thymus O
perturbs O
T O
- O
cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc B
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 O
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 O
- O
Runx2 O
transgene O
either O
with O
a O
Pim1 O
transgene O
( O
E O
( O
mu O
) O
- O
Pim1 O
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

Analysis O
of O
known O
Moloney O
MLV O
target O
genes O
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 O
or O
Pim2 O
( O
23 O
% O
) O
, O
and O
at O
Pal1 O
/ O
Gfi1 O
( O
18 O
% O
) O
. O

The O
involvement O
of O
TNF B
- I
alpha I
- O
related O
apoptosis O
- O
inducing O
ligand O
in O
the O
enhanced O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
human O
dendritic O
cells O
to O
tumor O
cells O
. O

TNF B
- I
alpha I
- O
related O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
is O
characterized O
by O
its O
preferential O
induction O
of O
apoptosis O
of O
tumor O
cells O
but O
not O
normal O
cells O
. O

TRAIL O
expression O
on O
immature O
CD34DCs O
or O
MoDCs O
was O
greatly O
up O
- O
regulated O
after O
IFN B
- I
beta I
stimulation O
. O

Moreover O
, O
IFN B
- I
beta I
could O
strikingly O
enhance O
the O
ability O
of O
CD34DCs O
or O
MoDCs O
to O
kill O
TRAIL O
- O
sensitive O
tumor O
cells O
, O
but O
LPS O
did O
not O
have O
such O
an O
effect O
. O

The O
up O
- O
regulation O
of O
TRAIL O
on O
IFN B
- I
beta I
- O
stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS O
: O
Pretreatment O
of O
TRAIL O
- O
sensitive O
tumor O
cells O
with O
caspase O
- O
3 O
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
DCS O
: O
In O
contrast O
, O
NF O
- O
kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor O
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS O
- O
stimulated O
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN B
- I
beta I
- O
stimulated O
DCs O
are O
functionally O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 O
with O
specific O
monoclonal B
antibodies I
. O

T B
- I
cell I
factor I
- I
1 I
expression O
during O
human O
natural O
killer O
cell O
development O
and O
in O
circulating O
CD56 B
( I
+ I
) I
bright O
natural O
killer O
cells O
. O

Transcription B
factors I
are O
essential O
to O
govern O
differentiation O
along O
the O
lymphoid O
lineage O
from O
uncommitted O
hematopoietic O
stem O
cells O
. O

Although O
many O
of O
these O
transcription B
factors I
have O
putative O
roles O
based O
on O
murine O
knockout O
experiments O
, O
their O
function O
in O
human O
lymphoid O
development O
is O
less O
known O
and O
was O
studied O
further O
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
- O
DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA B
- I
3 I
but O
not O
T B
- I
cell I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
or O
Id B
- I
3 I
. O

Culture O
with O
the O
murine O
fetal O
liver O
cell O
line O
AFT024 O
and O
defined O
cytokines B
was O
capable O
of O
inducing O
TCF B
- I
1 I
mRNA I
. O

Id B
- I
3 I
, O
a O
basic O
helix O
loop O
helix O
factor O
with O
dominant O
negative O
function O
for O
T O
- O
cell O
differentiation O
transcription B
factors I
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T O
- O
cell O
maturation O
. O

CD56 O
( O
+ O
bright O
) O
, O
but O
not O
CD56 O
( O
+ O
dim O
) O
, O
NK O
cells O
constitutively O
express O
TCF B
- I
1 I
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
and O
Western O
blot O
analysis O
. O

The O
TCF O
- O
1 O
isoform O
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin B
but O
not O
immunoglobulin O
class O
I O
recognizing O
inhibitory O
receptors O
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

These O
results O
suggest O
that O
TCF B
- I
1 I
does O
not O
target O
human O
killer O
immunoglobulin O
receptor O
genes O
, O
TCF B
- I
1 I
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF O
- O
1 O
isoforms O
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

We O
show O
here O
that O
Bright O
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional B
activator I
. O

Two O
of O
the O
three O
previously O
identified O
binding B
sites I
in O
E O
mu O
are O
required O
for O
full O
Bright O
transactivation O
. O

BCL B
- I
6 I
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin O
( O
Ig O
) O
genes O
by O
somatic O
mutations O
. O

The O
5 B
' I
- I
noncoding I
region I
of O
the O
BCL B
- I
6 I
gene I
is O
even O
a O
target O
for O
the O
mutation O
machinery O
. O

Translocations O
of O
the O
BCL B
- I
6 I
gene I
to O
heterologous B
promoters I
and O
mutations O
of O
its O
5 O
' O
- O
noncoding O
regulatory O
region O
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL B
- I
6 I
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

With O
only O
one O
exception O
, O
there O
were O
no O
lymphoma O
- O
specific O
recurrent O
BCL O
- O
6 O
mutations O
detected O
, O
and O
BCL B
- I
6 I
protein I
was O
absent O
from O
the O
HRS O
cells O
of O
most O
cases O
. O

In O
conclusion O
, O
( O
1 O
) O
somatic O
BCL O
- O
6 O
mutations O
are O
restricted O
to O
cHD O
cases O
of O
B O
- O
cell O
origin O
, O
and O
( O
2 O
) O
the O
BCL O
- O
6 O
mutations O
represent O
mostly O
irrelevant O
somatic O
base O
substitutions O
without O
consequences O
for O
BCL B
- I
6 I
protein I
expression O
and O
the O
pathogenesis O
of O
cHD O
. O

Gadd45gamma O
, O
a O
family O
member O
of O
the O
growth O
arrest O
and O
DNA O
damage O
- O
inducible O
gene O
family O
45 O
( O
Gadd45 O
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

While O
in O
most O
tissues O
all O
Gadd45 O
family O
members O
are O
expressed O
, O
Gadd45gamma O
is O
the O
only O
member O
that O
is O
induced O
by O
IL B
- I
2 I
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma O
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine O
kinase O
Jak3 O
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma O
is O
not O
impaired O
and O
Gadd45gamma O
- O
deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL B
- I
2 I
. O

Gadd45gamma O
is O
also O
dispensable O
for O
IL B
- I
2 I
- O
induced O
T O
- O
cell O
proliferation O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl B
- I
xL I
, O
bad B
, O
caspase B
- I
3 I
, O
and O
c O
- O
myc O
family O
genes O
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc O
family O
genes O
, O
c B
- I
myc I
and O
max B
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

These O
results O
indicate O
that O
c B
- I
myc I
- O
mediated O
signaling O
is O
abnormal O
in O
MG O
thymuses O
. O

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc B
, O
such O
as O
STAM O
, O
prothymosin O
- O
alpha O
, O
and O
NFkappaB O

Skin O
lesions O
of O
dermatophytosis O
are O
thought O
to O
be O
a O
result O
of O
a O
T O
cell O
- O
dependent O
inflammatory O
response O
that O
is O
mediated O
by O
various O
cytokines B
. O

The O
pattern O
of O
IFN B
- I
gamma I
staining O
appeared O
to O
be O
intracellular O
in O
mononuclear O
lymphoid O
cells O
. O

Th1 O
response O
, O
which O
is O
characterized O
by O
IFN B
- I
gamma I
release O
, O
is O
thought O
to O
be O
involved O
in O
the O
host O
defense O
against O
dermatophytes O
and O
to O
reflect O
cutaneous O
reaction O
in O
dermatophytosis O
. O

Regulation O
of O
the O
helix B
- I
loop I
- I
helix I
proteins I
, O
E2A B
and O
Id3 B
, O
by O
the O
Ras B
- O
ERK B
MAPK B
cascade O
. O

Activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathways O
leads O
to O
cellular O
differentiation O
and O
/ O
or O
proliferation O
in O
a O
wide O
variety O
of O
cell O
types O
, O
including O
developing O
thymocytes O
. O

The O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
proteins O
E12 B
and O
E47 B
and O
an O
inhibitor O
HLH O
protein O
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

We O
show O
here O
that O
E2A B
DNA O
binding O
is O
lowered O
in O
primary O
immature O
thymocytes O
consequent O
to O
T O
cell O
receptor O
( O
TCR O
) O
- O
mediated O
ligation O
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 O
transcripts O
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR B
. O

Activation O
of O
Id3 O
transcription O
is O
regulated O
in O
a O
dose O
- O
dependent O
manner O
by O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK B
) O
MAPK B
module O
. O

These O
observations O
directly O
connect O
the O
ERK B
MAPK B
cascade O
and O
HLH B
proteins I
in O
a O
linear O
pathway O
. O

Investigation O
of O
mast O
cell O
responsiveness O
toward O
retinoic O
acid O
( O
RA O
) O
revealed O
selective O
promotion O
of O
ICAM B
- I
3 I
expression O
in O
the O
human O
mast O
cell O
line O
HMC O
- O
1 O
. O

ICAM B
- I
3 I
modulation O
was O
found O
to O
be O
cell O
- O
type O
dependent O
, O
detectable O
also O
for O
HL O
- O
60 O
cells O
and O
monocytes O
but O
not O
U O
- O
937 O
and O
only O
weakly O
for O
KU812 O
cells O
. O

Terminally O
differentiated O
skin O
mast O
cells O
also O
failed O
to O
up O
- O
modulate O
their O
ICAM B
- I
3 I
, O
suggesting O
the O
requirement O
for O
some O
degree O
of O
immaturity O
for O
the O
process O
. O

RA O
- O
mediated O
effects O
on O
ICAM B
- I
1 I
expression O
, O
studied O
in O
parallel O
, O
were O
clearly O
distinct O
from O
those O
on O
ICAM B
- I
3 I
. O

Investigation O
of O
retinoid O
receptor O
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR O
alpha O
, O
RAR O
gamma O
, O
RXR O
beta O
, O
and O
RXR O
gamma O
transcripts O
in O
all O
cell O
lines O
studied O
, O
and O
HMC O
- O
1 O
cells O
were O
the O
only O
line O
lacking O
RXR B
alpha I
. O

RAR B
beta I
, O
not O
expressed O
at O
baseline O
, O
was O
induced O
by O
RA O
in O
a O
fashion O
obviously O
correlating O
with O
ICAM B
- I
3 I
up O
- O
regulation O
. O

Increased O
ICAM B
- I
3 I
expression O
was O
of O
functional O
significance O
, O
such O
that O
processes O
stimulated O
or O
co O
- O
stimulated O
via O
ICAM B
- I
3 I
( O
homotypic O
aggregation O
, O
IL O
- O
8 O
secretion O
) O
were O
clearly O
enhanced O
upon O
RA O
pretreatment O
, O
suggesting O
that O
RA O
may O
contribute O
via O
hitherto O
unrecognized O
pathways O
to O
immune O
function O
and O
host O
defense O
. O

CD28 B
and O
T O
cell O
co O
- O
stimulation O
. O

Focusing O
on O
recent O
advances O
in O
our O
understanding O
of O
CD28 B
, O
we O
discuss O
four O
areas O
of O
T O
cell O
activation O
where O
co O
- O
stimulation O
may O
play O
a O
role O
. O

Regulation O
of O
activator B
protein I
- I
1 I
and O
NF B
- I
kappa I
B I
in O
CD8 O
+ O
T O
cells O
exposed O
to O
peripheral O
self O
- O
antigens O
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP B
- I
1 I
- O
and O
NF B
- I
kappa I
B I
- O
mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self O
Ag O
expressed O
exclusively O
on O
hepatocytes O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP B
- I
1 I
and O
high O
NF B
- I
kappa I
B I
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP B
- I
1 I
and O
only O
weak O
NF B
- I
kappa I
B I
transcriptional O
activity O
. O

The O
differences O
in O
NF B
- I
kappa I
B I
transcriptional O
activity O
correlated O
with O
the O
generation O
of O
distinct O
NF B
- I
kappa I
B I
complexes I
. O

These O
observations O
suggest O
that O
fine O
regulation O
of O
NF B
- I
kappa I
B I
complex I
formation O
may O
determine O
T O
cell O
fate O
. O

The O
transcription B
factors I
that O
mediate O
these O
processes O
are O
often O
expressed O
broadly O
in O
many O
cell O
types O
. O

The O
emerging O
theme O
is O
one O
of O
cell O
- O
type O
- O
specific O
regulation O
, O
affecting O
not O
only O
the O
functional O
activation O
of O
transcription B
factors I
but O
also O
their O
access O
to O
appropriate O
regions O
of O
DNA O
. O

Existence O
of O
retinoic B
acid I
- I
receptor I
- O
independent O
retinoid B
X I
- I
receptor I
- O
dependent O
pathway O
in O
myeloid O
cell O
function O
. O

We O
previously O
reported O
that O
ER O
- O
27191 O
( O
4 O
- O
[ O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
hexahydro O
- O
7 O
, O
7 O
, O
10 O
, O
10 O
- O
tetramethyl O
- O
1 O
- O
( O
3 O
- O
pyridylmethyl O
) O
anthra O
[ O
1 O
, O
2 O
- O
b O
] O
pyrrol O
- O
3 O
- O
yl O
] O
benzoic O
acid O
) O
is O
a O
potent O
antagonist O
of O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
ER O
- O
35795 O
( O
( O
2E O
, O
4E O
, O
6E O
) O
- O
7 O
- O
[ O
1 O
- O
( O
1 O
- O
methylethyl O
) O
- O

8 O
- O
chloro O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydroquinolin O
- O
6 O
- O
yl O
] O
- O
6 O
- O
fluoro O
- O
3 O
- O
methyl O
- O
2 O
, O
4 O
, O
6 O
- O
nonatrienoic O
acid O
) O
is O
a O
novel O
retinoid B
X I
receptor I
( O
RXR B
) O
- O
specific O
agonist O
. O

By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR B
- O
dependent O
and O
RXR B
- O
dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR B
pathway O
on O
cellular O
function O
. O

However O
, O
the O
differentiation O
induced O
by O
the O
ER O
- O
35795 O
was O
not O
antagonized O
at O
all O
by O
the O
RAR B
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR O
homodimer O
antagonist O
( O
LGD100754 O
, O
( O
2E O
, O
4E O
, O
6Z O
) O
- O
7 O
- O
( O
3 O
- O
n O
- O
propoxy O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O
- O
5 O
, O
5 O
, O
8 O
, O
8 O
- O
tetramethylnaphthale O
- O
2 O
- O
yl O
) O
- O
3 O
- O
methylocta O
- O
2 O
, O
4 O
, O
6 O
- O
trienoic O
acid O
) O

Its O
agonistic O
action O
on O
RXR O
/ O
RAR O
heterodimer O
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR B
antagonist O
. O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta O
mRNA O
, O
while O
the O
RXR B
had O
no O
effect O
. O

Interestingly O
, O
a O
functional O
RXR B
- O
pathway O
was O
also O
seen O
in O
lipopolysaccharide O
- O
induced O
inhibition O
of O
mouse O
splenocyte O
proliferation O
. O

These O
results O
strongly O
suggest O
the O
existence O
of O
a O
pharmacological O
RXR B
- O
dependent O
pathway O
that O
is O
activated O
by O
a O
ligand O
that O
can O
bind O
to O
RXR B
. O

Targeting O
Src O
homology O
2 O
domain O
- O
containing O
tyrosine O
phosphatase O
( O
SHP B
- I
1 I
) O
into O
lipid O
rafts O
inhibits O
CD3 B
- O
induced O
T O
cell O
activation O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs O
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs O
in O
subdomains O
of O
plasma O
membrane O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
- O
- O
10 O
% O
of O
Src O
homology O
2 O
domain O
- O
containing O
tyrosine O
phosphatase O
( O
SHP B
- I
1 I
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP O
- O
2 O
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

Similar O
to O
transmembrane O
PTP O
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP O
- O
2 O
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck O
, O
linker O
for O
activation O
of O
T O
cells O
, O
and O
CD3 O
zeta O
are O
enriched O
. O

We O
further O
demonstrated O
that O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs O
are O
inhibited O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP B
- I
1 I
into O
lipid O
rafts O
by O
using O
the O
N O
- O
terminal O
region O
of O
Lck O
( O
residues O
1 O
- O
- O
14 O
) O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck O
/ O
SHP O
- O
1 O
chimera O
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 O
zeta O
/ O
epsilon O
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF B
- I
AT I
. O

Collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs O
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B
/ O
CD3 B
activation O

An O
instructive O
component O
in O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
development O
mediated O
by O
GATA B
- I
3 I
. O

Although O
interleukin B
( I
IL I
) I
- I
12 I
and O
IL B
- I
4 I
polarize O
naive O
CD4 O
( O
+ O
) O
T O
cells O
toward O
T O
helper O
cell O
type O
1 O
( O
Th1 O
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines B
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells O
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O

We O
observe O
IL B
- I
4 I
- O
dependent O
redirection O
of O
phenotype O
in O
cells O
that O
have O
already O
committed O
to O
a O
non O
- O
IL O
- O
4 O
- O
producing O
fate O
, O
inconsistent O
with O
predictions O
of O
the O
selective O
model O
. O

In O
vitro O
- O
activated O
human O
lupus O
T O
cells O
express O
normal O
estrogen O
receptor O
proteins O
which O
bind O
to O
the O
estrogen B
response I
element I
. O

We O
have O
shown O
that O
estrogen B
receptor I
( O
ERalpha O
, O
ERbeta B
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

Mechanism O
of O
the O
inhibitory O
effect O
of O
protease O
inhibitor O
on O
tumor B
necrosis I
factor I
alpha I
production O
of O
monocytes O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
and O
interleukin B
- I
( I
IL I
) I
10 I
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

The O
value O
of O
TNFalpha B
and O
IL B
- I
10 I
in O
the O
culture O
medium O
of O
monocytes O
was O
measured O
and O
each O
mRNA O
expression O
was O
assayed O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B
kinase I
C I
( O
PKC B
) O
and O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
were O
also O
evaluated O
. O

GM O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
as O
shown O
by O
the O
inhibition O
of O
mRNA O
expression O
and O
increased O
the O
IL B
- I
10 I
production O
of O
LPS O
- O
stimulated O
monocytes O
. O

GM O
also O
suppressed O
the O
NFkappaB B
activity O
of O
LPS O
- O
stimulated O
monocytes O
. O

UTI O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha O
mRNA O
expression O
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B
. O

Homocysteine O
stimulates O
the O
expression O
of O
monocyte B
chemoattractant I
protein I
- I
1 I
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

Monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
is O
a O
potent O
chemokine B
that O
stimulates O
the O
migration O
of O
monocytes O
into O
the O
intima O
of O
the O
arterial O
wall O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
homocysteine O
on O
MCP B
- I
1 I
production O
in O
endothelial O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 O
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

Homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B
MAP I
kinase I
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B
MAP I
kinase I
pathway O
might O
be O
involved O
in O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
. O

In O
contrast O
, O
staurosporine O
, O
a O
protein B
kinase I
C I
inhibitor O
, O
had O
no O
effect O
on O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
. O

In O
conclusion O
, O
our O
results O
indicate O
that O
homocysteine O
stimulates O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

Further O
, O
surface O
immunoglobulin O
signaling O
for O
inducible O
Fas B
- O
resistance O
bypasses O
Btk B
, O
requires O
NF B
- I
kappaB I
, O
and O
entails O
new O
macromolecular O
synthesis O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti O
- O
apoptotic O
gene O
products O
, O
Bcl B
- I
xL I
and O
FLIP O
, O
and O
a O
novel O
anti O
- O
apoptotic O
gene O
that O
encodes O
FAIM O
( O
Fas O
Apoptosis O
Inhibitory O
Molecule O
) O
. O

Inducible O
resistance O
to O
Fas B
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen O
- O
specific O
B O
cells O
during O
potentially O
hazardous O
interactions O
with O
FasL O
- O
bearing O
T O
cells O
, O
whereas O
autoreactive O
B O
cells O
fail O
to O
become O
Fas B
- O
resistant O
and O
are O
deleted O
via O
Fas B
- O
dependent O
cytotoxicity O
. O

Inadvertent O
or O
aberrant O
acquisition O
of O
Fas B
- O
resistance O
may O
permit O
autoreactive O
B O
cells O
to O
escape O
Fas B
deletion O
, O
and O
malignant O
lymphocytes O
to O
impede O
anti O
- O
tumor O
immunity O
. O

In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription B
factor I
NF I
- I
kappa I
B I
in O
SDF1 O
alpha O
- O
induced O
T O
cell O
migration O
. O

SDF1 O
alpha O
treatment O
of O
Jurkat O
T O
cells O
increased O
the O
activity O
of O
NO B
synthase I
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat O
cells O
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 O
alpha O
- O
induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO B
synthase I
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration O
- O
dependent O
manner O
. O

Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
, O
which O
is O
linked O
to O
NO O
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 O
alpha O
- O
induced O
chemotactic O
response O
. O

These O
studies O
suggest O
that O
NO O
- O
related O
signaling O
pathways O
may O
mediate O
SDF1 O
alpha O
- O
induced O
chemotaxis O
, O
but O
not O
mitogen B
- I
activated I
protein I
kinase I
activation O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR O
transgene O
, O
dominant O
negative O
ras O
/ O
Mek O
proteins O
and O
a O
reporter B
gene I
construct I
with O
AP O
- O
1 O
or O
NF O
- O
kappa O
B O
binding O
sites O
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

Lack O
of O
NF B
- I
kappa I
B I
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen O
. O

AP B
- I
1 I
induction O
was O
dependent O
on O
the O
integrity O
of O
the O
ras O
/ O
Mek O
pathway O
indicating O
that O
this O
pathway O
was O
activated O
in O
the O
DP O
thymocytes O
. O

In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon O
isoform O
of O
Protein O
Kinase O
C O
( O
PKC B
) O
in O
DP O
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral O
T O
cells O
. O

Taken O
together O
the O
results O
suggest O
that O
the O
lack O
of O
PKC B
epsilon I
in O
DP O
thymocytes O
could O
lead O
to O
the O
absence O
of O
NF B
- I
kappa I
B I
activity O
after O
antigenic O
stimulation O
contributing O
to O
negative O
selection O
. O

CD2 O
stimulation O
leads O
to O
the O
delayed O
and O
prolonged O
activation O
of O
STAT1 B
in O
T O
cells O
but O
not O
NK O
cells O
. O

OBJECTIVE O
: O
T O
lymphocytes O
can O
be O
activated O
by O
soluble O
factors O
such O
as O
cytokines B
or O
through O
direct O
cell O
- O
cell O
interactions O
. O

Although O
cytokine B
receptors I
are O
known O
to O
signal O
through O
STAT O
family O
transcription O
factors O
, O
the O
mechanisms O
by O
which O
other O
cell B
- I
surface I
molecules I
, O
such O
as O
CD2 B
, O
transduce O
signals O
is O
unclear O
. O

The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T O
cells O
through O
CD2 B
recapitulates O
aspects O
of O
cytokine B
- O
induced O
T O
- O
cell O
activation O
by O
use O
of O
STAT B
transcription I
factors I
. O

MATERIALS O
AND O
METHODS O
: O
T O
cells O
were O
treated O
with O
anti B
- I
CD2 I
antibodies I
or O
cells O
bearing O
the O
natural O
CD2 O
ligand O
CD58 O
, O
after O
which O
signaling O
through O
STAT B
transcription I
factors I
was O
assessed O
. O

RESULTS O
: O
Stimulation O
of O
CD2 B
on O
primary O
T O
lymphocytes O
leads O
to O
the O
tyrosine O
phosphorylation O
, O
nuclear O
translocation O
, O
and O
DNA O
binding O
of O
STAT1 B
. O

In O
contrast O
to O
stimulation O
by O
cytokines B
, O
the O
activation O
of O
STAT1 B
in O
response O
to O
CD2 O
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak B
kinases I
. O

Furthermore O
, O
while O
STAT O
phosphorylation O
induced O
by O
cytokines B
is O
generally O
transient O
, O
STAT1 O
phosphorylation O
following O
CD2 O
stimulation O
persists O
for O
a O
period O
of O
days O
. O

Transcription O
of O
key O
target O
genes O
such O
as O
IRF1 O
and O
c B
- I
fos I
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

This O
pathway O
appears O
to O
be O
restricted O
to O
T O
cells O
, O
as O
stimulation O
of O
CD2 B
on O
NK O
cells O
does O
not O
lead O
to O
STAT1 O
activation O
. O

CONCLUSION O
: O
Stimulation O
of O
T O
cells O
through O
cell B
- I
surface I
molecules I
such O
as O
CD2 B
involves O
activation O
of O
STAT B
transcription I
factors I
, O
thus O
recapitulating O
elements O
of O
cytokine O
signaling O
. O

Nevertheless O
, O
doubly O
deficient O
B O
cells O
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 O
and O
IgE B
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O

The O
PML O
protein O
is O
induced O
by O
interferon B
, O
involved O
in O
major B
histocompatibility I
complex I
class I
I I
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

SUMO O
- O
1 O
modification O
of O
PML B
is O
known O
to O
be O
required O
for O
the O
formation O
of O
PML O
bodies O
. O

To O
examine O
whether O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV O
immediate O
- O
early O
genes O
BZLF1 O
( O
Z O
) O
and O
BRLF1 O
( O
R O
) O
in O
EBV O
- O
positive O
cell O
lines O
and O
examined O
PML B
localization O
. O

Both O
Z O
and O
R O
expression O
resulted O
in O
PML B
dispersion O
in O
EBV O
- O
positive O
cells O
. O

We O
show O
that O
dispersion O
of O
PML O
bodies O
by O
Z B
requires O
a O
portion O
of O
the O
transcriptional B
activation I
domain I
of O
Z B
but O
not O
the O
DNA O
- O
binding O
function O
. O

As O
was O
previously O
reported O
for O
the O
HSV O
- O
1 O
ICP0 O
and O
CMV O
IE1 O
proteins O
, O
Z B
reduces O
the O
amount O
of O
SUMO O
- O
1 O
- O
modified O
PML O
. O

We O
also O
found O
that O
Z B
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B
competes O
with O
PML B
for O
limiting O
amounts O
of O
SUMO O
- O
1 O
. O

Furthermore O
, O
Z B
may O
potentially O
alter O
the O
function O
of O
a O
variety O
of O
cellular O
proteins O
by O
inhibiting O
SUMO O
- O
1 O
modification O

Suppression O
of O
nuclear B
factor I
- I
kappaB I
and O
stimulation O
of O
inhibitor O
kappaB O
by O
troglitazone O
: O
evidence O
for O
an O
anti O
- O
inflammatory O
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O

To O
elucidate O
whether O
troglitazone O
exerts O
an O
antiinflammatory O
effect O
in O
humans O
, O
in O
vivo O
, O
we O
investigated O
the O
suppression O
of O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
in O
mononuclear O
cells O
( O
MNC O
) O
by O
this O
drug O
. O

Plasma O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
, O
soluble O
intercellular O
adhesion O
molecule O
- O
1 O
( O
sICAM O
- O
1 O
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen O
activator O
inhibitor O
type O
1 O
( O
PAI B
- I
1 I
) O
, O
C O
- O
reactive O
protein O
( O
CRP O
) O
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory O
cytokine O
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory O
transcription O
factor O
NFkappaB O
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear O
NFkappaB O
, O
total O
cellular O
NFkappaB O
, O
IkappaBalpha B
, O
and O
p47 O
( O
phox O
) O
subunit O
and O
ROS O
generation O
were O
determined O
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM O
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP O
, O
and O
IL B
- I
10 I
. O

There O
was O
a O
fall O
in O
intranuclear O
NFkappaB O
, O
total O
cellular O
NFkappaB O
, O
and O
p47 O
( O
phox O
) O
subunit O
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

Plasma O
TNF B
- I
alpha I
, O
sICAM O
- O
1 O
, O
MCP B
- I
1 I
, O
and O
PAI B
- I
1 I
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
IL B
- I
10 I
concentration O
increased O
significantly O
, O
whereas O
plasma O
CRP O
concentrations O
decreased O
. O

Tyrosine O
phosphorylation O
- O
dependent O
activation O
of O
NF B
- I
kappa I
B I
. O

Phosphorylation O
of O
the O
N B
- I
terminal I
domain I
of O
I O
kappa O
B O
inhibitory O
subunits O
induces O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
. O

Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome O
- O
mediated O
degradation O
of O
I B
kappa I
B I
- I
alpha I
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF B
- I
kappa I
B I
in O
T O
cells O
as O
a O
consequence O
of O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
[ O
Imbert O
, O
V O
. O
, O
Rupec O
, O
R O
. O
A O
. O
, O
Livolsi O
, O
A O
. O
, O
Pahl O
, O
H O
. O
L O
. O
, O
Traenckner O
, O
B O
. O
M O
. O
, O
Mueller O
- O
Dieckmann O
, O
C O

The O
involvement O
of O
the O
tyrosine B
kinases I
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate O
- O
induced O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
on O
Tyr42 O
and O
NF B
- I
kappa I
B I
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
- O
deficient O
Jurkat O
mutants O
, O
NF B
- I
kappa I
B I
could O
still O
associate O
with O
I B
kappa I
B I
- I
alpha I
despite O
phosphorylation O
on O
Tyr42 O
. O

Furthermore O
, O
the O
SH2 B
domain I
of O
p56 B
( I
lck I
) I
appeared O
to O
be O
required O
for O
pervanadate O
- O
induced O
NF B
- I
kappa I
B I
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
T O
cells O
, O
is O
an O
activator O
of O
NF B
- I
kappa I
B I
through O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
. O

The O
gene O
that O
encodes O
nuclear O
factor O
kappaB O
( O
NF O
- O
kappaB O
) O
essential O
modulator O
( O
or O
NEMO O
, O
also O
known O
as O
IKKgamma O
) O
is O
required O
for O
activation O
of O
the O
transcription B
factor I
NF I
- I
kappaB I
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF O
- O
kappaB O
alpha O
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF O
- O
kappaB O
- O
regulated O
cytokines O
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

CD40L B
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM O
- O
ED O
patients O
shows O
that O
the O
putative O
zinc O
- O
finger O
domain O
of O
NEMO O
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B
- O
mediated O
NF O
- O
kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class O
- O
switching O
. O

In O
addition O
, O
nuclear O
body O
reorganization O
to O
macropunctated O
structures O
, O
as O
well O
as O
the O
degradation O
of O
PML B
- I
RAR I
alpha I
, O
was O
found O
to O
be O
similar O
for O
ATRA O
and O
all O
of O
its O
metabolites O
. O

METHODS O
: O
Expression O
of O
oestrogen B
receptors I
( O
ER B
) O
and O
progesterone B
receptors I
( O
PR B
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

The O
cells O
positive O
for O
ER B
or O
PR B
were O
confirmed O
by O
spatial O
location O
, O
dual O
immunolabelling O
, O
and O
histochemical O
staining O
. O

RESULTS O
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4 O
+ O
( O
T O
helper O
/ O
inducer O
) O
, O
CD8 O
+ O
( O
cytotoxic O
/ O
suppressor O
) O
, O
CD68 O
+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B
antibodies I
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER B
/ O
PR O
labelling O
with O
their O
polyclonal O
and O
monoclonal O
antibodies O
. O

The O
expression O
of O
ER B
/ O
PR B
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0 O
. O
973 O
, O
p O
< O
0 O
. O
001 O
for O
ER B
; O
r O
= O
0 O
. O
955 O
, O
p O
< O
0 O
. O
001 O
for O
PR B
) O
. O

Fewer O
than O
5 O
% O
of O
mast O
cells O
were O
found O
to O
be O
negative O
for O
ER B
/ O
PR B
expression O
. O

CONCLUSIONS O
: O
Mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
, O
or O
other O
immune O
cells O
, O
express O
ER B
/ O
PR B
in O
human O
upper O
airways O
. O

Our O
previous O
studies O
have O
implicated O
the O
nuclear O
transcription O
factor O
kappa O
B O
( O
NF B
kappa I
B I
) O
in O
the O
regulation O
of O
adhesion B
molecule I
expression O
in O
endothelial O
cells O
exposed O
to O
anoxia O
- O
reoxygenation O
( O
A O
/ O
R O
) O
or O
a O
redox O
imbalance O
. O

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein O

tyrosine O
phosphatase O
( O
PTPase O
) O
and O
/ O
or O
protein B
kinase I
C I
( O
PKC B
) O
. O

The O
results O
demonstrate O
that O
both O
A O
/ O
R O
and O
redox O
imbalance O
led O
to O
I O
kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF B
kappa I
B I
and O
subsequent O
nuclear O
translocation O
of O
the O
activated O
p65 O
subunit O
. O

Inhibition O
of O
PKC B
blocked O
I B
kappa I
B I
alpha I
degradation O
and O
p65 B
translocation O
in O
A O
/ O
R O
- O
challenged O
, O
but O
not O
redox O
- O
altered O
, O
endothelial O
cells O
. O

However O
, O
both O
A O
/ O
R O
- O
and O
redox O
- O
induced O
NF O
kappa O
B O
activation O
was O
blocked O
by O
inhibition O
of O
PTK B
. O

Similarly O
, O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B
or O
PTK B
, O
while O
only O
PTK B
inhibited O
the O
redox O
- O
induced O
adhesion O
response O
. O

Collectively O
, O
these O
findings O
indicate O
that O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC B
and O
PTK B
, O
which O
signal O
rapid O
activation O
of O
NF B
kappa I
B I
. O

This O
A O
/ O
R O
- O
induced O
NF B
kappa I
B I
signaling O
response O
appears O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
intracellular O
redox O
imbalance O
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic O
hydrocarbon O
receptor O
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase O
- O
9 O
. O

ZVAD O
- O
FMK O
, O
a O
broad O
- O
spectrum O
inhibitor O
of O
caspases B
, O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
completely O
. O

While O
an O
inhibitor O
of O
caspase O
- O
9 O
, O
as O
well O
as O
caspase O
- O
9 O
and O
caspase O
- O
3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase B
- I
3 I
had O
a O
moderate O
inhibitory O
effect O
. O

Unlike O
Fas B
- O
mediated O
apoptosis O
, O
the O
initiator O
caspase O
, O
caspase O
- O
8 O
, O
was O
not O
involved O
in O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
. O

Transfection O
of O
Jurkat O
cells O
with O
Bcl B
- I
2 I
prevented O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
led O
to O
a O
complete O
blockage O
of O
apoptosis O
. O

The O
activation O
of O
caspases B
occurs O
downstream O
of O
mitochondrial O
damage O
, O
and O
the O
dysfunction O
of O
mitochondria O
appears O
to O
be O
sufficient O
for O
triggering O
all O
downstream O
events O
leading O
to O
apoptosis O
. O

Inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
mediated O
by O
SOCS1 O
. O

Interleukin B
6 I
( O
IL B
- I
6 I
) O
is O
a O
cytokine B
produced O
by O
immune O
and O
nonimmune O
cells O
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O

IL B
- I
6 I
plays O
an O
important O
role O
in O
the O
differentiation O
of O
several O
cell O
types O
. O

Here O
, O
we O
describe O
a O
novel O
function O
of O
IL B
- I
6 I
: O
the O
negative O
regulation O
of O
CD4 B
+ O
Th1 O
cell O
differentiation O
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

IL B
- I
6 I
upregulates O
suppressor O
of O
cytokine O
signaling O
1 O
( O
SOCS1 O
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal O
transducer O
and O
activator O
of O
transcription O
1 O
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Inhibition O
of O
IFNgamma B
receptor O
- O
mediated O
signals O
by O
IL B
- I
6 I
prevents O
autoregulation O
of O
IFNgamma O
gene O
expression O
by O
IFNgamma B
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Thus O
, O
IL B
- I
6 I
promotes O
CD4 B
+ O
Th2 O
differentiation O
and O
inhibits O
Th1 O
differentiation O
by O
two O
independent O
molecular O
mechanisms O
. O

Interaction O
between O
CCAAT B
/ I
enhancer I
binding I
protein I
and O
cyclic O
AMP O
response O
element O
binding O
protein O
1 O
regulates O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
cells O
of O
the O
monocyte O
/ O
macrophage O
lineage O
. O

Additionally O
, O
sequence O
variation O
at O
C O
/ O
EBP O
site O
I O
, O
which O
lies O
immediately O
upstream O
of O
the O
distal O
nuclear O
factor O
kappa O
B O
site O
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating O
transcription O
factor O
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF O
/ O
CREB O
family O
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF O
/ O
CREB O
binding O
site O
could O
affect O
C O
/ O
EBP O
protein O
binding O
to O
C O
/ O
EBP O
site O
I O
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF O
/ O
CREB O
site O
variants O
assisted O
in O
the O
recruitment O
of O
C B
/ I
EBP I
proteins I
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low O
- O
affinity O
C B
/ I
EBP I
site I
. O

First O
, O
low O
amounts O
of O
CREB B
- I
1 I
and O
C B
/ I
EBP I
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF O
/ O
CREB O
and O
C O
/ O
EBP O
binding O
sites O
. O

This O
interaction O
is O
reciprocal O
, O
since O
C O
/ O
EBP O
dimer O
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF O
/ O
CREB O
sites O
that O
are O
weakly O
bound O
by O
CREB B
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF O
/ O
CREB O
binding O
site O
affected O
basal O
LTR B
activity O
as O
well O
as O
LTR B
function O
following O
interleukin B
- I
6 I
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

Thus O
, O
HIV B
- I
1 I
LTR I
ATF O
/ O
CREB O
binding O
site O
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B
promoter I
through O
the O
C O
/ O
EBP O
pathway O

This O
study O
is O
the O
first O
in O
which O
concentrations O
of O
ASA O
in O
the O
therapeutic O
range O
were O
found O
to O
significantly O
reduce O
interleukin B
( I
IL I
) I
- I
4 I
secretion O
and O
RNA O
expression O
in O
freshly O
isolated O
and O
mitogen O
- O
primed O
human O
CD4 O
+ O
T O
cells O
. O

In O
contrast O
, O
ASA O
did O
not O
affect O
IL B
- I
13 I
, O
interferon B
- I
gamma I
, O
and O
IL B
- I
2 I
expression O
. O

ASA O
inhibited O
IL B
- I
4 I
, O
but O
not O
IL B
- I
2 I
, O
promoter O
- O
driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat O
T O
cells O
. O

The O
structurally O
unrelated O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
indomethacin O
and O
flurbiprofen O
did O
not O
affect O
cytokine O
gene O
expression O
in O
T O
cells O
, O
whereas O
the O
weak O
cyclo O
- O
oxygenase O
inhibitor O
salicylic O
acid O
was O
at O
least O
as O
effective O
as O
ASA O
in O
inhibiting O
IL B
- I
4 I
expression O
and O
promoter O
activity O
. O

It O
is O
concluded O
that O
anti O
- O
inflammatory O
salicylates O
, O
by O
means O
of O
a O
previously O
unrecognized O
mechanism O
of O
action O
, O
can O
influence O
the O
nature O
of O
adaptive O
immune O
responses O
by O
selectively O
inhibiting O
the O
expression O
of O
IL B
- I
4 I
, O
a O
critical O
effector O
of O
these O
responses O
, O
in O
CD4 O
+ O
T O
cells O
. O

Molecular O
and O
cellular O
mediators O
of O
interleukin B
- I
1 I
- O
dependent O
acute O
inflammatory O
arthritis O
. O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated O
bovine O
serum O
albumin O
( O
mBSA O
) O
and O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
. O

Flow O
cytometry O
and O
RNase O
protection O
were O
used O
to O
analyze O
IL B
- I
1 I
- O
dependent O
events O
. O

B6 O
mice O
lacking O
T O
and O
B O
cells O
( O
RAG1 O
- O
/ O
- O
) O
or O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
( O
MHCII O
- O
/ O
- O
) O
, O
and O
B6 O
mice O
treated O
with O
a O
CD4 O
+ O
T O
cell O
- O
depleting O
monoclonal O
antibody O
, O
were O
resistant O
to O
disease O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage O
inhibitory O
protein O
2 O
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP O
- O
1beta O
, O
in O
vivo O
and O
in O
vitro O
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA O
/ O
IL B
- I
1 I
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B
. O

IL B
- I
1 I
contributes O
to O
leukocyte O
recruitment O
to O
the O
synovium O
and O
directly O
induces O
chemokine O
mRNA O
production O
by O
synovial O
cells O
. O

This O
model O
of O
acute O
monarticular O
arthritis O
is O
particularly O
suitable O
for O
further O
investigations O
into O
cell O
- O
mediated O
immunity O
in O
arthritis O
and O
the O
role O
of O
IL B
- I
1 I
. O

Our O
results O
demonstrate O
that O
RARalpha B
is O
dispensable O
for O
granulopoiesis O
, O
as O
RARalpha O
( O
- O
/ O
- O
) O
mice O
have O
a O
normal O
granulocyte O
population O
despite O
an O
impaired O
ability O
to O
respond O
to O
retinoids O
. O

However O
, O
although O
it O
is O
not O
absolutely O
required O
, O
RARalpha B
can O
bidirectionally O
modulate O
granulopoiesis O
. O

RARalpha B
stimulates O
differentiation O
in O
response O
to O
exogenous O
retinoic O
acid O
. O

Conversely O
, O
RARalpha B
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand O
because O
granulocyte O
precursors O
from O
RARalpha O
( O
- O
/ O
- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha B
fusion B
proteins I
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded O
RARalpha O
. O

The O
Runt O
family O
transcription O
factor O
CBFalpha2 O
( O
AML1 B
, O
PEBP2alphaB O
, O
or O
Runx1 O
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T O
- O
lineage O
cells O
. O

In O
human O
T O
cells O
CBFalpha2 O
is O
usually O
transcribed O
from O
a O
different O
promoter O
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Here O
, O
we O
report O
that O
both O
coding O
and O
noncoding O
sequences O
of O
the O
distal O
5 O
' O
end O
are O
highly O
conserved O
between O
the O
human O
and O
the O
murine O
genes O
, O
and O
the O
distal B
promoter I
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

The O
distal O
N O
- O
terminal O
isoform O
binds O
to O
functionally O
important O
regulatory O
sites O
from O
known O
target B
genes I
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal O
N O
- O
terminal O
isoform O
. O

Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3 B
- I
K I
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte O
- O
monocyte O
colony O
- O
stimulating O
factor O
( O
GM B
- I
CSF I
) O
- O
dependent O
autocrine O
loop O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

Lymphokine B
dependence O
of O
STAT3 O
activation O
produced O
by O
surface O
immunoglobulin O
cross O
- O
linking O
and O
by O
phorbol O
ester O
plus O
calcium O
ionophore O
treatment O
in O
B O
cells O
. O

Stimulation O
of O
B O
cells O
by O
surface B
immunoglobulin I
( O
sIg B
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B
transcription I
factors I
. O

sIg B
- O
induced O
activation O
of O
STAT3 B
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL O
- O
6 O
- O
or O
IL O
- O
10 O
- O
deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B
antibodies I
directed O
against O
either O
of O
these O
lymphokines B
. O

sIg B
- O
induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL O
- O
6 O
- O
and O
IL O
- O
10 O
- O
specific O
neutralizing O
antibodies O
, O
or O
by O
adding O
individual O
neutralizing B
antibodies I
to O
B O
cells O
obtained O
from O
lymphokine O
- O
deficient O
animals O
. O

In O
contrast O
, O
IL B
- I
10 I
alone O
appeared O
to O
account O
for O
STAT3 O
activation O
resulting O
from O
B O
cell O
stimulation O
with O
phorbol O
ester O
and O
calcium O
ionophore O
. O

In O
keeping O
with O
these O
results O
, O
soluble O
IL B
- I
6 I
and O
IL B
- I
10 I
were O
found O
in O
supernatant O
fluid O
obtained O
from O
stimulated O
B O
cells O
. O

This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 O
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen B
receptor I
and O
through O
pharmacological O
mimicry O
of O
signaling O
mediators O
. O

The O
octamer B
element I
is O
common O
to O
all O
Ig O
promoters O
and O
pivotal O
for O
their O
function O
. O

However O
, O
other O
conserved B
sequence I
motifs I
, O
that O
differ O
between O
Ig O
variable O
gene O
families O
, O
are O
required O
for O
normal O
promoter O
function O
. O

These O
conserved O
motifs O
do O
not O
stimulate O
transcription O
in O
the O
absence O
of O
an O
octamer B
. O

One O
example O
is O
an O
E B
- I
box I
of O
the O
E47 O
/ O
E12 O
type O
( O
5 O
' O
- O
CAGCTG O
- O
3 O
' O
) O
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human O
and O
murine O
Ig O
- O
kappa O
gene O
subgroups O
/ O
families O
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine O
families O
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription O
factor O
AP O
- O
4 O
, O
and O
not O
E47 B
, O
interacts O
specifically O
with O
the O
kappa O
promoter O
E O
- O
boxes O
when O
tested O
in O
electrophoretic O
mobility O
- O
shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B O
- O
cell O
lines O
. O

Furthermore O
, O
AP O
- O
4 O
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa O
promoters O
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila O
transcription O
factor O
( O
Antennapedia O
) O
, O
a O
60 O
amino O
acid O
protein O
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

The O
ability O
of O
the O
hybrid O
peptide O
to O
be O
processed O
and O
presented O
by O
APCs O
was O
similar O
, O
whether O
the O
SIINFEKL O
sequence O
was O
appended O
at O
the O
C B
- I
terminus I
or O
N B
- I
terminus I
of O
the O
Antennapedia O
peptide O
. O

Protein B
Kinase I
A I
( O
PKA B
) O
, O
a O
cAMP O
kinase O
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B
cytokine I
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

Additionally O
, O
IL O
- O
4 O
- O
mediated O
signal O
transduction O
and O
activation O
of O
transcription O
( O
STAT B
- I
6 I
) O
phosphorylation O
was O
slightly O
increased O
. O

These O
results O
show O
that O
the O
BMC O
inhibition O
is O
mediated O
by O
soluble B
factors I
( O
cytokines B
) O
and O
that O
cell O
- O
cell O
contact O
in O
this O
autologous O
system O
is O
not O
required O
, O
so O
that O
BMC O
( O
at O
least O
partially O
, O
via O
cytokine O
production O
) O
promote O
TH2 O
polarization O
in O
culture O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 B
associated O
PKA B
, O
CCR3 O
, O
and O
STAT B
- I
6 I
phosphorylation O
are O
enhanced O
by O
BMC O
. O

Reduction O
in O
DNA O
binding O
activity O
of O
the O
transcription B
factor I
Pax B
- I
5a I
in O
B O
lymphocytes O
of O
aged O
mice O
. O

The O
transcription B
factor I
Pax B
- I
5 I
is O
a O
key O
regulator O
of O
B O
cell O
development O
. O

Pax O
- O
5a O
/ O
B O
cell O
- O
specific O
activator O
protein O
and O
an O
alternatively O
spliced O
isoform O
, O
Pax O
- O
5d O
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B
domain I
in O
Pax B
- I
5d I
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax O
- O
5a O
and O
5d O
proteins O
were O
present O
in O
both O
age O
groups O
. O

The O
observed O
decrease O
in O
Pax B
- I
5a I
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax O
- O
5 O
target O
genes O
in O
aged O
B O
cells O
. O

Expression O
of O
the O
Ig O
J O
chain O
and O
the O
secreted O
form O
of O
Ig O
mu O
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax B
- I
5a I
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J O
chain O
, O
and O
secretion O
of O
IgM O

Proliferative O
responses O
of O
lymphoid O
cells O
to O
IL B
- I
2 I
and O
IL B
- I
4 I
depend O
on O
activation O
of O
the O
cells O
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines B
is O
not O
fully O
understood O
. O

The O
NF B
- I
kappaB I
/ I
Rel I
family I
represents O
one O
signal O
transduction O
pathway O
induced O
during O
such O
activation O
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha O
( O
DeltaN O
) O
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

However O
, O
transgenic O
cells O
exhibited O
a O
dramatic O
defect O
in O
Stat5A O
activation O
treatment O
with O
IL B
- I
2 I
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL B
- I
4 I
- O
induced O
Stat5 B
. O

In O
contrast O
, O
T O
lymphoid O
cells O
with O
inhibition O
of O
NF B
- I
kappaB I
showed O
normal O
insulin O
receptor O
substrate O
- O
2 O
phosphorylation O
and O
only O
a O
modest O
decrease O
in O
Stat6 O
activation O
and O
insulin O
receptor O
substrate O
- O
1 O
phosphorylation O
after O
IL O
- O
4 O
stimulation O
. O

These O
results O
indicate O
that O
the O
NF O
- O
kappaB O
/ O
Rel O
/ O
IkappaBalpha O
system O
can O
regulate O
cytokine B
receptor I
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat O
transcription O
factor O
family O
. O

In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg O
/ O
kg O
for O
1 O
month O
, O
BMS O
- O
189453 O
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline B
phosphatase I
and O
alanine O
aminotransferase O
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O

Sequential O
involvement O
of O
NFAT B
and O
Egr O
transcription B
factors I
in O
FasL O
regulation O
. O

The O
critical O
function O
of O
NFAT B
proteins I
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp B
and O
NFAT4 B
( O
DKO O
) O
. O

DKO O
mice O
exhibit O
increased O
lymphoproliferation O
, O
decreased O
activation O
- O
induced O
cell O
death O
, O
and O
impaired O
induction O
of O
FasL B
. O

The O
transcription B
factors I
Egr2 B
and O
Egr3 O
are O
potent O
activators O
of O
FasL O
expression O
. O

Here O
we O
find O
that O
Egr2 B
and O
Egr3 O
are O
NFAT B
target I
genes I
. O

Activation O
of O
FasL B
occurs O
via O
the O
NFAT B
- O
dependent O
induction O
of O
Egr3 O
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B
to O
restore O
Egr O
- O
dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Further O
, O
Egr3 O
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

High O
glucose O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
( O
ICAM B
- I
1 I
) O
expression O
through O
an O
osmotic O
effect O
in O
rat O
mesangial O
cells O
is O
PKC O
- O
NF O
- O
kappa O
B O
- O
dependent O
. O

We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular O
adhesion O
molecule O
- O
1 O
by O
flow O
cytometry O
and O
semiquantitative O
RT O
- O
PCR O
in O
mesangial O
cells O
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial O
cells O
. O

METHODS O
/ O
RESULTS O
: O
Cells O
exposed O
to O
high O
D O
- O
glucose O
( O
30 O
mmol O
/ O
l O
) O
caused O
an O
increase O
in O
[ O
3H O
] O
- O
thymidine O
incorporation O
and O
cell O
numbers O
at O
24 O
and O
48 O
h O
and O
normalized O
at O
72 O
h O
( O
p O
< O
0 O
. O
05 O
) O
, O
whereas O
these O
changes O
were O
not O
found O
in O
high O
mannitol O
( O
30 O
mmol O
/ O
l O
) O
, O
IL B
- I
1 I
beta I
, O
or O
TNF B
alpha I
- O
stimulated O
mesangial O
cells O
. O

Cells O
exposed O
to O
high O
- O
glucose O
( O
15 O
, O
30 O
, O
or O
60 O
mmol O
/ O
l O
) O
or O
osmotic O
agents O
( O
L O
- O
glucose O
, O
raffinose O
and O
mannitol O
) O
showed O
that O
intercellular B
adhesion I
molecule I
- I
1 I
expression O
began O
to O
increase O
after O
24 O
h O
, O
reached O
its O
maximum O
at O
24 O
and O
48 O
h O
and O
gradually O
decreased O
afterwards O
. O

Up O
- O
regulation O
of O
ICAM B
- I
1 I
protein O
and O
mRNA O
was O
also O
found O
in O
IL B
- I
1 I
- I
beta I
and O
TNF B
- I
alpha I
- O
stimulated O
mesangial O
cells O
. O

Notably O
, O
the O
protein O
kinase O
C O
inhibitors O
calphostin O
C O
and O
staurosporine O
reduced O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
mRNA O
expression O
and O
high O
glucose O
- O
induced O
proliferation O
. O

Furthermore O
, O
the O
NF O
- O
kappa O
B O
inhibitor O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
reduced O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
mRNA O
expression O
and O
high O
glucose O
- O
induced O
proliferation O
. O

Functional O
blocking O
of O
intercellular B
adhesion I
molecule I
- I
1 I
on O
mesangial O
cells O
with O
rat O
intercellular O
adhesion O
molecule O
- O
1 O
monoclonal O
antibody O
, O
calphostin O
C O
, O
staurosporine O
, O
or O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose O
- O
or O
high O
mannitol O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0 O
. O
05 O
) O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

More O
than O
90 O
% O
of O
patients O
with O
severe O
congenital O
neutropenia O
( O
SCN O
) O
respond O
to O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G B
- I
CSF I
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B
domain I
of O
the O
G B
- I
CSF I
receptor I
( O
GCSF O
- O
R O
) O
. O

The O
in O
vitro O
effect O
of O
G B
- I
CSF I
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine O
myeloid O
cell O
line O
32D O
expressing O
the O
patient O
' O
s O
mutated O
G O
- O
CSFR O
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

Clonogenic O
assays O
of O
the O
patient O
' O
s O
marrow O
mononuclear O
cells O
incorporating O
either O
G B
- I
CSF I
or O
hydrocortisone O
produced O
little O
neutrophil O
growth O
. O

In O
contrast O
, O
inclusion O
of O
both O
G B
- I
CSF I
and O
hydrocortisone O
in O
the O
cytokine O
` O
` O
cocktail O
' O
' O
markedly O
increased O
the O
neutrophil O
numbers O
. O

Proliferation O
of O
32D O
cells O
expressing O
the O
mutated O
receptor O
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G B
- I
CSF I
and O
dexamethasone O
. O

These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G B
- I
CSF I
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G B
- I
CSF I
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9 O
- O
cis O
retinoic O
acid O
( O
9 O
- O
cRA O
) O
, O
an O
activator O
of O
both O
retinoic B
acid I
receptors I
( O
RARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial O
adhesion O
molecules O
, O
fibronectin B
and O
osteopontin O
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular O
adhesion O
molecule O
- O
1 O
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR O
- O
gamma O
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

In O
mammals O
, O
defensins B
are O
among O
the O
most O
abundant O
of O
these O
broad O
- O
spectrum O
antibiotics O
, O
and O
are O
expressed O
in O
epithelial O
and O
hematopoietic O
cells O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B
factors I
such O
as O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
and O
NF O
interleukin O
- O
6 O
. O

Multiple O
signals O
required O
for O
cyclic B
AMP I
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
binding O
protein O
interaction O
induced O
by O
CD3 O
/ O
CD28 O
costimulation O
. O

The O
optimal O
activation O
of O
cAMP B
- I
responsive I
element I
binding I
protein I
( O
CREB B
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B
and O
CD28 B
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B
and O
CREB B
- I
binding I
protein I
( O
CBP B
) O
, O
in O
this O
study O
we O
found O
that O
CREB B
binds O
to O
CBP B
only O
by O
engagement O
of O
both O
CD3 B
and O
CD28 B
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium O
/ O
calmodulin O
- O
dependent O
protein O
kinase O
( O
CaMK O
) O
IV O
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

Extracellular O
signal O
- O
regulated O
kinase O
, O
CaMKIV O
, O
and O
p38 B
MAPK I
were O
also O
the O
kinases O
involved O
in O
CREB B
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 B
/ I
CD28 I
. O

A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB B
- O
CBP B
interaction O
and O
CREB B
trans O
- O
activation O
were O
attained O
when O
these O
three O
kinase O
pathways O
were O
simultaneously O
activated O
in O
T O
cells O
. O

Our O
results O
demonstrate O
that O
coordinated O
activation O
of O
different O
kinases B
leads O
to O
full O
activation O
of O
CREB B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B
- O
CBP B
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B
and O
CD28 B
are O
stimulated O
. O

The O
murine B
IL I
- I
2 I
promoter I
contains O
distal O
regulatory O
elements O
responsive O
to O
the O
Ah B
receptor I
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH O
- O
PAS O
transcription O
factor O
family O
. O

Signaling O
through O
the O
TCR B
and O
costimulatory O
signals O
primarily O
control O
transcription O
of O
the O
IL B
- I
2 I
gene I
in O
naive O
T O
cells O
. O

The O
minimal B
promoter I
necessary O
for O
this O
expression O
lies O
proximal O
, O
between O
- O
300 O
and O
the O
transcription B
start I
site I
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon O
receptor O
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH O
- O
PAS O
family O
of O
transcription O
factors O
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

The O
AHR B
is O
abundant O
in O
the O
thymus O
and O
may O
play O
a O
role O
for O
the O
development O
of O
the O
immune O
system O
. O

The O
IL B
- I
2 I
gene I
can O
be O
induced O
by O
the O
AHR B
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR B
. O

The O
AHR B
mediates O
the O
IL O
- O
2 O
induction O
as O
shown O
with O
AHR B
- O
deficient O
mice O
. O

However O
, O
in O
spleen O
cells O
in O
vitro O
costimulation O
via O
the O
TCR B
is O
necessary O
for O
optimal O
IL B
- I
2 I
gene I
induction O
. O

Thus O
, O
the O
IL B
- I
2 I
promoter I
region I
contains O
novel O
distal O
regulatory O
elements O
that O
can O
be O
addressed O
by O
the O
AHR B
to O
induce O
IL B
- I
2 I
and O
can O
cooperate O
with O
the O
proximal O
promoter O

Visualization O
of O
Syk O
- O
antigen O
receptor O
interactions O
using O
green O
fluorescent O
protein O
: O
differential O
roles O
for O
Syk B
and O
Lyn B
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

The O
cross O
- O
linking O
of O
the O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein B
tyrosine I
kinases I
of O
both O
the O
Src O
and O
Syk O
families O
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green O
fluorescent O
protein O
. O

Treatment O
of O
these O
cells O
with O
anti O
- O
IgM O
Abs O
leads O
to O
the O
recruitment O
of O
the O
kinase B
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross O
- O
linked O
receptor O
at O
the O
plasma O
membrane O
. O

Syk B
is O
not O
demonstrably O
associated O
with O
the O
internalized O
receptor O
. O

Catalytically O
active O
Syk B
promotes O
and O
stabilizes O
the O
formation O
of O
tightly O
capped O
BCR O
complexes O
at O
the O
plasma O
membrane O
. O

Lyn B
is O
not O
required O
for O
the O
recruitment O
of O
Syk B
to O
the O
cross O
- O
linked O
receptor O
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR O
complexes O
. O

In O
the O
absence O
of O
Lyn B
, O
receptor O
- O
Syk O
complexes O
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor O
- O
mediated O
activation O
of O
the O
NF B
- I
AT I
transcription I
factor I
is O
enhanced O
. O

Thus O
, O
Lyn B
appears O
to O
function O
to O
negatively O
regulate O
aspects O
of O
BCR B
- O
dependent O
signaling O
by O
stimulating O
receptor O
internalization O
and O
down O
- O
regulation O
. O

The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen O
types O
III O
and O
IV O
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific B
antibodies I
. O

Also O
determined O
were O
the O
mRNA O
levels O
of O
transforming B
growth I
factor I
- I
beta I
by O
Northern O
blot O
analysis O
. O

Nuclear B
factor I
- I
kappaB I
activity O
was O
assessed O
by O
gel O
shift O
assay O
. O

The O
mRNA O
level O
of O
transforming B
growth I
factor I
- I
beta I
was O
significantly O
higher O
in O
the O
OBK O
of O
wild O
mice O
with O
UUO O
compared O
with O
sham O
- O
operated O
mice O
. O

Finally O
, O
UUO O
resulted O
in O
activation O
of O
nuclear B
factor I
- I
kappaB I
in O
wild O
mice O
but O
was O
inhibited O
in O
the O
OBK O
of O
mutant O
mice O
. O

In O
this O
study O
, O
we O
utilized O
this O
technology O
to O
identify O
HLA B
DQ I
- O
restricted O
Ag O
- O
specific O
T O
cells O
in O
the O
peripheral O
blood O
of O
human O
subjects O
and O
to O
identify O
immunodominant O
epitopes O
associated O
with O
viral O
infection O
. O

Down O
- O
regulation O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
in O
classical O
Hodgkin O
disease O
but O
not O
in O
lymphocyte O
predominant O
Hodgkin O
disease O
correlates O
with O
immunoglobulin O
transcription O
. O

In O
contrast O
to O
the O
tumor O
cells O
( O
L O
& O
H O
cells O
) O
of O
lymphocyte O
predominant O
Hodgkin O
disease O
( O
LPHD O
) O
, O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD O
) O
are O
unable O
to O
transcribe O
immunoglobulin B
, O
despite O
the O
presence O
of O
rearranged O
immunoglobulin O
genes O
. O

Although O
initial O
studies O
have O
suggested O
crippling O
immunoglobulin O
gene O
mutations O
to O
be O
the O
cause O
of O
absent O
immunoglobulin O
expression O
in O
cHD O
, O
recent O
work O
of O
our O
group O
has O
demonstrated O
an O
impaired O
activation O
of O
the O
immunoglobulin B
promoter I
as O
a O
superior O
mechanism O
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B O
- O
cell O
transcription O
factors O
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B
factors I
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B
in O
LPHD O
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin O
promoter O
constructs O
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin O
V O
genes O
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down O
- O
regulation O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
. O

This O
study O
further O
revealed O
Oct2 B
as O
a O
new O
and O
valuable O
marker O
for O
the O
identification O
of O
L O
& O
H O
cells O
and O
their O
distinction O
from O
HRS O
cells O
. O

The O
impairment O
of O
immunoglobulin O
transcription O
with O
a O
down O
- O
regulated O
synthesis O
of O
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
is O
the O
first O
established O
general O
recurrent O
defect O
found O
in O
HRS O
cells O
. O

Constitutive O
expression O
of O
NF B
- I
kappa I
B I
is O
a O
characteristic O
feature O
of O
mycosis O
fungoides O
: O
implications O
for O
apoptosis O
resistance O
and O
pathogenesis O
. O

Recently O
, O
members O
of O
the O
NF B
- I
kappaB I
family I
, O
including O
p65 B
( I
Rel I
A I
) I
, O
have O
been O
implicated O
in O
promoting O
survival O
of O
various O
hematopoeitic O
neoplasms O
, O
including O
T O
cell O
malignancies O
such O
as O
adult O
T O
cell O
leukemia O
- O
lymphoma O
. O

We O
investigated O
the O
expression O
of O
active O
NF O
- O
kappa O
B O
p65 O
( O
Rel O
A O
) O
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF B
- I
kappa I
B I
on O
apoptosis O
in O
cutaneous O
T O
cell O
lymphoma O
( O
CTCL O
) O
cell O
lines O
. O

Paraffin O
- O
embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF O
were O
evaluated O
for O
p65 O
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal O
mouse O
antibody O
that O
detects O
the O
activated O
form O
of O
p65 B
( I
Rel I
A I
) I
. O

Nuclear O
expression O
of O
p65 B
( I
Rel I
A I
) I
before O
and O
after O
treatment O
with O
the O
various O
inhibitory O
compounds O
was O
measured O
by O
immunofluorescence O
staining O
in O
each O
CTCL O
cell O
line O
. O

In O
CTCL O
cell O
lines O
, O
the O
significant O
decrease O
in O
nuclear O
NF O
- O
kappa O
B O
expression O
and O
the O
marked O
increase O
in O
spontaneous O
apoptosis O
caused O
by O
chemical O
NF O
- O
kappa O
B O
inhibition O
suggest O
a O
critical O
role O
for O
NF B
- I
kappa I
B I
in O
the O
pathogenesis O
and O
tumor O
cell O
maintenance O
of O
CTCLs O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
tax B
protein I
activates O
transcription O
through O
AP B
- I
1 I
site I
by O
inducing O
DNA O
binding O
activity O
in O
T O
cells O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

We O
examined O
the O
activity O
of O
Tax B
in O
transcription O
through O
AP B
- I
1 I
- I
binding I
sites I
( O
AP B
- I
1 I
site I
) O
in O
T O
cells O
. O

Transient O
transfection O
studies O
showed O
that O
Tax B
activated O
the O
expression O
of O
a O
luciferase B
gene I
regulated O
by O
two O
copies O
of O
an O
AP B
- I
1 I
site I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Tax B
activates O
the O
expression O
of O
viral B
and I
cellular I
genes I
through O
two O
different O
enhancers O
: O
a O
cAMP O
- O
responsive O
( O
CRE O
) O
- O
like O
element O
and O
a O
kappaB B
element I
. O

Two O
Tax B
mutants I
differentially O
activated O
expression O
of O
these O
two O
elements O
. O

Tax703 O
preferentially O
activated O
the O
kappaB B
element I
but O
not O
the O
CRE O
- O
like O
one O
, O
whereas O
TaxM22 O
showed O
the O
reverse O
. O

In O
addition O
, O
Tax703 O
and O
Tax B
, O
but O
not O
TaxM22 O
, O
converted O
cell O
growth O
of O
a O
mouse O
T O
- O
cell O
line O
from O
being O
interleukin O
( O
IL O
) O
- O
2 O
- O
dependent O
to O
being O
IL O
- O
2 O
- O
independent O
. O

Unlike O
the O
wild O
- O
type O
Tax O
, O
Tax703 O
and O
TaxM22 O
only O
weakly O
activated O
the O
AP B
- I
1 I
site I
in O
the O
T O
- O
cell O
line O
. O

Thus O
, O
Tax B
seems O
to O
activate O
the O
AP B
- I
1 I
site I
via O
mechanisms O
distinct O
from O
those O
of O
kappaB O
or O
CRE O
- O
like O
elements O
, O
and O
the O
activation O
of O
the O
AP B
- I
1 I
site I
is O
dispensable O
for O
IL O
- O
2 O
- O
independent O
growth O
of O
CTLL O
- O
2 O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B
induced O
strong O
binding O
activity O
to O
an O
AP B
- I
1 I
site I
in O
CTLL O
- O
2 O
, O
whereas O
Tax703 O
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP B
- I
1 I
site I
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B
. O

The O
binding O
complex O
induced O
by O
Tax B
in O
CTLL O
- O
2 O
contained O
JunD B
and O
Fra O
- O
2 O
. O

Other O
AP B
- I
1 I
proteins I
were O
undetectable O
. O

Activation O
of O
transcription O
through O
the O
AP B
- I
1 I
site I
in O
Jurkat O
cells O
by O
JunD B
and O
/ O
or O
Fra O
- O
2 O
was O
weak O
. O

c B
- I
Jun I
, O
JunB B
, O
and O
c B
- I
Fos I
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B
. O

Thus O
, O
the O
induction O
of O
AP O
- O
1 O
mRNA O
by O
Tax B
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP B
- I
1 I
site I
by O
Tax B
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE O
- O
like O
and O
kappaB O
elements O
. O

Synovial O
fluid O
induced O
nuclear B
factor I
- I
kappaB I
DNA O
binding O
in O
a O
monocytic O
cell O
line O
. O

OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
the O
Mono O
Mac O
6 O
monocytic O
/ O
macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

RESULTS O
: O
Induction O
of O
NF B
- I
kappaB I
DNA O
binding O
by O
the O
p65 O
( O
RelA O
) O
/ O
p50 O
heterodimer O
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells O
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Incubation O
of O
SF O
with O
neutralizing B
antibodies I
against O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
but O
not O
antibodies B
against O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

Unexpectedly O
, O
a O
slowly O
migrating O
SF O
inducible O
NF B
- I
kappaB I
- O
binding O
complex O
was O
observed O
in O
EMSA O
of O
Mono O
Mac O
6 O
cells O
after O
incubation O
with O
SF O
from O
5 O
of O
8 O
RA O
and O
2 O
of O
5 O
OA O
subjects O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet O
derived O
growth O
factor O
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
slowly O
migrating O
complex O
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

A O
NF B
- I
kappaB I
- I
binding I
complex I
with O
similar O
slow O
mobility O
was O
observed O
in O
nuclear O
extracts O
prepared O
from O
fresh O
human O
RA O
synovial O
tissue O
. O

CONCLUSION O
: O
Biological O
activity O
of O
TNF B
- I
alpha I
in O
SF O
from O
RA O
and O
OA O
subjects O
is O
capable O
of O
inducing O
p65 O
/ O
p50 O
NF O
- O
kappaB O
DNA O
binding O
activity O
in O
macrophages O
. O

A O
property O
of O
SF O
that O
is O
independent O
of O
TNF B
- I
alpha I
and O
other O
cytokines B
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF B
- I
kappaB I
- I
binding I
complex I
. O

Soluble O
mediators O
in O
SF O
of O
subjects O
with O
RA O
and O
OA O
can O
therefore O
modulate O
binding O
of O
nuclear B
proteins I
to O
the O
NF B
- I
kappaB I
binding I
site I
in O
macrophages O
and O
may O
play O
a O
role O
in O
inflammatory O
gene O
expression O
in O
arthritis O
. O

These O
leukemic O
cells O
are O
resistant O
to O
Fas O
- O
mediated O
apoptosis O
despite O
expressing O
high O
levels O
of O
Fas B
. O

Treatment O
of O
leukemic O
LGL O
with O
the O
JAK O
- O
selective O
tyrosine O
kinase O
inhibitor O
AG O
- O
490 O
induced O
apoptosis O
with O
a O
corresponding O
decrease O
in O
STAT B
- O
DNA O
binding O
activity O
. O

Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v O
- O
src O
overexpression O
in O
NIH3T3 O
induced O
STAT3 B
- O
dependent O
transcriptional O
activity O
from O
the O
mcl O
- O
1 O
promoter O
and O
increased O
endogenous O
Mcl O
- O
1 O
protein O
levels O
. O

We O
conclude O
that O
STAT3 B
activation O
contributed O
to O
accumulation O
of O
the O
leukemic O
LGL O
clones O
. O

These O
findings O
suggest O
that O
investigation O
should O
focus O
on O
novel O
strategies O
targeting O
STAT3 B
in O
the O
treatment O
of O
LGL O
leukemia O
. O

To O
better O
define O
the O
role O
of O
ATF B
- I
2 I
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant O
ATF O
- O
2 O
protein O
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti B
- I
CD3 I
antibody I
or O
virus O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Stimulation O
of O
T O
lymphocytes O
by O
anti B
- I
CD3 I
antibody I
also O
showed O
less O
induction O
of O
IL B
- I
1 I
and O
IL B
- I
6 I
in O
ATF O
- O
2 O
mutant O
tissues O
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra O
- O
2 O
. O

ATF B
- I
2 I
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion B
molecules I
and O
cytokine B
genes I
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O

Furthermore O
, O
engagement O
of O
LIGHT O
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF O
- O
kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Activity O
of O
the O
distal O
region O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets O
- O
1 O
and O
USF O
- O
1 O
proteins O
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

The O
Ets O
- O
1 O
and O
USF O
- O
1 O
proteins O
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV O
- O
1 O
LTR O
distal O
enhancer O
region O
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant O
Ets O
- O
1 O
lacking O
trans O
- O
activation O
domains O
on O
the O
transcriptional O
activity O
of O
the O
LTR B
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets O
- O
1 O
and O
USF O
- O
1 O
proteins O
in O
HIV O
- O
1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant O
- O
negative O
mutant O
of O
Ets B
- I
1 I
( O
dnEts O
- O
1 O
) O
on O
HIV O
- O
1 O
infection O
of O
T O
cells O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly O
active O
USF O
- O
1 O
/ O
Ets O
- O
1 O
complex O
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF O
- O
1 O
and O
Ets B
- I
1 I
with O
the O
HIV B
- I
1 I
LTR I
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

BACKGROUND O
: O
Eosinophils O
are O
now O
known O
to O
produce O
a O
variety O
of O
proinflammatory B
cytokines I
, O
although O
the O
molecular O
factors O
that O
regulate O
their O
production O
are O
poorly O
understood O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B
produced O
by O
eosinophils O
, O
including O
the O
proallergic O
cytokine O
IL O
- O
4 O
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
family O
of O
transcription O
factors O
. O

OBJECTIVE O
: O
We O
sought O
to O
characterize O
the O
expression O
of O
different O
NFAT B
proteins I
in O
resting O
and O
activated O
eosinophils O
. O

NFAT B
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA O
- O
binding O
assays O
, O
and O
RT O
- O
PCR O
analysis O
of O
eosinophil O
mRNA O
. O

In O
addition O
, O
eosinophils O
were O
found O
to O
constitutively O
express O
NFATc B
mRNA I
. O

A O
brief O
incubation O
with O
the O
T O
( O
H O
) O
2 O
cytokines O
IL B
- I
4 I
and O
IL B
- I
5 I
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B
. O

Eosinophil O
nuclear O
extracts O
contain O
multiple O
factors O
that O
can O
specifically O
recognize O
the O
IL O
- O
4 O
promoter O
P1 O
NFAT O
site O
in O
DNA O
- O
binding O
assays O
, O
including O
NFATp B
. O

CONCLUSION O
: O
NFATp B
and O
NFATc B
can O
regulate O
the O
expression O
of O
cytokines B
and O
other O
genes O
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these O
cells O
. O

BLyS O
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION B
FACTORS I
NF B
- I
kappaB I
AND O
ELF B
- I
1 I
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled O
BLyS O
to O
its O
cognate B
receptor I
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS O
binding O
. O

In O
addition O
we O
report O
that O
BLyS O
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets O
family O
transcription O
factor O
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo O
- O
like O
kinase O
( O
PLK O
) O
. O

Design O
and O
use O
of O
an O
inducibly O
activated O
human O
immunodeficiency O
virus O
type O
1 O
Nef B
to O
study O
immune O
modulation O
. O

The O
Nef O
protein O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell B
surface I
proteins I
, O
and O
associate O
with O
many O
intracellular B
proteins I
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef B
has O
been O
obtaining O
good O
expression O
of O
Nef O
protein O
in O
T O
cells O
. O

This O
has O
been O
attributed O
to O
effects O
of O
Nef B
on O
cell O
proliferation O
and O
apoptosis O
. O

Using O
this O
inducible O
Nef B
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B
and O
HLA O
- O
A2 O
downmodulation O
in O
a O
SupT1 O
T O
- O
cell O
line O
. O

Half O
- O
maximal O
downmodulation O
of O
cell B
surface I
CD4 I
required O
very O
little O
active O
Nef O
- O
ER O
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4 O
- O
HT O
. O

In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA O
- O
A2 O
by O
Nef B
required O
16 O
to O
24 O
h O
and O
about O
50 O
- O
to O
100 O
- O
fold O
- O
greater O
concentrations O
of O
4 O
- O
HT O
. O

These O
data O
suggest O
that O
HLA O
- O
A2 O
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef B
. O

The O
differential O
timing O
of O
CD4 B
and O
HLA O
- O
A2 O
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O

Since O
MIP B
- I
2 I
is O
a O
potent O
PMN O
chemoattractant O
and O
MIP B
- I
1alpha I
is O
a O
potent O
macrophage O
/ O
monocyte O
chemoattractant O
has O
been O
well O
known O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP O
- O
2 O
mRNA O
expression O
, O
suggesting O
that O
MIP B
- I
2 I
is O
involved O
in O
the O
development O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP O
- O
1alpha O
mRNA O
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP B
- I
1alpha I
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5 B
' I
- I
flanking I
region I
of O
the O
MIP O
- O
2 O
gene O
. O

The O
promotor O
region O
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF B
- I
kappaB I
, O
not O
AP B
- I
1 I
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP O
- O
2 O
mRNA O
. O

p65 B
( I
Rel I
A I
) I
and O
p50 O
protein O
appears O
to O
be O
involved O
in O
MIP O
- O
2 O
NF B
- I
kappaB I
binding O
. O

Taken O
together O
, O
our O
studies O
suggest O
that O
MIP B
- I
2 I
is O
an O
important O
mediator O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
in O
the O
rat O
model O
. O

In O
addition O
, O
elevated O
MIP O
- O
2 O
mRNA O
levels O
are O
accompanied O
by O
increased O
NF B
- I
kappaB I
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP B
- I
2 I
transcriptional O
regulation O
through O
NF B
- I
kappaB I
. O

This O
effect O
was O
prevented O
by O
neutralizing O
antibodies O
against O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV O
- O
infected O
cells O
, O
subsequent O
to O
the O
induction O
of O
cytokines B
such O
as O
IFNs B
and O
TNF B
- I
alpha I
. O

The O
physical O
association O
of O
protein O
kinase O
C O
theta O
with O
a O
lipid O
raft O
- O
associated O
inhibitor O
of O
kappa O
B O
factor O
kinase O
( O
IKK O
) O
complex O
plays O
a O
role O
in O
the O
activation O
of O
the O
NF O
- O
kappa O
B O
cascade O
by O
TCR B
and O
CD28 B
. O

We O
investigated O
the O
role O
of O
protein O
kinase O
C O
theta O
( O
PKCtheta O
) O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Among O
six O
or O
so O
PKC B
isoforms I
expressed O
in O
T O
cells O
, O
only O
PKCtheta O
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B
with O
Ag B
. O

Signaling O
via O
both O
the O
TCR B
and O
CD28 B
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit O
IkappaB O
kinase O
( O
IKK O
) O
complex O
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
Ca O
( O
2 O
+ O
) O
- O
independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

Constitutively O
active O
but O
not O
kinase O
- O
inactive O
PKCtheta O
activated O
IKKbeta B
in O
Jurkat O
T O
cells O
. O

Expression O
of O
dominant O
- O
active O
PKCtheta O
also O
had O
stimulatory O
effects O
on O
the O
CD28 B
response I
element I
of O
the O
IL B
- I
2 I
promoter I
. O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta O
by O
the O
TCR B
and O
CD28 B
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK O
complexes O
in O
the O
T O
cell O
membrane O

T O
- O
cell O
- O
mediated O
regulation O
of O
osteoclastogenesis O
by O
signalling O
cross O
- O
talk O
between O
RANKL B
and O
IFN B
- I
gamma I
. O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T O
- O
cell O
expression O
of O
RANKL B
( O
receptor O
activator O
of O
nuclear O
factor O
( O
NF O
) O
- O
kappaB O
ligand O
) O
, O
a O
member O
of O
the O
tumour O
- O
necrosis O
factor O
family O
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

However O
, O
whether O
activated O
T O
cells O
maintain O
bone O
homeostasis O
by O
counterbalancing O
the O
action O
of O
RANKL B
remains O
unknown O
. O

Here O
we O
show O
that O
T O
- O
cell O
production O
of O
interferon B
( I
IFN I
) I
- I
gamma I
strongly O
suppresses O
osteoclastogenesis O
by O
interfering O
with O
the O
RANKL B
- O
RANK O
signalling O
pathway O
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK O
adapter O
protein O
, O
TRAF6 B
( O
tumour O
necrosis O
factor O
receptor O
- O
associated O
factor O
6 O
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B
in O
precursor O
cells O
, O
which O
indicates O
that O
TRAF6 B
is O
the O
target O
critical O
for O
the O
IFN B
- I
gamma I
action O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL B
, O
and O
IFN B
- I
gamma I
- O
induced O
activation O
of O
the O
ubiquitin O
- O
proteasome O
system O
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour B
necrosis I
factor I
and O
IFN O
families O
of O
cytokines B
, O
through O
which O
IFN B
- I
gamma I
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

Stromal O
- O
derived O
factor O
1 O
and O
thrombopoietin B
regulate O
distinct O
aspects O
of O
human O
megakaryopoiesis O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal O
- O
derived O
factor O
1 O
( O
SDF O
- O
1 O
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

In O
this O
study O
it O
was O
found O
that O
SDF O
- O
1 O
, O
unlike O
TPO B
, O
does O
not O
stimulate O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase O
9 O
( O
MMP B
- I
9 I
) O
and O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
by O
these O
cells O
, O
and O
both O
SDF O
- O
1 O
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin O
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF O
- O
1 O
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen O
- O
activated O
protein O
kinase O
[ O
MAPK O
] O
p42 O
/ O
44 O
, O
MAPK B
p38 I
, O
and O
AKT O
[ O
protein O
kinase O
B O
] O
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF O
- O
1 O
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI O
- O
3K O
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF O
, O
the O
inhibition O
of O
MAPK O
p42 O
/ O
44 O
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Hence O
, O
it O
is O
suggested O
that O
the O
proliferative O
effect O
of O
TPO B
is O
more O
related O
to O
activation O
of O
the O
JAK O
- O
STAT O
pathway O
( O
unique O
to O
TPO B
) O
, O
and O
the O
PI O
- O
3K O
- O
AKT O
axis O
is O
differentially O
involved O
in O
TPO O
- O
and O
SDF O
- O
1 O
- O
dependent O
signaling O
. O

Accordingly O
, O
PI O
- O
3K O
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin O
, O
and O
SDF O
- O
1 O
- O
mediated O
migration O
. O

This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF O
- O
1 O
and O
TPO B
in O
normal O
human O
megakaryopoiesis O
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL O
- O
6 O
gene O
trascription O
factors O
( O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 O
and O
alpha6beta4 O
integrins O
. O

Key O
molecules O
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines B
and O
growth B
factors I
secreted O
by O
the O
two O
cell O
types O
and O
adhesion B
receptors I
mediating O
cell O
contact O
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
gene O
transcription O
factors O
and O
enhanced O
IL O
- O
6 O
production O
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 O
, O
but O
not O
alpha2beta1 O
heterodimers O
at O
the O
TEC O
surface O
and O
iii O
) O
up O
- O
regulated O
the O
nuclear O
binding O
activity O
of O
NF B
- I
kappaB I
transcription I
factor I
and O
the O
IL O
- O
6 O
secretion O
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C B
terminus I
and O
N B
- I
terminal I
SCAN O
box O
and O
KRAB O
domains O
. O

This O
pattern O
of O
expression O
closely O
mirrored O
that O
of O
GATA B
- I
3 I
in O
the O
same O
cells O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT O
- O
2 O
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL O
- O
4 O
but O
not O
the O
IL O
- O
5 O
promoter O
, O
contrasting O
with O
the O
ability O
of O
GATA B
- I
3 I
to O
activate O
both O
promoters B
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT O
- O
2 O
, O
thus O
SKAT O
- O
2 O
is O
a O
novel O
Th2 O
- O
specific O
gene O
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B
genes I
in O
T O
cells O
. O

hsp70 O
interacting O
protein O
Hip O
does O
not O
affect O
glucocorticoid B
receptor I
folding O
by O
the O
hsp90 O
- O
based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG O
- O
1 O
. O

Using O
purified O
proteins O
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop O
, O
hsp40 O
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

STAT4 B
and O
STAT6 B
are O
essential O
for O
the O
development O
of O
CD4 O
( O
+ O
) O
Th1 O
and O
Th2 O
development O
, O
respectively O
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
transforms O
primary O
human O
T O
cells O
in O
vitro O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax B
to O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
( O
AP B
- I
1 I
site I
) O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B
can O
activate O
transcription O
through O
the O
AP B
- I
1 I
- I
binding I
site I
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP B
- I
1 I
proteins I
did O
so O
much O
less O
than O
Tax B
, O
indicating O
that O
the O
activation O
of O
the O
AP B
- I
1 I
site I
by O
Tax B
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP O
- O
1 O
mRNA O
. O

However O
, O
the O
HTLV O
- O
1 O
genes O
, O
including O
tax B
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia O
cells O
from O
ATL O
patients O
. O

Our O
present O
results O
suggest O
that O
activation O
of O
AP B
- I
1 I
occurs O
through O
Tax O
- O
dependent O
and O
- O
independent O
mechanisms O
in O
HTLV O
- O
1 O
- O
infected O
T O
cells O
, O
which O
may O
play O
some O
roles O
in O
dysregulated O
phenotypes O
of O
HTLV O
- O
1 O
- O
infected O
cells O
. O

In O
addition O
, O
caspase B
- I
3 I
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
- O
induced O
apoptosis O
. O

Effects O
of O
deregulated O
Raf O
activation O
on O
integrin B
, O
cytokine O
- O
receptor O
expression O
and O
the O
induction O
of O
apoptosis O
in O
hematopoietic O
cells O
. O

The O
cytokine O
- O
dependent O
murine O
myeloid O
FDC O
- O
P1 O
and O
human O
erythroleukemic O
TF O
- O
1 O
cell O
lines O
were O
transformed O
to O
grow O
in O
response O
to O
deregulated O
Raf O
expression O
in O
the O
absence O
of O
exogenous B
cytokines I
. O

The O
conditionally O
active O
Raf O
proteins O
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf O
catalytic O
, O
but O
lacking O
negative O
- O
regulatory O
domains O
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf O
: O
ER O
) O
. O

Continuous O
deltaRaf O
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous B
cytokines I
and O
altered O
the O
morphology O
of O
the O
FD O
/ O
deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental O
cytokine O
- O
dependent O
FDC O
- O
P1 O
cells O
grew O
in O
smaller O
grape O
- O
like O
clusters O
( O
< O
10 O
cells O
) O
. O

In O
contrast O
, O
when O
these O
cells O
were O
cultured O
in O
IL B
- I
3 I
, O
higher O
levels O
of O
these O
adhesion B
molecules I
were O
detected O
. O

In O
contrast O
when O
the O
Raf O
- O
responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM B
- I
CSF I
, O
in O
the O
absence O
of O
deltaRaf O
: O
ER O
activation O
, O
increased O
levels O
of O
the O
CD11b O
and O
CD18 O
molecules O
were O
detected O
. O

Retinoic O
acid O
( O
RA O
) O
inhibited O
3H O
- O
thymidine O
incorporation O
in O
response O
to O
GM B
- I
CSF I
. O

Cyclic O
AMP O
activates O
p38 B
mitogen I
- I
activated I
protein I
kinase I
in O
Th2 O
cells O
: O
phosphorylation O
of O
GATA B
- I
3 I
and O
stimulation O
of O
Th2 O
cytokine O
gene O
expression O
. O

Elevation O
of O
intracellular O
cAMP O
in O
T O
cells O
, O
induced O
by O
agents O
such O
as O
IL B
- I
1alpha I
or O
PGs O
, O
inhibits O
T O
cell O
activation O
. O

In O
effector O
T O
cells O
, O
an O
increase O
in O
the O
level O
of O
intracellular O
cAMP O
inhibits O
cytokine B
production O
in O
Th1 O
cells O
but O
stimulates O
cytokine B
production O
in O
Th2 O
cells O
. O

Here O
we O
report O
that O
cAMP O
- O
induced O
effects O
in O
Th2 O
cells O
occur O
independently O
of O
the O
protein B
kinase I
A I
pathway O
, O
which O
is O
the O
major O
mediator O
of O
cAMP O
- O
induced O
signaling O
events O
in O
most O
cell O
types O
. O

Instead O
, O
cAMP O
stimulates O
activation O
of O
p38 B
mitogen I
- I
activated I
protein I
kinase I
in O
Th2 O
cells O
. O

This O
appears O
to O
be O
a O
Th2 O
- O
selective O
event O
because O
cAMP O
barely O
increased O
p38 B
phosphorylation O
in O
Th1 O
cells O
. O

We O
show O
that O
in O
Th2 O
cells O
, O
cAMP O
promotes O
the O
production O
of O
both O
IL B
- I
5 I
and O
IL B
- I
13 I
, O
which O
play O
distinct O
but O
critical O
roles O
in O
asthma O
pathogenesis O
. O

Our O
data O
also O
show O
that O
cAMP O
causes O
increased O
phosphorylation O
of O
the O
transcription B
factor I
GATA I
- I
3 I
, O
which O
we O
have O
shown O
is O
a O
critical O
regulator O
of O
Th2 O
cytokine O
gene O
expression O
and O
, O
in O
turn O
, O
of O
airway O
inflammation O
in O
mice O
. O

Thus O
, O
Th2 O
- O
specific O
GATA B
- I
3 I
expression O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
activation O
together O
provide O
a O
molecular O
basis O
for O
the O
differential O
effects O
of O
cAMP O
in O
the O
two O
T O
helper O
cell O
subsets O
. O

Characterization O
of O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
dependent O
on O
the O
human O
IL O
- O
13 O
receptor O
alpha O
chain O
1 O
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
are O
pleiotropic O
cytokines O
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL O
- O
13 O
receptor O
alpha O
chain O
1 O
( O
IL O
- O
13R O
alpha O
1 O
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL O
- O
13R O
alpha O
1 O
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL O
- O
13R O
alpha O
1 O
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human O
IL O
- O
13R O
alpha O
1 O
, O
and O
analyzed O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
using O
an O
IL O
- O
13R O
alpha O
1 O
- O
transfected O
human O
B O
cell O
line O
. O

Expression O
of O
IL O
- O
13R O
alpha O
1 O
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL O
- O
13R O
alpha O
1 O
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Replacement O
of O
the O
two O
tyrosine O
residues O
completely O
abolished O
STAT3 B
activation O
, O
although O
replacing O
either O
tyrosine O
residue O
alone O
retained O
it O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 O
region O
and O
the O
C O
- O
terminal O
tail O
of O
IL O
- O
13R O
alpha O
1 O
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin O
receptor O
substrate O
- O
1 O
and O
STAT6 B
respectively O
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL O
- O
13R O
alpha O
1 O
to O
activate O
STAT3 B
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
transforms O
cytokine B
- O
dependent O
T O
lymphocytes O
and O
causes O
adult O
T O
cell O
leukemia O
. O

Janus O
tyrosine O
kinase O
( O
Jak O
) O
3 O
and O
transcription B
factors I
Stat5a B
and O
Stat5b B
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific O
Ab O
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 O
- O
responsive O
beta O

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 O
/ O
p65 O
components O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
activated O
by O
the O
HTLV O
- O
1 O
- O
encoded O
phosphoprotein O
, O
Tax O
. O

The O
present O
work O
focuses O
on O
a O
region O
of O
Wp B
which O
in O
reporter O
assays O
confers O
B O
- O
cell O
- O
specific O
activity O
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX O
family O
of O
proteins O
, O
notably O
RFX1 B
, O
RFX3 O
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites O
B O
and O
D O
both O
bind O
the O
B O
- O
cell O
- O
specific O
activator O
protein O
BSAP O
/ O
Pax5 O
. O

In O
reporter O
assays O
with O
mutant O
Wp O
constructs O
, O
the O
loss O
of O
factor O
binding O
to O
any O
one O
of O
these O
sites O
severely O
impaired O
promoter O
activity O
in O
B O
cells O
, O
while O
the O
wild B
- I
type I
promoter I
could O
be O
activated O
in O
non O
- O
B O
cells O
by O
ectopic O
BSAP O
expression O
. O

We O
suggest O
that O
Wp B
regulation O
by O
BSAP B
helps O
to O
ensure O
the O
B O
- O
cell O
specificity O
of O
EBV O
' O
s O
growth O
- O
transforming O
function O
. O

Two O
sequences O
in O
the O
Tip O
protein O
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck B
. O

A O
proline B
- I
rich I
region I
, O
residues O
132 O
- O
141 O
, O
binds O
to O
the O
SH3 O
domain O
of O
the O
Lck O
protein O
. O

We O
show O
here O
that O
the O
other O
Lck O
- O
binding O
domain O
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl O
- O
terminal O
half O
of O
Lck B
and O
that O
this O
binding O
does O
not O
require O
the O
Lck O
SH3 O
domain O
. O

Mutated O
Tip B
containing O
only O
one O
functional O
Lck O
- O
binding O
domain O
can O
bind O
stably O
to O
Lck B
, O
although O
not O
as O
strongly O
as O
wild O
- O
type O
Tip O
. O

Interaction O
of O
Tip B
with O
Lck B
through O
either O
Lck O
- O
binding O
domain O
increases O
the O
activity O
of O
Lck B
in O
vivo O
. O

Simultaneous O
binding O
of O
both O
domains O
is O
required O
for O
maximal O
activation O
of O
Lck B
. O

The O
transient O
expression O
of O
Tip B
in O
T O
cells O
was O
found O
to O
stimulate O
both O
Stat3 B
- O
dependent O
and O
NF B
- I
AT I
- O
dependent O
transcription O
. O

Mutant O
forms O
of O
Tip B
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck O
- O
binding O
domains O
retained O
the O
ability O
to O
stimulate O
Stat3 B
- O
dependent O
transcription O
. O

Tip B
lacking O
the O
proline O
- O
rich O
Lck O
- O
binding O
domain O
exhibited O
almost O
wild O
- O
type O
activity O
in O
this O
assay O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck O
- O
binding O
domain O
abolished O
the O
ability O
of O
Tip B
to O
stimulate O
NF B
- I
AT I
- O
dependent O
transcription O
. O

Full O
biological O
activity O
of O
Tip B
, O
therefore O
, O
appears O
to O
require O
both O
Lck O
- O
binding O
domains O
. O

Accumulation O
of O
RXR B
alpha I
during O
activation O
of O
cycling O
human O
T O
lymphocytes O
: O
modulation O
of O
RXRE O
transactivation O
function O
by O
mitogen O
- O
activated O
protein O
kinase O
pathways O
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen O
- O
activated O
protein O
kinase O
pathways O
, O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
and O
extracellular B
signal I
- I
regulated I
kinase I
( O
ERK B
) O
, O
in O
modulating O
RXRE O
- O
dependent O
transcription O
, O
was O
explored O
. O

The O
expression O
of O
constitutively O
active O
MAP B
/ I
ERK I
kinase I
kinase I
1 I
( O
MEKK1 B
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant O
negative O
MEKK1 O
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B
signaling O
pathways O
in O
the O
process O
. O

In O
contrast O
, O
expression O
of O
constitutively O
active O
MEK1 O
, O
which O
activates O
ERK B
pathway O
, O
enhanced O
RXRE O
- O
dependent O
activation O
. O

When O
both O
were O
activated O
simultaneously O
, O
JNK B
pathway O
was O
dominant O
over O
ERK B
pathway O
and O
resulted O
in O
inhibition O
of O
RXRE O
- O
mediated O
transcription O
. O

The O
proteasome B
regulates O
receptor O
- O
mediated O
endocytosis O
of O
interleukin B
- I
2 I
. O

Recent O
studies O
have O
increasingly O
implicated O
the O
proteasome B
in O
the O
regulation O
of O
cell B
surface I
receptors I
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome B
for O
ligand O
- O
dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin O
- O
2 O
( O
IL O
- O
2 O
) O
- O
interleukin O
- O
2 O
receptor O
( O
IL O
- O
2R O
) O
complex O
. O

Proteasome O
inhibitors O
impaired O
internalization O
of O
IL O
- O
2 O
. O
IL O
- O
2R O
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine B
. O

Based O
on O
time O
- O
course O
studies O
, O
proteasome B
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL O
- O
2 O
. O
IL O
- O
2R O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic O
tailless O
beta O
- O
or O
gamma O
c O
- O
subunits O
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta O
- O
or O
gamma O
c O
- O
subunits O
and O
their O
associated O
signaling O
components O
. O

Therefore O
, O
a O
functional O
proteasome B
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL O
- O
2R O
/ O
ligand O
complex O
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL B
- I
2 I
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

OBJECTIVE O
: O
The O
transcription B
factor I
NF I
- I
E2 I
, O
a O
heterodimeric O
protein O
complex O
composed O
of O
p45 B
and O
small O
Maf O
family O
proteins O
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter B
genes I
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter O
fragments O
were O
transfected O
to O
human O
hematopoietic O
cell O
lines O
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid O
- O
megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF O
- O
E2 O
, O
suggesting O
that O
fNF B
- I
E2 I
promoter I
is O
more O
erythroid O
specific O
. O

Functional O
analysis O
of O
fNF B
- I
E2 I
promoter I
showed O
that O
the O
promoter O
is O
active O
only O
in O
erythroid O
- O
megakaryocytic O
cells O
and O
that O
the O
double O
GATA O
sit O
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O

The O
time O
course O
of O
heme O
oxygenase O
- O
1 O
and O
- O
2 O
, O
cytokine O
- O
induced O
neutrophil O
chemoattractant O
- O
1 O
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
studied O
by O
Northern O
analysis O
. O

DNA O
- O
binding O
activity O
of O
nuclear B
factor I
- I
kappaB I
was O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

RESULTS O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
- O
15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B
factor I
- I
kappaB I
and O
intercellular B
adhesion I
molecule I
- I
1 I
and O
cytokine O
- O
induced O
neutrophil O
chemoattractant O
- O
1 O
mRNAs O
. O

Blockade O
of O
heme O
oxygenase O
activity O
with O
tin O
- O
protoporphyrin O
- O
IX O
abrogated O
acetaminophen O
- O
induced O
hepatic O
neutrophil O
accumulation O
and O
nuclear B
factor I
- I
kappaB I
activation O
, O
but O
failed O
to O
affect O
sinusoidal O
perfusion O
and O
liver O
injury O
. O

These O
data O
argue O
against O
a O
central O
role O
of O
nuclear B
factor I
- I
kappaB I
activation O
and O
neutrophil O
infiltration O
as O
perpetuating O
factors O
of O
liver O
injury O
in O
acetaminophen O
toxicity O
. O

Tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
proliferation O
requires O
synthesis O
of O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
. O

OBJECTIVE O
: O
Tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
induces O
a O
variety O
of O
cellular O
responses O
, O
some O
of O
them O
being O
at O
least O
seemingly O
contradictory O
. O

Thus O
, O
we O
set O
out O
to O
find O
differences O
in O
the O
modes O
of O
proliferative O
and O
apoptotic O
responses O
to O
TNF B
- I
alpha I
. O

MATERIALS O
AND O
METHODS O
: O
We O
screened O
a O
panel O
of O
acute O
myeloid O
leukemia O
- O
derived O
cell O
lines O
for O
TNF B
- I
alpha I
- O
responsiveness O
. O

In O
two O
lines O
( O
OCI O
- O
AML O
- O
1 O
, O
OCI O
- O
AML O
- O
11 O
) O
, O
TNF B
- I
alpha I
acted O
as O
an O
apoptotic O
agent O
; O
in O
others O
( O
HU O
- O
3 O
, O
M O
- O
07e O
, O
TF O
- O
1 O
) O
, O
it O
had O
the O
opposite O
effect O
, O
preventing O
apoptosis O
and O
inducing O
proliferation O
. O

Direct O
and O
indirect O
signaling O
mechanisms O
, O
including O
NF B
- I
kappaB I
activation O
and O
cytokine O
synthesis O
, O
were O
analyzed O
. O

RESULTS O
: O
All O
cell O
lines O
tested O
expressed O
TNF O
- O
alpha O
receptors O
I O
and O
II O
and O
responded O
to O
TNF B
- I
alpha I
by O
upregulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

In O
contrast O
to O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
TNF B
- I
alpha I
did O
not O
activate O
the O
MAP B
kinase I
and O
p70S6 O
kinase O
pathways O
. O

Nevertheless O
, O
inhibitors O
of O
these O
pathways O
clearly O
reduced O
the O
TNF B
- I
alpha I
- O
induced O
cell O
growth O
, O
indicating O
that O
TNF O
- O
alpha O
- O
proliferative O
cells O
produced O
a O
growth O
factor O
that O
induced O
proliferation O
upon O
stimulation O
of O
the O
above O
pathways O
. O

Anti O
- O
GM O
- O
CSF O
antibodies O
inhibited O
the O
TNF B
- I
alpha I
- O
induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM B
- I
CSF I
. O

Supporting O
this O
notion O
, O
TNF B
- I
alpha I
- O
induced O
upregulation O
of O
GM B
- I
CSF I
mRNA I
levels O
and O
protein O
secretion O
in O
the O
TNF B
- I
alpha I
- O
proliferative O
, O
but O
not O
in O
the O
TNF O
- O
alpha O
- O
apoptotic O
cell O
lines O
. O

CONCLUSION O
: O
These O
data O
identify O
GM B
- I
CSF I
synthesis O
as O
an O
early O
and O
essential O
step O
in O
TNF O
- O
alpha O
- O
induced O
proliferation O
. O

We O
show O
for O
the O
first O
time O
that O
TNF O
- O
alpha O
- O
treated O
cell O
lines O
producing O
no O
or O
only O
minimal O
amounts O
of O
GM B
- I
CSF I
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines O
with O
high O
GM B
- I
CSF I
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O

In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF B
- I
kappaB I
as O
regulator O
of O
GM B
- I
CSF I
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF B
- I
alpha I
- O
induced O
apoptosis O

Glucocorticoid B
receptor I
content O
of O
T O
lymphocytes O
: O
evidence O
for O
heterogeneity O
. O

Glucocorticoid B
receptors I
were O
measured O
in O
T O
lymphocytes O
that O
were O
isolated O
from O
peripheral O
blood O
by O
either O
nylon O
wool O
filtration O
or O
E O
- O
rosette O
sedimentation O
. O

These O
findings O
suggest O
that O
T O
cells O
are O
heterogeneous O
with O
respect O
to O
their O
quantity O
of O
glucocorticoid B
receptors I
. O

Isolation O
of O
T O
cells O
by O
E O
- O
rosette O
sedimentation O
enriches O
for O
T O
cells O
that O
have O
a O
greater O
number O
of O
glucocorticoid B
receptors I
, O
and O
isolation O
of O
T O
cells O
by O
nylon O
wool O
filtration O
enriches O
for O
T O
cells O
that O
have O
a O
lesser O
number O
of O
glucocorticoid B
receptors I
. O

Glucocorticoid B
receptors I
and O
glucocorticoid O
sensitivity O
of O
human O
leukemic O
cells O
. O

We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
human O
white O
cells O
using O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
as O
the O
ligand O
, O
and O
the O
subsequent O
determination O
of O
the O
GR B
content O
in O
normal O
human O
lymphocytes O
and O
in O
leukemic O
cells O
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O

A O
number O
of O
leukemia O
cell O
lines O
in O
continuous O
culture O
were O
also O
subjected O
to O
the O
GR B
assay O
, O
and O
the O
results O
were O
correlated O
with O
the O
sensitivity O
of O
these O
cell O
lines O
to O
glucocorticoid O
steroids O
in O
vitro O
. O

The O
GR B
content O
of O
normal O
human O
lymphocytes O
amounted O
to O
4 O
, O
850 O
+ O
/ O
- O
1 O
, O
340 O
( O
mean O
+ O
/ O
- O
SD O
) O
receptors O
/ O
cell O
. O

The O
mean O
equilibrium O
dissociation O
constant O
( O
KD O
) O
of O
the O
interaction O
of O
[ O
3H O
] O
dexamethasone O
with O
the O
GR B
was O
1 O
. O
2 O
x O
10 O
( O
- O
8 O
) O
M O
. O

The O
GR B
content O
of O
the O
blast O
cells O
obtained O
from O
eight O
patients O
suffering O
from O
acute O
leukemia O
and O
four O
patients O
with O
a O
blast O
crisis O
of O
chronic O
myelocytic O
leukemia O
was O
found O
to O
be O
highly O
variable O
( O
3 O
, O
230 O
- O
29 O
, O
900 O
receptors O
/ O
cell O
) O
, O
while O
the O
lymphocytes O
of O
six O
patients O
with O
chronic O
lymphatic O
leukemia O
contained O
a O
rather O
stable O
GR B
content O
( O
2 O
, O
930 O
- O
5 O
, O
120 O
receptors O
/ O
cell O
) O
, O
which O
was O
comparable O
with O
that O
of O
normal O
lymphocytes O
. O

GR B
was O
identified O
in O
all O
the O
12 O
malignant O
continuous O
white O
cell O
lines O
studied O
. O

Large O
cells O
contained O
more O
GR B
than O
the O
smaller O
ones O
. O

There O
was O
no O
apparent O
correlation O
between O
the O
GR B
concentration O
and O
the O
sensitivity O
of O
the O
cells O
in O
vitro O
to O
glucocorticoids O
as O
judged O
by O
[ O
3H O
] O
thymidine O
incorporation O
studies O
. O

Distribution O
of O
the O
surface O
markers O
in O
the O
leukemic O
cell O
lines O
did O
not O
relate O
to O
the O
GR B
concentration O
. O

We O
conclude O
that O
the O
presence O
of O
GR B
is O
probably O
a O
universal O
feature O
of O
the O
leukemic O
cells O
, O
and O
, O
from O
a O
clinical O
standpoint O
, O
probably O
does O
not O
alone O
imply O
steroid O
responsiveness O
. O

Evidence O
for O
a O
steroid B
receptor I
in O
rheumatoid O
synovial O
tissue O
cells O
. O

Clinical O
implications O
of O
glucocorticoid B
receptors I
in O
human O
leukemia O
. O

Normal O
lymphocytes O
contain O
low O
levels O
of O
glucocorticoid B
receptor I
( O
approximately O
2 O
, O
500 O
sites O
/ O
cell O
) O
which O
are O
identical O
in O
T O
- O
and O
non O
- O
T O
- O
fractions O
. O

Phytohemagglutinin B
treatment O
increases O
levels O
about O
3 O
- O
fold O
. O

Quantitative O
determination O
of O
glucocorticoid B
receptor I
levels O
in O
acute O
lymphoblastic O
leukemia O
may O
be O
of O
value O
both O
as O
an O
independent O
prognostic O
variable O
and O
in O
suggesting O
which O
patients O
should O
receive O
glucocorticoid O
therapy O
. O

The O
Src O
- O
like O
protein O
- O
tyrosine O
kinase O
Fyn B
is O
associated O
with O
T B
- I
cell I
antigen I
receptor I
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B
, O
having O
Phe O
- O
528 O
instead O
of O
Tyr O
- O
528 O
or O
Thr O
- O
338 O
instead O
of O
Ile O
- O
338 O
, O
in O
Jurkat O
T O
- O
cells O
stimulated O
the O
serum O
response O
element O
( O
SRE B
) O
, O
12 O
- O
O O
- O
tetradecanoyl O
- O
phorbol O
- O
13 O
- O
acetate O
response O
element O
, O
cyclic B
AMP I
response I
element I
, O
and O
c B
- I
fos I
promoter I
. O

The O
stimulation O
of O
SRE B
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn B
but O
also O
with O
normal O
( O
wild O
- O
type O
) O
Fyn O
. O

SRE B
was O
also O
stimulated O
by O
both O
normal O
and O
active O
Lck O
. O

Furthermore O
, O
normal O
and O
active O
Fyn O
stimulated O
transcription O
from O
the O
IL B
- I
2 I
gene I
promoter I
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin O
A O
plus O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

Under O
the O
same O
conditions O
, O
Lck B
did O
not O
stimulate O
IL B
- I
2 I
promoter I
unless O
it O
was O
activated O
by O
mutation O
. O

Csk O
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

These O
data O
suggest O
that O
Fyn B
and O
Lck B
, O
whose O
activities O
are O
regulated O
by O
Csk O
, O
are O
involved O
in O
different O
phases O
of O
T O
- O
cell O
activation O
. O

A O
novel O
NF B
- I
kappa I
B I
complex I
containing O
p65 O
homodimers O
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric O
complex O
containing O
two O
Rel O
- O
related O
DNA O
- O
binding O
subunits O
, O
termed O
p65 O
and O
p50 B
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 O
and O
p50 O
subunits O
are O
expressed O
independently O
as O
stable O
homodimers O
, O
p65 B
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 B
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

While O
authentic O
p50 B
homodimers I
( O
previously O
termed O
KBF1 B
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 O
homodimers O
in O
vivo O
was O
lacking O
. O

As O
with O
the O
prototypical O
NF B
- I
kappa I
B I
p50 I
- I
p65 I
heterodimer I
, O
this O
novel O
p65 O
homodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B
kinase I
A I
( O
RRPS O
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel B
homology I
domain I
that O
mediates O
self O
- O
association O
. O

In O
contrast O
, O
mutations O
at O
these O
two O
sites O
do O
not O
affect O
heterodimerization O
of O
p65 B
with O
p50 B
or O
its O
functional O
interaction O
with O
I O
kappa O
B O
alpha O
. O

These O
later O
findings O
indicate O
that O
neither O
homo O
- O
nor O
heterodimer O
formation O
is O
an O
absolute O
prerequisite O
for O
I B
kappa I
B I
alpha I
recognition O
of O
p65 B
. O

Taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 O
and O
p50 O
homodimers O
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF B
- I
kappa I
B I
/ O
Rel B
- O
directed O
gene O
expression O
. O

Effects O
of O
IL B
- I
4 I
and O
Fc O
gamma O
receptor O
II O
engagement O
on O
Egr B
- I
1 I
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

Egr B
- I
1 I
is O
an O
immediate B
early I
gene I
that O
is O
rapidly O
upregulated O
in O
response O
to O
mitogenic O
signals O
induced O
by O
antigen O
receptor O
crosslinking O
on O
murine O
B O
lymphocytes O
. O

It O
has O
been O
shown O
that O
levels O
of O
Egr B
- I
1 I
expression O
are O
closely O
correlated O
with O
B O
cell O
proliferation O
in O
several O
models O
of O
B O
cell O
activation O
and O
tolerance O
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab O
' O
2 O
and O
IgG O
anti O
- O
immunoglobulin O
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab O
' O
2 O
anti O
- O
Ig O
is O
mitogenic O
while O
IgG O
anti O
- O
Ig O
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane O
Ig O
. O

While O
mitogenic O
doses O
of O
Fab O
' O
2 O
anti O
- O
Ig O
induce O
large O
and O
rapid O
increases O
in O
Egr O
- O
1 O
expression O
, O
IgG O
anti O
- O
Ig O
results O
in O
smaller O
increases O
in O
Egr B
- I
1 I
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab O
' O
2 O
anti O
- O
Ig O
. O

However O
, O
the O
correlation O
between O
Egr O
- O
1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL B
- I
4 I
is O
added O
as O
a O
co O
- O
mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG O
anti O
- O
Ig O
or O
submitogenic O
concentrations O
of O
Fab O
' O
2 O
anti O
- O
Ig O
. O

No O
corresponding O
increases O
in O
Egr B
- I
1 I
mRNA I
levels O
are O
observed O
when O
IL B
- I
4 I
is O
added O
. O

Therefore O
, O
IL B
- I
4 I
overcomes O
Fc O
receptor O
- O
mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr B
- I
1 I
mRNA I
induction O
, O
as O
demonstrated O
earlier O
for O
c B
- I
myc I
mRNA I
in O
this O
system O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
, O
a O
cytokine B
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types O
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O

In O
this O
paper O
, O
TNF B
- I
alpha I
mRNA I
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T B
cell I
receptor I
( O
TCR B
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

We O
have O
identified O
a O
human O
TNF O
- O
alpha O
promoter O
element O
, O
kappa B
3 I
, O
which O
plays O
a O
key O
role O
in O
the O
calcium O
- O
mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
an O
oligonucleotide O
containing O
kappa B
3 I
forms O
two O
DNA O
protein O
complexes O
with O
proteins O
that O
are O
present O
in O
extracts O
from O
unstimulated O
T O
cells O
. O

Induction O
of O
the O
inducible O
nuclear B
complexes I
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA O
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF B
- I
alpha I
mRNA I
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O

Our O
studies O
indicate O
that O
the O
kappa B
3 I
binding I
factor I
resembles O
the O
preexisting O
component O
of O
nuclear B
factor I
of O
activated O
T O
cells O
. O

Thus O
, O
the O
TNF B
- I
alpha I
gene I
is O
an O
immediate O
early O
gene O
in O
activated O
T O
cells O
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA O
- O
sensitive O
gene O
induction O
in O
activated O
T O
cells O
. O

Differences O
in O
expression O
of O
transcription B
factor I
AP I
- I
1 I
in O
human O
promyelocytic O
HL O
- O
60 O
cells O
during O
differentiation O
towards O
macrophages O
versus O
granulocytes O
. O

The O
commitment O
stage O
towards O
PMA O
- O
induced O
macrophage O
differentiation O
was O
associated O
with O
increases O
in O
jun O
B O
and O
c O
- O
fos O
mRNA O
levels O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
binding O
activity O
of O
transcription B
factor I
AP I
- I
1 I
. O

Nevertheless O
, O
gel O
retardation O
analysis O
indicated O
that O
the O
AP B
- I
1 I
activity O
detected O
in O
untreated O
cells O
was O
drastically O
reduced O
during O
the O
commitment O
stage O
of O
DMSO O
- O
induced O
HL O
- O
60 O
differentiation O
towards O
granulocytes O
. O

Treatment O
of O
HL O
- O
60 O
cells O
with O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
, O
another O
monocytic O
differentiation O
agent O
, O
induced O
a O
weak O
, O
but O
appreciable O
, O
increase O
in O
AP B
- I
1 I
activity O
. O

These O
data O
indicate O
that O
formation O
of O
AP B
- I
1 I
is O
not O
required O
for O
the O
induction O
of O
HL O
- O
60 O
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic O
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP B
- I
1 I
activity O
. O

The O
differential O
expression O
of O
AP B
- I
1 I
activity O
may O
be O
critical O
in O
the O
differentiation O
of O
HL O
- O
60 O
cells O
towards O
monocytic O
or O
granulocytic O
lineages O

Glucocorticoid B
receptors I
and O
sensitivity O
in O
leukemias O
. O

In O
an O
attempt O
to O
investigate O
the O
utility O
of O
glucocorticoid B
receptor I
determination O
to O
predict O
clinical O
responsiveness O
in O
human O
leukemias O
we O
have O
studied O
glucocorticoid B
receptors I
in O
the O
leukemic O
cells O
from O
46 O
patients O
and O
in O
the O
lymphocytes O
from O
18 O
normal O
donors O
. O

The O
blasts O
from O
17 O
patients O
with O
ANLL O
had O
on O
average O
higher O
levels O
of O
binding B
sites I
per O
cell O
( O
Median O
= O
7 O
, O
250 O
, O
range O
: O
0 O
to O
15 O
, O
295 O
) O
than O
the O
other O
leukemias O
. O

There O
was O
no O
marked O
correlation O
between O
glucocorticoid B
receptor I
levels O
and O
in O
vitro O
sensitivity O
. O

An O
attempt O
to O
correlate O
receptor O
levels O
with O
clinical O
responsiveness O
demonstrated O
that O
glucocorticoid B
receptor I
determination O
might O
be O
of O
value O
in O
patients O
with O
lymphoid O
malignancies O
but O
probably O
not O
in O
patients O
with O
other O
leukemias O
. O

Activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid O
- O
receptor O
complex O
for O
DNA B
and O
an O
altered O
elution O
profile O
from O
ion O
- O
exchange O
resins O
. O

We O
report O
here O
that O
DEAE O
- O
cellulose O
chromatography O
of O
steroid O
- O
receptor O
complexes O
from O
CEM O
- O
C7 O
, O
a O
cloned O
human O
leukaemic O
T O
- O
cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid O
- O
resistant O
subclone O
4R4 O
demonstrated O
that O
steroid B
receptors I
of O
clone O
4R4 O
can O
not O
form O
stable O
activated O
complexes O
. O

Identification O
of O
glucocorticoid B
receptors I
in O
monocytes O
and O
macrophages O
. O

Two O
assays O
of O
binding O
were O
used O
- O
- O
an O
assay O
with O
intact O
cells O
in O
suspension O
or O
monolayers O
, O
and O
an O
assay O
of O
cytosol O
and O
nuclear O
forms O
of O
glucocorticoid B
receptors I
. O

Binding O
of O
dexamethasone O
to O
cytosol O
and O
nuclear O
forms O
of O
the O
receptor B
complex I
and O
temperature O
- O
sensitive O
translocation O
of O
cytosol O
forms O
to O
nuclear O
forms O
were O
shown O
. O

Nitric O
oxide O
signaling O
: O
a O
possible O
role O
for O
G B
proteins I
. O

We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling O
- O
through O
direct O
activation O
of O
guanine O
nucleotide O
- O
binding O
proteins O
( O
G B
proteins I
) O
. O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs B
alpha I
, O
Gi O
alpha O
1 O
, O
and O
p21ras B
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

In O
support O
of O
the O
existence O
of O
this O
pathway O
in O
whole O
cells O
, O
we O
found O
that O
the O
G O
protein O
inhibitor O
, O
GDP O
- O
beta O
- O
S O
, O
blocked O
NF B
- I
kappa I
B I
translocation O
induced O
by O
nitric O
oxide O
or O
LPS O
in O
permeabilized O
cells O
. O

Because O
G B
proteins I
play O
a O
central O
role O
in O
many O
diverse O
signaling O
systems O
, O
activation O
by O
an O
endogenous O
and O
inducible O
oxidant O
may O
represent O
a O
novel O
signaling O
pathway O
. O

The O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
promoter O
cis O
- O
acting O
element O
CLE0 B
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B
and O
NFAT B
. O

Expression O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
in O
T O
cells O
is O
activated O
by O
the O
combination O
of O
phorbol O
ester O
( O
phorbol O
myristate O
acetate O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
, O
which O
mimic O
antigen O
stimulation O
through O
the O
T B
- I
cell I
receptor I
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp O
- O
95 O
to O
+ O
27 O
of O
the O
mouse B
GM I
- I
CSF I
promoter I
can O
confer O
inducibility O
to O
reporter B
genes I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis B
- I
acting I
element I
( O
positions O
- O
54 O
to O
- O
40 O
) O
, O
referred O
to O
as O
CLE0 B
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 B
but O
not O
with O
templates O
with O
deleted O
or O
mutated O
CLE0 O
. O

We O
also O
observed O
that O
two O
distinct O
signals O
were O
required O
for O
the O
stimulation O
through O
CLE0 B
, O
since O
only O
extracts O
from O
cells O
treated O
with O
both O
phorbol O
myristate O
acetate O
and O
A23187 O
supported O
optimal O
induction O
. O

Stimulation O
probably O
was O
mediated O
by O
CLE0 O
- O
binding O
proteins O
because O
depletion O
of O
these O
proteins O
specifically O
reduced O
GM B
- I
CSF I
transcription O
. O

One O
of O
the O
binding B
factors I
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription O
factor O
AP1 O
. O

The O
presence O
of O
CLE0 O
- O
like O
elements O
in O
the O
promoters B
of O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
, O
IL O
- O
4 O
, O
IL O
- O
5 O
, O
GM O
- O
CSF O
, O
and O
NFAT O
sites O
in O
the O
IL B
- I
2 I
promoter I
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T O
- O
cell O
activation O
. O

Identification O
and O
characterization O
of O
an O
Alu O
- O
containing O
, O
T O
- O
cell O
- O
specific O
enhancer O
located O
in O
the O
last O
intron B
of O
the O
human O
CD8 O
alpha O
gene O
. O

As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis O
- O
acting O
regulatory O
regions O
by O
DNase B
I I
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites O
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O

By O
using O
a O
reporter O
- O
based O
expression O
approach O
, O
a O
T B
- I
cell I
- I
specific I
enhancer I
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T O
- O
cell O
- O
restricted O
hypersensitive O
sites O
in O
the O
last O
intron O
of O
the O
CD8 O
alpha O
gene O
. O

DNA O
sequence O
analysis O
of O
the O
minimal O
enhancer O
revealed O
a O
striking O
cluster O
of O
consensus B
binding I
sites I
for O
Ets O
- O
1 O
, O
TCF O
- O
1 O
, O
CRE O
, O
GATA O
- O
3 O
, O
LyF O
- O
1 O
, O
and O
bHLH O
proteins O
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
addition O
, O
the O
5 B
' I
end I
of O
the O
enhancer B
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA O
- O
3 O
, O
bHLH O
, O
and O
LyF O
- O
1 O
binding O
sites O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
human O
CD8 O
alpha O
gene O
is O
regulated O
by O
the O
interaction O
of O
multiple O
T O
- O
cell O
nuclear O
proteins O
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron B
of O
the O
gene O
. O

Comparison O
of O
the O
CD8 O
alpha O
enhancer O
with O
other O
recently O
identified O
T O
- O
cell O
- O
specific O
regulatory O
elements O
suggests O
that O
a O
common O
set O
of O
transcription B
factors I
regulates O
several O
T B
- I
cell I
genes I
. O

Interleukin B
3 I
( O
IL B
- I
3 I
) O
is O
a O
hematopoietic O
stem O
- O
cell O
growth O
and O
differentiation O
factor O
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

We O
have O
now O
identified O
DNA B
sequences I
that O
are O
required O
for O
T O
cell O
- O
restricted O
IL B
- I
3 I
gene I
transcription O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human O
IL O
- O
3 O
- O
chloramphenicol O
acetyltransferase O
( O
CAT O
) O
reporter O
plasmids O
in O
T O
and O
non O
- O
T O
cells O
revealed O
that O
a O
plasmid B
containing O
319 O
bp O
of O
5 B
' I
flanking I
sequences I
was O
active O
exclusively O
in O
T O
cells O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 O
- O
bp O
fragment O
( O
bp O
- O
319 O
to O
- O
270 O
) O
that O
included O
a O
potential O
binding O
site O
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding O
site O
for O
Elf O
- O
1 O
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

DNaseI B
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA O
- O
144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49 O
- O
bp O
region O
contains O
a O
nuclear O
protein O
binding O
region O
that O
includes O
consensus O
AP O
- O
1 O
and O
Elf O
- O
1 O
binding O
sites O
. O

Transient O
transfection O
studies O
in O
MLA O
- O
144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP B
- I
1 I
site I
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf O
- O
1 O
site O
or O
the O
NF O
- O
IL O
- O
3 O
site O
, O
a O
previously O
described O
nuclear O
protein O
binding O
site O
( O
bp O
. O
- O
155 O
to O
- O
148 O
) O
in O
the O
IL B
- I
3 I
promoter I
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild O
- O
type O
constructs O
. O

We O
conclude O
that O
expression O
of O
the O
human O
IL O
- O
3 O
gene O
requires O
the O
AP O
- O
1 O
and O
Elf O
- O
1 O
binding O
sites O
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP O
- O
1 O
and O
Elf O
- O
1 O
factors O
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

Combination O
IL B
- I
2 I
and O
IL B
- I
4 I
reduces O
glucocorticoid O
receptor O
- O
binding O
affinity O
and O
T O
cell O
response O
to O
glucocorticoids O
. O

We O
examined O
the O
possibility O
that O
certain O
cytokines O
, O
specifically O
IL B
- I
2 I
and O
IL B
- I
4 I
, O
could O
affect O
T O
cell O
response O
to O
glucocorticoids O
. O

A O
[ O
3H O
] O
dexamethasone O
radioligand O
- O
binding O
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR O
asthma O
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines B
. O

PBMC O
from O
normal O
donors O
incubated O
for O
48 O
h O
in O
the O
presence O
of O
combination O
IL B
- I
2 I
+ O
IL B
- I
4 I
had O
nuclear O
GR O
with O
significantly O
reduced O
binding O
affinity O
( O
GR O
Kd O
= O
36 O
. O
1 O
+ O
/ O
- O
1 O
. O
63 O
nM O
, O
mean O
+ O
/ O
- O
SEM O
; O
p O
= O
0 O
. O
0001 O
) O
as O
compared O
with O
PBMC O
incubated O
with O
medium O
alone O
( O
GR O
Kd O
= O
6 O
. O
74 O
+ O
/ O
- O
0 O
. O
46 O
nM O
) O
. O

However O
, O
when O
PBMC O
were O
incubated O
with O
IL B
- I
2 I
alone O
or O
IL B
- I
4 I
alone O
, O
no O
change O
in O
GR O
- O
binding O
affinity O
was O
observed O
. O

More O
importantly O
, O
the O
alteration O
in O
PBMC O
GR O
- O
binding O
affinity O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
was O
associated O
with O
a O
functional O
change O
in O
T O
cell O
response O
to O
methylprednisolone O
MPN O
, O
i O
. O
e O
. O
, O
a O
reduced O
inhibitory O
effect O
of O
MPN O
on O
PMA O
/ O
ionomycin O
- O
induced O
T O
cell O
proliferation O
. O

These O
effects O
of O
IL B
- I
2 I
+ O
IL B
- I
4 I
on O
PBMC O
GR B
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co O
- O
incubation O
with O
IFN B
- I
gamma I
. O

The O
altered O
PBMC O
GR O
binding O
from O
patients O
with O
SR O
asthma O
reversed O
to O
normal O
when O
incubated O
with O
medium O
alone O
, O
but O
was O
sustained O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
. O

These O
observations O
suggest O
that O
with O
persistent O
inflammation O
certain O
cytokines B
may O
contribute O
to O
an O
impaired O
response O
to O
glucocorticoids O
. O

Furthermore O
, O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
4 I
were O
blocked O
by O
IFN B
- I
gamma I
. O

Characterization O
of O
the O
human O
CD4 O
gene O
promoter O
: O
transcription O
from O
the O
CD4 O
gene O
core O
promoter O
is O
tissue O
- O
specific O
and O
is O
activated O
by O
Ets B
proteins I
. O

We O
analyzed O
the O
5 O
' O
transcription O
control O
sequences O
of O
the O
human B
CD4 I
gene I
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 O
core O
promoter O
( O
positions O
- O
40 O
to O
+ O
16 O
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator O
positioning O
consensus O
sequence O
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

Another O
ETS B
consensus I
sequence I
is O
located O
1060 O
nt O
upstream O
. O

Electrophoretic O
- O
mobility O
- O
shift O
assays O
showed O
that O
the O
core O
promoter O
ETS O
motif O
binds O
an O
Ets B
- I
related I
protein I
specifically O
expressed O
at O
high O
levels O
in O
CD4 O
+ O
cells O
. O

Moreover O
, O
in O
CD4 O
- O
cells O
, O
overexpression O
of O
Ets B
- I
1 I
or O
Ets B
- I
2 I
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B
promoter I
and O
core B
promoter I
. O

These O
data O
indicate O
that O
Ets B
transcription I
factors I
play O
a O
central O
role O
in O
controlling O
CD4 O
gene O
expression O
, O
by O
binding O
to O
both O
a O
classical O
remote O
site O
and O
an O
unusual O
proximal O
activator O
sequence O

The O
inactivation O
of O
glucocorticoid B
receptors I
that O
occurs O
when O
cytosol O
from O
normal O
IM O
- O
9 O
cells O
is O
incubated O
at O
25 O
degrees O
C O
is O
inhibited O
by O
molybdate O
, O
vanadate O
, O
fluoride O
, O
ATP O
, O
and O
several O
other O
nucleotides O
. O

The O
experiments O
with O
intact O
human O
lymphoblasts O
suggest O
that O
assays O
of O
specific O
glucocorticoid O
- O
binding O
capacity O
do O
not O
necessarily O
reflect O
the O
cellular O
content O
of O
receptor B
protein I
. O

Cell O
cycle O
- O
dependent O
changes O
in O
glucocorticoid B
receptor I
content O
. O

To O
study O
variations O
in O
glucocorticoid B
receptor I
levels O
during O
the O
cell O
cycle O
, O
we O
have O
separated O
mitogen O
- O
stimulated O
human O
peripheral O
lymphocytes O
and O
rat O
lymph O
node O
cells O
by O
unit O
gravity O
sedimentation O
and O
measured O
glucocorticoid O
binding O
in O
the O
resultant O
fractions O
. O

These O
observations O
together O
with O
those O
from O
other O
studies O
indicate O
that O
formation O
of O
new O
glucocorticoid B
receptors I
near O
the O
S O
phase O
may O
be O
a O
general O
phenomenon O
in O
proliferating O
cells O
. O

We O
propose O
that O
this O
increase O
in O
glucocorticoid B
receptors I
during O
the O
cell O
cycle O
may O
explain O
the O
increase O
in O
glucocorticoid B
receptors I
in O
mitogen O
- O
stimulated O
lymphocytes O
. O

Glucocorticoid B
receptor I
levels O
and O
steroid O
induced O
inhibition O
of O
nucleic O
acid O
precursors O
have O
been O
examined O
in O
lymphocytes O
from O
27 O
patients O
at O
different O
stages O
of O
chronic O
lymphatic O
leukaemia O
. O

No O
correlation O
can O
be O
found O
between O
the O
level O
of O
glucocorticoid B
receptors I
and O
the O
stage O
of O
the O
disease O
. O

Pyrrolidine O
dithiocarbamate O
inhibits O
NF B
- I
kappa I
B I
mobilization O
and O
TNF O
production O
in O
human O
monocytes O
. O

The O
human B
TNF I
promoter I
contains O
four O
potential O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
- O
binding O
sites O
, O
with O
the O
strongest O
binding O
seen O
for O
the O
- O
605 O
motif O
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific O
binding O
protein O
( O
complex B
II I
) O
, O
consistent O
with O
a O
constitutive O
p50 O
homodimer O
. O

Stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex B
II I
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex B
I I
) O
, O
which O
represents O
the O
p50 O
/ O
65 O
heterodimer O
. O

Treatment O
of O
Mono O
Mac O
6 O
cells O
with O
pyrrolidine O
- O
dithiocarbamate O
( O
PDTC O
) O
at O
300 O
microM O
will O
block O
the O
LPS O
- O
induced O
complex O
I O
almost O
completely O
and O
will O
reduce O
complex B
II I
to O
the O
constitutive O
level O
. O

Binding O
activity O
of O
other O
nuclear B
factors I
that O
recognize O
the O
SP O
- O
1 O
and O
c O
/ O
EBP O
motifs O
of O
the O
human B
TNF I
promoter I
is O
not O
affected O
by O
such O
treatment O
. O

Kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF B
- I
kappa I
B I
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF O
protein O
at O
4 O
h O
. O

PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF O
- O
kappa O
B O
mobilization O
, O
TNF B
transcripts I
, O
and O
TNF O
protein O
over O
the O
entire O
8 O
- O
h O
observation O
period O
. O

Analysis O
of O
freshly O
isolated O
, O
LPS O
- O
stimulated O
blood O
monocytes O
showed O
a O
similar O
blockade O
of O
NF B
- I
kappa I
B I
. O

Furthermore O
, O
in O
these O
primary O
cells O
, O
induction O
of O
TNF B
transcripts I
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF O
protein O
production O
. O

These O
data O
show O
that O
dithiocarbamates O
can O
profoundly O
affect O
cytokine O
expression O
and O
suggest O
that O
NF B
- I
kappa I
B I
is O
involved O
in O
LPS O
- O
induced O
TNF O
gene O
expression O
in O
human O
monocytes O
. O

Comparing O
regions O
of O
the O
Epstein B
- I
Barr I
virus I
ZEBRA I
protein I
which O
function O
as O
transcriptional O
activating O
sequences O
in O
Saccharomyces O
cerevisiae O
and O
in O
B O
cells O
. O

The O
ZEBRA B
protein I
activates O
expression O
of O
Epstein O
- O
Barr O
virus O
early O
- O
lytic O
- O
cycle O
genes O
in O
human O
B O
lymphocytes O
. O

Here O
it O
is O
shown O
that O
ZEBRA B
also O
behaves O
as O
a O
sequence O
- O
specific O
transcriptional O
activator O
in O
Saccharomyces O
cerevisiae O
. O

Deletional O
mutagenesis O
defined O
three O
regions O
of O
ZEBRA B
that O
participate O
in O
activation O
in O
S O
. O
cerevisiae O
. O

Two O
of O
the O
three O
regions O
of O
the O
native O
ZEBRA B
protein I
act O
together O
to O
mediate O
activation O
when O
assayed O
on O
ZEBRA B
binding I
sites I
. O

However O
, O
when O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL O
4 O
and O
assayed O
on O
GAL4 O
binding O
sites O
, O
regions O
YII O
and O
YIII O
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

Regions O
of O
ZEBRA B
which O
affected O
activation O
in O
S O
. O
cerevisiae O
were O
also O
required O
in O
human O
B O
lymphocytes O
. O

The O
amino B
- I
terminal I
region I
of O
ZEBRA B
( O
aa O
1 O
to O
98 O
) O
was O
required O
for O
activation O
both O
in O
S O
. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy O
- O
terminal O
18 O
aa O
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

Thus O
, O
the O
behavior O
of O
ZEBRA B
in O
human O
B O
cells O
and O
S O
. O
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal O
activation O
motifs O
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O

However O
, O
certain O
deletion B
mutants I
of O
ZEBRA B
containing O
mutations O
in O
the O
N B
- I
terminal I
region I
exhibited O
discordant O
behaviors O
in O
S O
. O
cerevisiae O
and O
in O
B O
cells O
. O

Functional O
interaction O
of O
the O
v O
- O
Rel O
and O
c O
- O
Rel O
oncoproteins O
with O
the O
TATA B
- I
binding I
protein I
and O
association O
with O
transcription O
factor O
IIB O
. O

Rel B
family I
proteins I
regulate O
the O
expression O
of O
genes O
linked O
to O
kappa O
B O
- O
binding O
motifs O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken O
c O
- O
Rel O
and O
the O
F9 O
cell O
- O
specific O
activation O
region O
common O
to O
both O
v O
- O
Rel O
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription O
factor O
IIB O
( O
TFIIB O
) O
in O
vitro O
and O
in O
vivo O
. O

Combined O
with O
the O
observation O
that O
the O
mouse O
c O
- O
Rel O
and O
human O
RelA O
proteins O
also O
interact O
with O
TBP B
and O
TFIIB O
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal O
transcription O
factors O
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

p21ras B
and O
calcineurin O
synergize O
to O
regulate O
the O
nuclear B
factor I
of O
activated O
T O
cells O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

One O
immediate O
consequence O
of O
T O
cell O
activation O
via O
the O
TCR B
is O
an O
increase O
in O
cytosolic O
calcium O
. O

Calcium O
signals O
are O
important O
for O
NFAT O
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin B
, O
a O
calcium B
- I
calmodulin I
dependent I
serine I
- I
threonine I
phosphatase I
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T O
cells O
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

The O
experiments O
presented O
here O
show O
that O
expression O
by O
transfection O
of O
mutationally O
activated O
calcineurin B
or O
activated O
p21ras B
alone O
is O
insufficient O
for O
NFAT O
transactivation O
. O

These O
data O
identify O
calcineurin B
and O
p21ras B
as O
cooperative O
partners O
in O
T O
cell O
activation O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional O
regulatory O
domains O
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator O
proteins O
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi O
- O
gene O
family O
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

In O
the O
primitive O
erythroid O
lineage O
, O
transcription O
of O
the O
embryonic O
epsilon O
- O
globin O
gene O
parallels O
GATA O
- O
1 O
expression O
while O
the O
switch O
to O
beta O
- O
globin O
transcription O
in O
definitive O
erythroid O
cells O
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA B
- I
3 I
accumulation O
. O

The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs B
during O
avian O
erythroid O
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA B
factor I
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O

Molecular O
regulation O
of O
human O
interleukin O
2 O
and O
T O
- O
cell O
function O
by O
interleukin B
4 I
. O

Distinct O
functional O
T O
- O
cell O
subsets O
, O
differing O
in O
the O
patterns O
of O
lymphokines B
produced O
, O
regulate O
cell O
- O
mediated O
and O
humoral O
immune O
responses O
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B
4 I
and O
interferon B
gamma I
( O
IL B
- I
4 I
and O
IFN B
- I
gamma I
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

To O
analyze O
the O
molecular O
mechanism O
of O
IL O
- O
4 O
- O
mediated O
suppression O
of O
cell O
- O
mediated O
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin B
2 I
( O
IL B
- I
2 I
) O
and O
IFN B
- I
gamma I
. O

IL B
- I
4 I
pretreatment O
of O
Jurkat O
cells O
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription O
of O
the O
IL2 O
gene O
. O

IL B
- I
4 I
suppressed O
IL O
- O
2 O
and O
IFN O
- O
gamma O
mRNA O
levels O
in O
primary O
human O
T O
cells O
, O
and O
addition O
of O
anti B
- I
CD28 I
antibodies I
relieved O
this O
suppression O
. O

Using O
enhancer O
- O
reporter O
constructs O
, O
IL B
- I
4 I
specifically O
down O
- O
regulated O
the O
NFIL O
- O
2B O
element O
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL O
- O
2B O
binding O
site O
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL O
- O
2B O
complex O
and O
that O
the O
NFIL O
- O
2B O
DNA O
binding O
factor O
is O
distinct O
from O
AP O
- O
1 O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
regulate O
development O
and O
function O
of O
T O
- O
cell O
subsets O
involved O
in O
cell O
- O
mediated O
immunity O
in O
part O
by O
inhibiting O
factors O
required O
for O
transcription O
of O
the O
IL2 O
gene O

We O
have O
explored O
the O
possibility O
of O
using O
antibodies B
against O
purified O
rat O
liver O
glucocorticoid B
receptors I
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid B
receptors I
from O
murine O
and O
human O
malignant O
lymphocytes O
. O

Mouse O
thymus O
was O
used O
as O
a O
source O
of O
glucocorticoid B
receptor I
from O
normal O
CS O
lymphocytes O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
[ O
3H O
] O
triamcinolone O
acetonide O
- O
receptor O
complexes O
characteristic O
of O
the O
CS O
mouse O
and O
human O
lymphocytes O
, O
it O
failed O
to O
recognize O
the O
27 O
- O
to O
28 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
present O
in O
corticoid O
- O
resistant O
mouse O
lymphoma O
P1798 O
cells O
. O

Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross O
- O
reactivity O
between O
the O
antiserum O
against O
rat O
liver O
glucocorticoid O
receptor O
and O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
from O
species O
as O
diverse O
as O
mouse O
and O
humans O
. O

In O
leukocyte O
population O
freshly O
isolated O
from O
the O
blood O
of O
26 O
patients O
with O
acute O
leukemia O
, O
we O
have O
measured O
several O
parameters O
including O
glucocorticoid B
receptors I
, O
nucleoside O
incorporation O
, O
percentage O
of O
cells O
in O
S O
phase O
, O
and O
steroid O
- O
induced O
cell O
lysis O
. O

Although O
, O
in O
all O
the O
patients O
studied O
, O
leukocytes O
were O
found O
to O
contain O
glucocorticoid B
receptors I
, O
we O
failed O
to O
demonstrate O
any O
correlation O
between O
the O
level O
of O
binding O
sites O
and O
the O
in O
vitro O
or O
in O
vivo O
response O
to O
glucocorticoids O
. O

Glucocorticoid B
receptors I
in O
cytosol O
and O
nuclear O
extract O
of O
human O
leukocytes O
. O

The O
suggestion O
is O
offered O
that O
the O
immunologic O
response O
to O
self B
- I
antigens I
exposed O
by O
disease O
or O
trauma O
may O
be O
suppressed O
by O
corticosteroid O
to O
offset O
the O
likelihood O
of O
autoimmune O
attack O
. O

Protein B
tyrosine I
kinase I
activation O
is O
required O
for O
lipopolysaccharide O
induction O
of O
cytokines B
in O
human O
blood O
monocytes O
. O

Bacterial O
LPS O
induce O
production O
of O
cytokines B
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
, O
and O
TNF B
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

However O
, O
the O
mechanisms O
by O
which O
LPS O
activates O
these O
cells O
to O
express O
cytokines B
are O
not O
completely O
characterized O
. O

The O
present O
study O
addressed O
the O
role O
of O
different O
protein B
kinases I
in O
the O
LPS O
induction O
of O
cytokines B
. O

Protein B
kinase I
C I
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF B
- I
alpha I
, O
whereas O
it O
had O
no O
effects O
on O
IL B
- I
6 I
and O
IL O
- O
1 O
beta O
. O

Inhibition O
of O
protein B
kinase I
A I
by O
H89 O
reduced O
IL B
- I
6 I
mRNA I
levels O
but O
did O
not O
detectably O
change O
IL O
- O
1 O
beta O
or O
TNF O
- O
alpha O
mRNA O
levels O
. O

In O
addition O
to O
cytokine B
mRNA I
levels O
, O
LPS O
- O
induced O
IL O
- O
6 O
protein O
synthesis O
and O
IL O
- O
6 O
bioactivity O
were O
also O
reduced O
to O
baseline O
levels O
by O
the O
PTK O
inhibitors O
herbimycin O
A O
and O
genistein O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

The O
activation O
of O
NF B
- I
kappa I
B I
was O
also O
reduced O
by O
H89 O
, O
whereas O
staurosporine O
had O
no O
effect O
on O
this O
response O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

In O
vivo O
control O
of O
NF B
- I
kappa I
B I
activation O
by O
I B
kappa I
B I
alpha I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor O
protein O
I O
kappa O
B O
alpha O
. O

It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I B
kappa I
B I
alpha I
from O
these O
complexes O
results O
in O
active O
NF O
- O
kappa O
B O
. O

In O
this O
report O
we O
show O
that O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
activation O
of O
B O
or O
pre O
- O
B O
cells O
results O
in O
loss O
of O
I B
kappa I
B I
alpha I
from O
NF B
- I
kappa I
B I
complexes I
in O
vivo O
. O

Many O
liberated O
NF O
- O
kappa O
B O
dimers O
reached O
the O
nucleus O
, O
where O
increased O
c B
- I
rel I
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O

Some O
liberated O
dimers O
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 B
or O
p100 B
, O
which O
also O
retain O
rel O
family O
members O
in O
the O
cytoplasm O
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active O
NF O
- O
kappa O
B O
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I B
kappa I
B I
alpha I
provides O
the O
ability O
to O
turn O
off O
NF B
- I
kappa I
B I
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

Identification O
of O
a O
killer O
cell O
- O
specific O
regulatory O
element O
of O
the O
mouse B
perforin I
gene I
: O
an O
Ets O
- O
binding O
site O
- O
homologous O
motif O
that O
interacts O
with O
Ets B
- I
related I
proteins I
. O

The O
gene O
encoding O
the O
cytolytic O
protein O
perforin B
is O
selectively O
expressed O
by O
activated O
killer O
lymphocytes O
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
mouse B
perforin I
gene I
( O
Pfp O
) O
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross O
- O
linking O
experiments O
revealed O
that O
NF O
- O
P1 O
and O
NF O
- O
P2 O
may O
possess O
common O
DNA B
- I
binding I
subunits I
. O

In O
view O
of O
the O
homology O
between O
the O
NF O
- O
P O
motif O
and O
other O
Ets O
proto O
- O
oncoprotein O
- O
binding O
sites O
, O
it O
is O
postulated O
that O
NF O
- O
P1 O
and O
NF O
- O
P2 O
belong O
to O
the O
Ets B
protein I
family I
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF O
- O
P1 O
and O
NF O
- O
P2 O
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF O
- O
AT O
/ O
Elf O
- O
1 O
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

The O
role O
of O
NF O
- O
kappa O
B1 O
( O
p50 O
/ O
p105 O
) O
gene O
expression O
in O
activation O
of O
human O
blood O
T O
- O
lymphocytes O
via O
CD2 B
and I
CD28 I
adhesion I
molecules I
. O

Stimulation O
of O
primary O
human O
T O
- O
lymphocytes O
via O
CD2 B
and I
CD28 I
adhesion I
molecules I
induces O
a O
long O
- O
lasting O
proliferation O
( O
> O
3 O
weeks O
) O
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin B
2 I
( O
IL B
- I
2 I
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25 O
/ O
IL O
- O
2 O
receptor O
alpha O
( O
IL O
- O
2R O
alpha O
) O
chain O
gene O
. O

The O
transcription B
factor I
NF I
- I
kappa I
B I
participates O
in O
the O
regulation O
of O
both O
IL O
- O
2 O
and O
IL O
- O
2R O
alpha O
genes O
, O
as O
well O
as O
multiple O
cellular O
genes O
involved O
in O
T O
- O
cell O
proliferation O
. O

To O
evaluate O
the O
role O
of O
NF B
- I
kappa I
B I
in O
human O
peripheral O
blood O
T O
- O
lymphocytes O
, O
we O
previously O
analyzed O
the O
activation O
of O
NF O
- O
kappa O
B O
- O
related O
complexes O
in O
response O
to O
CD2 O
+ O
CD28 O
costimulation O
. O

We O
demonstrated O
a O
long O
- O
term O
induction O
of O
p50 B
/ I
p65 I
heterodimer I
, O
a O
putative O
p65 O
/ O
c O
- O
Rel O
heterodimer O
, O
and O
a O
constitutive O
nuclear O
expression O
of O
KBF1 O
/ O
p50 O
homodimers O
. O

As O
the O
role O
of O
p50 O
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF B
- I
kappa I
B1 I
( O
p50 O
/ O
p105 O
) O
gene O
regulation O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF B
- I
kappa I
B1 I
gene I
expression O
during O
T O
- O
cell O
stimulation O
via O
CD2 O
+ O
CD28 O
. O

Partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF B
- I
kappa I
B1 I
antisense O
oligonucleotides O
significantly O
reduced O
T O
- O
cell O
proliferation O
and O
CD25 O
/ O
IL O
- O
2R O
alpha O
cell O
surface O
expression O
. O

Vitamin B
D I
receptor I
quantitation O
in O
human O
blood O
mononuclear O
cells O
in O
health O
and O
disease O
. O

Vitamin B
D I
receptor I
( O
VDR O
) O
concentration O
was O
quantitated O
in O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
from O
patients O
with O
absorptive O
hypercalciuria O
( O
AH O
) O
and O
patients O
with O
high O
1 O
, O
25 O
( O
OH O
) O
2D3 O
due O
to O
acquired O
or O
transient O
disease O
states O
and O
the O
results O
compared O
to O
those O
in O
normal O
subjects O
. O

Following O
activation O
with O
phytohemagglutinin B
, O
patients O
with O
hypercalcitriolemia O
demonstrated O
significantly O
greater O
VDR O
concentrations O
. O

Patients O
with O
AH O
demonstrated O
a O
normal O
value O
for O
the O
group O
, O
but O
6 O
patients O
had O
significantly O
greater O
concentrations O
of O
VDR B
despite O
normal O
plasma O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
four O
of O
the O
patients O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
PBMC O
provide O
a O
useful O
system O
for O
studying O
VDR B
status O
in O
transient O
or O
acquired O
states O
of O
hypercalcitriolemia O
. O

Reactive O
oxygen O
intermediates O
activate O
NF B
- I
kappa I
B I
in O
a O
tyrosine O
kinase O
- O
dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck O
and O
p59fyn O
tyrosine O
kinases O
in O
human O
lymphocytes O
. O

We O
have O
previously O
observed O
that O
ionizing O
radiation O
induces O
tyrosine O
phosphorylation O
in O
human O
B O
- O
lymphocyte O
precursors O
by O
stimulation O
of O
unidentified O
tyrosine B
kinases I
and O
this O
phosphorylation O
is O
substantially O
augmented O
by O
vanadate O
. O

We O
now O
provide O
evidence O
that O
the O
tyrosine O
kinase O
inhibitor O
herbimycin O
A O
and O
the O
free O
radical O
scavenger O
N O
- O
acetyl O
- O
cysteine O
inhibit O
both O
radiation O
- O
induced O
and O
H2O2 O
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
, O
indicating O
that O
activation O
triggered O
by O
ROI O
is O
dependent O
on O
tyrosine O
kinase O
activity O
. O

Although O
treatment O
of O
cells O
with O
H2O2 O
alone O
did O
not O
affect O
the O
activity O
of O
src B
family I
kinases I
, O
treatment O
with O
H2O2 O
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck O
and O
p59fyn O
tyrosine O
kinases O
. O

The O
combined O
inhibition O
of O
phosphatases B
and O
activation O
of O
kinases B
provides O
a O
potent O
mechanism O
for O
the O
synergistic O
effects O
of O
H2O2 O
plus O
vanadate O
. O

The O
influence O
of O
human O
serum O
albumin O
and O
sex O
hormone O
binding O
globulin O
( O
SHBG B
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

Total O
plasma O
and O
albumin B
delayed O
the O
conversion O
rate O
of O
androstenedione O
, O
while O
SHBG B
increased O
it O
markedly O
. O

The O
effect O
of O
SHBG B
was O
largely O
abolished O
by O
heating O
to O
60 O
degrees O
C O
for O
1 O
h O
and O
by O
saturating O
its O
binding O
sites O
by O
DHT O
. O

It O
appears O
that O
the O
binding O
sites O
of O
albumin B
provide O
a O
mechanism O
for O
retarding O
androstenedione O
uptake O
by O
the O
erythrocytes O
and O
that O
the O
high O
binding O
affinity O
of O
SHBG B
for O
testosterone O
facilitates O
the O
diffusion O
of O
this O
steroid O
out O
of O
the O
cell O
and O
thus O
, O
displaces O
the O
chemical O
equilibrium O
within O
the O
cell O
. O

Increased O
glucocorticoid B
receptor I
levels O
in O
antigen O
- O
stimulated O
lymphocytes O
. O

Recently O
a O
2 O
- O
to O
3 O
- O
fold O
increase O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
human O
peripheral O
lymphocytes O
has O
been O
noted O
after O
in O
vitro O
mitogen O
stimulation O
. O

Several O
of O
our O
results O
on O
energetics O
and O
kinetics O
of O
hormone O
binding O
to O
glucocorticoid B
receptors I
in O
rat O
thymus O
cells O
seem O
to O
require O
extension O
of O
the O
simplest O
model O
of O
hormone O
- O
receptor O
transformations O
in O
intact O
cells O
. O

ATP O
- O
depletion O
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the O
receptor O
; O
` O
` O
chase O
' O
' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear O
- O
bound O
receptor O
; O
experiments O
on O
depletion O
and O
replenishment O
of O
cytoplasmic B
receptor I
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear O
- O
bound O
hormone O
- O
receptor O
complex O
. O

We O
have O
found O
that O
mitogen O
or O
immunologic O
stimulation O
of O
human O
peripheral O
lymphocytes O
in O
culture O
leads O
within O
24 O
h O
or O
so O
to O
a O
striking O
increase O
in O
the O
number O
of O
glucocorticoid B
receptor I
sites O
per O
cell O
. O

We O
show O
here O
that O
the O
immediate O
upstream O
region O
( O
from O
position O
- O
12 O
to O
- O
270 O
) O
of O
the O
murine O
interleukin O
4 O
( O
Il O
- O
4 O
) O
gene O
harbors O
a O
strong O
cell O
- O
type O
specific O
transcriptional B
enhancer I
. O

In O
T O
lymphoma O
cells O
, O
the O
activity O
of O
the O
Il O
- O
4 O
promoter O
/ O
enhancer O
is O
stimulated O
by O
phorbol O
esters O
, O
Ca O
+ O
+ O
ionophores O
and O
agonists O
of O
protein B
kinase I
A I
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O

DNase O
I O
footprint O
protection O
experiments O
revealed O
six O
sites O
of O
the O
Il O
- O
4 O
promoter O
/ O
enhancer O
to O
be O
bound O
by O
nuclear B
proteins I
from O
lymphoid O
and O
myeloid O
cells O
. O

Among O
them O
are O
four O
purine O
boxes O
which O
have O
been O
described O
to O
be O
important O
sequence O
motifs O
of O
the O
Il B
- I
2 I
promoter I
. O

Three O
of O
the O
Il O
- O
4 O
NFAT O
- O
1 O
sites O
are O
closely O
linked O
to O
weak O
binding O
sites O
of O
Octamer B
factors I
. O

Several O
purine O
boxes O
and O
an O
AT O
- O
rich O
protein O
- O
binding O
site O
of O
the O
Il O
- O
4 O
promoter O
are O
also O
recognized O
by O
the O
high B
mobility I
group I
protein I
HMG B
I I
( I
Y I
) O
. O

Whereas O
the O
binding O
of O
NFAT B
- I
1 I
and O
Octamer B
factors I
enhance O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il B
- I
4 I
transcription O
in O
resting O
T O
lymphocytes O
. O

Phosphatidylcholine O
hydrolysis O
activates O
NF B
- I
kappa I
B I
and O
increases O
human O
immunodeficiency O
virus O
replication O
in O
human O
monocytes O
and O
T O
lymphocytes O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC O
- O
specific O
phospholipase O
C O
( O
PC O
- O
PLC O
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC O
- O
PLC O
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

Induction O
of O
NF B
- I
kappa I
B I
by O
PC O
- O
PLC O
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B
necrosis I
factor I
or O
interleukin B
1 I
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC O
- O
PLC O
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic O
kappa O
B O
enhancers O
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV O
long O
terminal O
repeat O
constructs O
. O

These O
results O
indicate O
that O
a O
cellular O
transduction O
pathway O
, O
dependent O
on O
specific O
PC O
breakdown O
, O
is O
functional O
in O
T O
lymphocytes O
and O
monocytes O
and O
may O
be O
used O
by O
various O
transmembrane O
receptors O
to O
activate O
HIV O
transcription O
through O
NF O
- O
kappa O
B O
- O
dependent O
induction O
of O
the O
HIV B
enhancer I
. O

Glucocorticoids O
inhibit O
signal O
transduction O
through O
IL B
- I
2 I
receptor I
. O

Interaction O
of O
IL B
- I
2 I
with O
its O
high O
affinity O
membrane O
receptor O
complex O
( O
IL B
- I
2R I
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

Glucocorticoids O
inhibit O
IL B
- I
2 I
production O
by O
inhibiting O
TCR O
- O
mediated O
signal O
transduction O
. O

We O
asked O
whether O
they O
also O
inhibit O
the O
action O
of O
IL B
- I
2 I
by O
inhibiting O
signal O
transduction O
through O
IL B
- I
2R I
. O

Human O
peripheral O
blood O
T O
cells O
, O
stimulated O
with O
PMA O
for O
48 O
h O
( O
PMA O
blasts O
) O
, O
were O
incubated O
with O
IL B
- I
2 I
in O
the O
presence O
of O
incremental O
dosages O
of O
dexamethasone O
( O
Dex O
; O
10 O
( O
- O
5 O
) O
- O
10 O
( O
- O
9 O
) O
M O
) O
. O

In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I O
- O
labeled O
IL O
- O
2 O
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL B
- I
2 I
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O

Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL O
- O
2 O
- O
dependent O
tyrosine O
phosphorylation O
of O
several O
intracellular B
proteins I
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma O
gene O
product O
Rb O
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells O
through O
the O
cell O
cycle O
. O

IL O
- O
2 O
- O
dependent O
IL O
- O
2R O
alpha O
expression O
in O
PMA O
blasts O
and O
NF B
- I
kB I
induction O
in O
resting O
human O
T O
cells O
were O
also O
inhibited O
by O
Dex O
. O

These O
results O
demonstrate O
that O
glucocorticoids O
inhibit O
preactivated O
T O
cells O
by O
down O
- O
regulating O
signal O
transduction O
through O
IL B
- I
2R I
. O

PLB O
- O
IIIB O
cells O
displayed O
a O
constitutive O
NF O
- O
kappa O
B O
- O
like O
binding O
activity O
that O
was O
distinct O
from O
that O
induced O
by O
tumor B
necrosis I
factor I
alpha I
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
treatment O
of O
the O
parental O
PLB O
- O
985 O
cell O
line O
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 O
, O
90 O
, O
and O
100 O
kDa O
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF B
- I
kappa I
B I
site I
within O
the O
PRDII B
domain I
of O
beta B
interferon I
. O

Virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B
( O
p65 B
) O
or O
NFKB1 B
( O
p50 B
) O
but O
rather O
affects O
the O
capacity O
of O
I B
kappa I
B I
alpha I
to O
sequester O
RelA B
( I
p65 I
) I
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF O
- O
kappa O
B O
- O
dependent O
gene O
activity O
. O

The O
virally O
induced O
90 O
- O
to O
100 O
- O
kDa O
proteins O
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT O
- O
rich O
sequence O
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

Double O
immunostaining O
with O
the O
anti O
- O
ER O
MAb O
and O
with O
specific O
MAb O
to O
detect O
different O
macrophage O
antigens O
( O
Ber O
- O
MAC3 O
, O
MAC387 O
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

